Inhibitors of RAF kinase

By providing specific structures of RAF inhibitor compounds, the problem of existing RAF kinase inhibitors is solved, which is difficult for existing RAF kinase inhibitors to cross the blood-brain barrier, enhances the therapeutic effect on brain tumors, and tries to overcome the problem of resistance, providing a new treatment plan .

CN118974036APending Publication Date: 2024-11-15PIERRE FABRE MEDICAMENT SAS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031462.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-03
Filing Date
2023-02-03
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing RAF kinase inhibitors are difficult to cross the blood-brain barrier and cannot effectively treat brain tumors and brain metastases. They also have primary and secondary resistance problems, which affects the treatment effect.

Method used

Provided is a pharmaceutical composition comprising a specific compound for inhibiting the activity of RAF kinase, including compounds having a specific structure or pharmaceutically acceptable salts or solvates thereof, through which diseases are treated, especially cancers and brain diseases .

Benefits of technology

Improves the ability of compounds to cross the blood-brain barrier, enhances the therapeutic effect on brain tumors, and attempts to overcome the resistance of existing RAF inhibitors, providing new treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974036A_ABST
    Figure CN118974036A_ABST
Patent Text Reader

Abstract

Provided herein are inhibitors of receptor tyrosine kinase effector RAF, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of disease. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. patent application No. 63 / 306,195, filed February 3, 2022, which is hereby incorporated by reference in its entirety. Background Art

[0003] RAF kinases play a role in the Ras-Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway (also known as the MAPK / ERK pathway) by phosphorylating and activating MEK. By altering the levels and activity of transcription factors, MAPKs cause transcriptional changes in genes important for the cell cycle. Dysregulation of MAPK activity often occurs in tumors. Therefore, there is a need for therapies targeting RAF kinase activity for the treatment of cancer and other diseases characterized by aberrant MAPK / ERK pathway signaling. Summary of the Invention

[0004] Provided herein are inhibitors of the receptor tyrosine kinase effector Raf (RAF), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat disease.

[0005] One embodiment provides a compound having the structure of formula (I) or a pharmaceutically acceptable salt or solvate thereof:

[0006]

[0007] in,

[0008] A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N;

[0009] X is N or CR 1 ;

[0010] Y is N or CR 2 ;

[0011] Z is N or CR 3 ;

[0012] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0013] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0014] One embodiment provides a compound having the structure of Formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:

[0015]

[0016] in,

[0017] X is N or CR 1 ;

[0018] Y is N or CR 2 ;

[0019] Z is N or CR 3 ;

[0020] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0021] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0022] One embodiment provides a compound having the structure of Formula (Ib) or a pharmaceutically acceptable salt or solvate thereof:

[0023]

[0024] in,

[0025] X is N or CR 1 ;

[0026] Y is N or CR 2 ;

[0027] Z is N or CR 3 ;

[0028] R 1 、R 2 and R 3is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0029] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0030] One embodiment provides a compound having the structure of formula (II) or a pharmaceutically acceptable salt or solvate thereof:

[0031]

[0032] in,

[0033] X is N or CR 1 ;

[0034] Z is N or CR 3 ;

[0035] R 1 and R 3 independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl;

[0036] R 4 is selected from optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and

[0037] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0038] One embodiment provides a compound having the structure of formula (III) or a pharmaceutically acceptable salt or solvate thereof:

[0039]

[0040] in,

[0041] L is -CO-NH- or -NH-CO-;

[0042] A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N;

[0043] X is N or CR 1 ;

[0044] Y is N or CR 2 ;

[0045] Z is N or CR 3 ;

[0046] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; or optionally, R 1 and R 2 can be connected to form a ring; or optionally, R 2 and R 3 Can be connected to form a ring;

[0047] R 4 is selected from H, halogen or optionally substituted C1-C3 alkyl;

[0048] K is N or CH;

[0049] E is N or CH;

[0050] M is N or CR 5 ;

[0051] Q is N or CR 5 ;

[0052] T is N or CR 5 ;

[0053] Each R 5 independently selected from H, halogen or optionally substituted C1-C3 alkyl;

[0054]

[0055] G is selected from and

[0056] W is selected from:

[0057] an optionally substituted nitrogen-containing heterocyclic group;

[0058] an optionally substituted nitrogen-containing heteroaryl group;

[0059] optionally substituted carbocyclyl;

[0060] optionally substituted aryl;

[0061] an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group or an optionally substituted cycloalkylalkyl group;

[0062] optionally substituted nitrogen-containing heteroaryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl;

[0063] optionally substituted carbocyclyl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and

[0064] Optionally substituted aryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl.

[0065] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), (Ia), (Ib), (II) or (III), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.

[0066] One embodiment provides a method of treating a disease or condition in a patient in need thereof, comprising administering to the patient a compound of Formula (I), (Ia), (Ib), (II), or (III), or a pharmaceutically acceptable salt or solvate thereof. Another embodiment provides the method, wherein the disease or condition is cancer.

[0067] Incorporation by reference

[0068] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purpose identified herein. DETAILED DESCRIPTION

[0069] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, reference to "a cell" includes reference to one or more cells (or cells) known to those skilled in the art and equivalents thereof, and so forth. When ranges are used herein for physical properties (e.g., molecular weight) or chemical properties (e.g., chemical formula), all combinations and subcombinations of ranges and specific embodiments thereof are intended to be included. The term "about" when referring to a value or a range of values ​​means that the referenced value or range of values ​​is an approximation within experimental variability (or statistical experimental error), such that, in some cases, the value or range of values ​​will vary between 1% and 15% of the stated value or range of values. The term "comprising" (and related terms such as "including" or "containing" or "having" or "containing") is not intended to exclude certain other embodiments, for example, embodiments of any composition of matter, composition, method, process, etc. described herein, that "consist of" or "consist essentially of" the stated features.

[0070] definition

[0071] As used in the specification and appended claims, unless otherwise indicated, the following terms have the meanings indicated below.

[0072] "Amino" refers to a -NH2 group.

[0073] "Cyano" refers to a -CN group.

[0074] "Nitro" refers to a -NO2 group.

[0075] "Oxa" refers to an -O- group.

[0076] "Oxo" refers to a =0 group.

[0077] "Thio" refers to a =S group.

[0078] "Imino" refers to a =NH group.

[0079] "Oximo" refers to a =N-OH group.

[0080] "Hydrazino" refers to the =N-NH2 group.

[0081] "Alkyl" refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturated bonds, and having from one to fifteen carbon atoms (e.g., C1-C 15 In certain embodiments, the alkyl group contains from one to thirteen carbon atoms (e.g., C1-C 13 In certain embodiments, the alkyl group comprises one to eight carbon atoms (e.g., C1-C8 alkyl). In other embodiments, the alkyl group comprises one to five carbon atoms (e.g., C1-C5 alkyl). In other embodiments, the alkyl group comprises one to four carbon atoms (e.g., C1-C4 alkyl). In other embodiments, the alkyl group comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, the alkyl group comprises one to two carbon atoms (e.g., C1-C2 alkyl). In other embodiments, the alkyl group comprises one carbon atom (e.g., C1 alkyl). In other embodiments, the alkyl group comprises five to fifteen carbon atoms (e.g., C5-C 15In other embodiments, the alkyl group comprises five to eight carbon atoms (e.g., C5-C8 alkyl). In other embodiments, the alkyl group comprises two to five carbon atoms (e.g., C2-C5 alkyl). In other embodiments, the alkyl group comprises three to five carbon atoms (e.g., C3-C5 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl group is connected to the rest of the molecule by a single bond. Unless otherwise specified in the specification, the alkyl group is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a )C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a )2 (where t is 1 or 2), where each R aIn certain embodiments, optionally substituted alkyl is a haloalkyl. In other embodiments, optionally substituted alkyl is a fluoroalkyl. In other embodiments, optionally substituted alkyl is a -CF3 group.

[0082] "Alkoxy" refers to a group of the formula -O-alkyl bonded through an oxygen atom wherein the alkyl group is an alkyl chain as defined above.

[0083] "Alkenyl" refers to a straight or branched hydrocarbon chain group consisting only of carbon atoms and hydrogen atoms, containing at least one carbon-carbon double bond and having two to twelve carbon atoms. In certain embodiments, alkenyl comprises two to eight carbon atoms. In other embodiments, alkenyl comprises two to four carbon atoms. Alkenyl is connected to the rest of the molecule by a single bond, such as ethenyl (i.e., vinyl (vinyl)), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, etc. Unless otherwise specified in the specification, alkenyl is optionally substituted by one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oximino, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a )C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O)t R a (where t is 1 or 2) and -S(O) t N(R a )2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0084] "Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and having two to twelve carbon atoms. In certain embodiments, the alkynyl group comprises two to eight carbon atoms. In other embodiments, the alkynyl group comprises two to six carbon atoms. In other embodiments, the alkynyl group comprises two to four carbon atoms. The alkynyl group is connected to the rest of the molecule by a single bond, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc. Unless otherwise specifically stated in the specification, the alkynyl group is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oximino, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a )C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(Ra )2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0085] "Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain connected to the rest of the molecule and a group, which consists only of carbon and hydrogen, does not contain unsaturated bonds, and has one to twelve carbon atoms, such as methylene, ethylene, propylene, n-butylene, etc. The alkylene chain is connected to the rest of the molecule by a single bond and is connected to the group by a single bond. The point of attachment of the alkylene chain to the rest of the molecule and the point of attachment to the group are through one carbon in the alkylene chain or through any two carbons in the chain. In certain embodiments, the alkylene group comprises one to eight carbon atoms (e.g., C1-C8 alkylene). In other embodiments, the alkylene group comprises one to five carbon atoms (e.g., C1-C5 alkylene). In other embodiments, the alkylene group comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, the alkylene group comprises one to three carbon atoms (e.g., C1-C3 alkylene). In other embodiments, the alkylene group comprises one to two carbon atoms (e.g., C1-C2 alkylene). In other embodiments, the alkylene group comprises one carbon atom (e.g., C1 alkylene). In other embodiments, the alkylene group comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, the alkylene group comprises two to five carbon atoms (e.g., C2-C5 alkylene). In other embodiments, the alkylene group comprises three to five carbon atoms (e.g., C3-C5 alkylene). Unless otherwise specifically stated in the specification, the alkylene chain is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a)C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a )2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0086] "Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain connected to the rest of the molecule and a group, consisting only of carbon and hydrogen, containing at least one carbon-carbon double bond, and having two to twelve carbon atoms. The alkenylene chain is connected to the rest of the molecule by a single bond and is connected to the group by a single bond. In certain embodiments, the alkenylene comprises two to eight carbon atoms (e.g., C2-C8 alkenylene). In other embodiments, the alkenylene comprises two to five carbon atoms (e.g., C2-C5 alkenylene). In other embodiments, the alkenylene comprises two to four carbon atoms (e.g., C2-C4 alkenylene). In other embodiments, the alkenylene comprises two to three carbon atoms (e.g., C2-C3 alkenylene). In other embodiments, the alkenylene comprises two carbon atoms (e.g., C2 alkenylene). In other embodiments, the alkenylene comprises five to eight carbon atoms (e.g., C5-C8 alkenylene). In other embodiments, the alkenylene comprises three to five carbon atoms (e.g., C3-C5 alkenylene). Unless otherwise specifically stated in the specification, the alkenylene chain is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a )C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a )2 (where t is 1 or 2), where each R a and R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0087] "Alkynylidene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain connected to the rest of the molecule and a group, consisting only of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having two to twelve carbon atoms. The alkynylene chain is connected to the rest of the molecule by a single bond and is connected to the group by a single bond. In certain embodiments, the alkynylene comprises two to eight carbon atoms (e.g., C2-C8 alkynylene). In other embodiments, the alkynylene comprises two to five carbon atoms (e.g., C2-C5 alkynylene). In other embodiments, the alkynylene comprises two to four carbon atoms (e.g., C2-C4 alkynylene). In other embodiments, the alkynylene comprises two to three carbon atoms (e.g., C2-C3 alkynylene). In other embodiments, the alkynylene comprises two carbon atoms (e.g., C2 alkynylene). In other embodiments, the alkynylene comprises five to eight carbon atoms (e.g., C5-C8 alkynylene). In other embodiments, the alkynylene comprises three to five carbon atoms (e.g., C3-C5 alkynylene). Unless otherwise specifically stated in the specification, the alkynylene chain is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a 、-SR a 、-OC(O)-R a 、-N(R a )2、-C(O)R a 、-C(O)OR a 、-C(O)N(R a )2、-N(R a )C(O)OR a 、-OC(O)-N(R a )2、-N(R a )C(O)R a 、-N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is 1 or 2) and -S(O) t N(R a )2 (where t is 1 or 2), where each R aand R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl).

[0088] "Aryl" refers to a radical derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing hydrogen atoms from ring carbon atoms. An aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon, has five to eighteen carbon atoms, wherein at least one ring in the ring system is fully unsaturated, that is, it contains a cyclic delocalized (4n+2) π electron system according to the Huckel theory. Ring systems from which aryl groups are derived include, but are not limited to, the following groups: benzene, fluorene, indane, indene, tetralin and naphthalene. Unless otherwise specified in the specification, the term "aryl" or the prefix "ar-" (e.g., "aralkyl") is intended to include aryl groups optionally substituted with one or more substituents independently selected from the following groups: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, cyano, nitro, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(Ra )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein R a 、R b or R c Each of the substituents is unsubstituted unless otherwise specified.

[0089] "Aralkyl" refers to a group of the formula -R c -aryl groups, where R c is an alkylene chain as defined above, for example, methylene, ethylene, etc. The alkylene chain portion of the aralkyl group is optionally substituted as described above for the alkylene chain. The aryl portion of the aralkyl group is optionally substituted as described above for the aryl group.

[0090] "Aralkenyl" refers to a group of the formula -R d -aryl groups, where R d is an alkenylene chain as defined above. The aryl portion of the aralkenyl group is optionally substituted as described above for aryl groups. The alkenylene chain portion of the aralkenyl group is optionally substituted as defined above for alkenyl groups.

[0091] "Arylalkynyl" refers to a group of the formula -R e -aryl groups, where R eis an alkynylene chain as defined above. The aryl portion of the aralkynyl group is optionally substituted as described above for an aryl group. The alkynylene chain portion of the aralkynyl group is optionally substituted as defined above for an alkynylene chain.

[0092] "Aralkyloxy" refers to a group of the formula -OR c - an aryl group bonded through an oxygen atom, wherein R c is an alkylene chain as defined above, for example, methylene, ethylene, etc. The alkylene chain portion of the aralkyl group is optionally substituted as described above for the alkylene chain. The aryl portion of the aralkyl group is optionally substituted as described above for the aryl group.

[0093] "Carbocyclyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting only of carbon atoms and hydrogen atoms, including fused ring systems or bridged ring systems, with three to fifteen carbon atoms. In certain embodiments, the carbocyclyl comprises three to ten carbon atoms. In other embodiments, the carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is connected to the rest of the molecule via a single bond. The carbocyclyl is saturated (i.e., only contains a C-C single bond) or unsaturated (i.e., contains one or more double bonds or triple bonds). Fully saturated carbocyclyls are also referred to as "cycloalkyls." Examples of monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Unsaturated carbocyclyls are also referred to as "cycloalkenyls." Examples of monocyclic cycloalkenyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic carbocyclyl includes, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. Unless otherwise specified in the specification, the term "carbocyclyl" is intended to include carbocyclyl groups optionally substituted by one or more substituents independently selected from the following groups: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, oxo, thioxo, cyano, nitro, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c-C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein R a 、R b or R c Each of the substituents is unsubstituted unless otherwise specified.

[0094] "Carbocyclylalkyl" refers to a group of the formula -R c -carbocyclic group, wherein R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl group are optionally substituted as defined above.

[0095] "Carbocyclylalkynyl" refers to a group of the formula -R c -carbocyclic group, wherein R c is an alkynylene chain as defined above. The alkynylene chain and the carbocyclyl group are optionally substituted as defined above.

[0096] "Carbocyclylalkoxy" refers to a group of the formula -OR c -Carbocyclic group bonded through an oxygen atom, wherein R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl group are optionally substituted as defined above.

[0097] "Halo" or "halogen" refers to a bromo, chloro, fluoro, or iodo substituent.

[0098] "Fluoroalkyl" refers to an alkyl group as defined above substituted with one or more fluoro groups as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group is optionally substituted as defined above for an alkyl group.

[0099] "Heterocyclyl" refers to a stable 3 to 18-membered non-aromatic ring group containing two to twelve carbon atoms and one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless otherwise specified in the specification, the heterocyclyl is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which optionally includes a fused ring system or a bridged ring system. The heteroatoms in the heterocyclyl are optionally oxidized. One or more nitrogen atoms (if present) are optionally quaternized. The heterocyclyl is partially saturated or fully saturated. The heterocyclyl is connected to the rest of the molecule through any atom of the ring. Examples of such heterocyclic groups include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidineyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specified in the specification, the term "heterocyclyl" is intended to include heterocyclyl as defined above which is optionally substituted by one or more substituents selected from the group consisting of optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, fluoroalkyl, oxo, thioxo, cyano, nitro, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -Rb -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b -N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein R a 、R b or R c Each of the substituents is unsubstituted unless otherwise specified.

[0100] "N-heterocyclyl" or "N-linked heterocyclyl" refers to a heterocyclyl as defined above containing at least one nitrogen atom, wherein the point of attachment of the heterocyclyl to the rest of the molecule is through the nitrogen atom in the heterocyclyl. N-heterocyclyl groups are optionally substituted as described above for heterocyclyl groups. Examples of such N-heterocyclyl groups include, but are not limited to, 1-morpholinyl, 1-piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, imidazolinyl, and imidazolidinyl.

[0101] "C-heterocyclyl" or "C-linked heterocyclyl" refers to a heterocyclyl as defined above containing at least one heteroatom, wherein the point of attachment of the heterocyclyl to the rest of the molecule is through a carbon atom in the heterocyclyl. C-heterocyclyl groups are optionally substituted as described above for heterocyclyl groups. Examples of such C-heterocyclyl groups include, but are not limited to, 2-morpholinyl, 2-, 3-, or 4-piperidinyl, 2-piperazinyl, 2- or 3-pyrrolidinyl, and the like.

[0102] "Heterocyclylalkyl" refers to a group of the formula -R c -heterocyclic group, wherein R c is an alkylene chain as defined above. If the heterocyclyl group is a nitrogen-containing heterocyclyl group, the heterocyclyl group is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heterocyclylalkyl group is optionally substituted as defined above for an alkylene chain. The heterocyclyl portion of the heterocyclylalkyl group is optionally substituted as defined above for a heterocyclyl group.

[0103] "Heterocyclylalkoxy" refers to a group of the formula -OR c - a heterocyclic group bonded through an oxygen atom, wherein R c is an alkylene chain as defined above. If the heterocyclyl group is a nitrogen-containing heterocyclyl group, the heterocyclyl group is optionally attached to an alkyl group at the nitrogen atom. The alkylene chain of the heterocyclylalkoxy group is optionally substituted as defined above for an alkylene chain. The heterocyclyl portion of the heterocyclylalkoxy group is optionally substituted as defined above for a heterocyclyl group.

[0104] "Heteroaryl" refers to a group derived from a 3- to 18-membered aromatic ring group containing two to seventeen carbon atoms and one to six heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, a heteroaryl is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system in which at least one ring in the ring system is fully unsaturated, that is, it contains a cyclic, delocalized (4n+2)π electron system according to the Huckel theory. Heteroaryls include fused ring systems or bridged ring systems. The heteroatoms in the heteroaryl are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl group is connected to the rest of the molecule through any atom of the ring. Examples of heteroaryls include, but are not limited to, aza 1,4-Benzodixanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzo benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, pentacyclyl[d]pyrimidinyl, 6,7-dihydro-5H-pentacyclyl[4,5]thiazolyl, pheno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]heptylcyclo[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanone, furano[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrooctylcyclo[d]pyrimidinyl, 5,6,7, 8,9,10-hexahydrooctylcyclo[d]pyridazinyl, 5,6,7,8,9,10-hexahydrooctylcyclo[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinone, oxadiazolyl, 2-oxoazepine yl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5-[[(4-d]-1-methyl-2-oxazol-1-yl)-1H-pyrrolyl]-1H-pyrrolyl]-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5-[[(4-d]-1-methyl-2-oxazol-1-yl)-1H-pyrrolyl]-1H-pyrrolyl, ,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-heptacyclyl[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl and thiophenyl (i.e., thienyl). Unless otherwise specified in the specification, the term "heteroaryl" is intended to include heteroaryl groups as defined above that are optionally substituted by one or more substituents selected from the following groups: optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halogen, optionally substituted fluoroalkyl, optionally substituted haloalkenyl, optionally substituted haloalkynyl, oxo, thioxo, cyano, nitro, -R b -OR a 、-R b -OC(O)-R a 、-R b -OC(O)-OR a 、-R b -OC(O)-N(R a )2. -R b -N(R a )2. -R b -C(O)R a 、-R b -C(O)OR a 、-R b -C(O)N(R a )2. -R b -OR c -C(O)N(R a )2. -R b -N(R a )C(O)OR a 、-R b -N(R a )C(O)R a 、-R b-N(R a )S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where each R a R is independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl) or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy or trifluoromethyl), each R b are independently a direct bond or a straight or branched alkylene or alkenylene chain, and R c is a straight or branched alkylene or alkenylene chain, and wherein R a 、R b or R c Each of the substituents is unsubstituted unless otherwise specified.

[0105] "N-heteroaryl" refers to a heteroaryl group as defined above containing at least one nitrogen atom, wherein the point of attachment of the heteroaryl group to the rest of the molecule is through the nitrogen atom in the heteroaryl group. N-heteroaryl groups are optionally substituted as described above for heteroaryl groups.

[0106] "C-heteroaryl" refers to a heteroaryl group as defined above, wherein the point of attachment of the heteroaryl group to the rest of the molecule is through a carbon atom in the heteroaryl group. A C-heteroaryl group is optionally substituted as described above for a heteroaryl group.

[0107] "Heteroarylalkyl" refers to a group of the formula -R c -heteroaryl groups, wherein R cis an alkylene chain as defined above. If the heteroaryl group is a nitrogen-containing heteroaryl group, the heteroaryl group is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkyl group is optionally substituted as defined above for the alkylene chain. The heteroaryl portion of the heteroarylalkyl group is optionally substituted as defined above for the heteroaryl group.

[0108] "Heteroarylalkoxy" refers to a group of the formula -OR c - a heteroaryl group bonded through an oxygen atom, wherein R c is an alkylene chain as defined above. If the heteroaryl group is a nitrogen-containing heteroaryl group, the heteroaryl group is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkoxy group is optionally substituted as defined above for an alkylene chain. The heteroaryl portion of the heteroarylalkoxy group is optionally substituted as defined above for a heteroaryl group.

[0109] In some embodiments, compounds disclosed herein contain one or more asymmetric centers, thus producing enantiomers, diastereomers and other stereoisomeric forms defined as (R)- or (S)- in terms of absolute stereochemistry. Unless otherwise stated, by this disclosure, it is intended to consider all stereoisomeric forms of compounds disclosed herein. When compounds as described herein contain olefinic double bonds, unless otherwise stated, this disclosure is intended to include E and Z geometric isomers (such as cis or trans). Similarly, it is also intended to include all possible isomers and racemates thereof and optically pure forms and all tautomeric forms. The term "geometric isomer" refers to the E or Z geometric isomers (such as cis or trans) of olefinic double bonds. The term "positional isomer" refers to the structural isomers around the central ring, such as ortho isomers, meta isomers and para isomers around the phenyl ring.

[0110] "Tautomers" refer to molecules in which a proton transfer from one atom of the molecule to another atom of the same molecule can occur. In certain embodiments, the compounds described herein exist as tautomers. Where tautomerization is possible, the tautomers will exist in chemical equilibrium. The exact ratio of the tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibrium include:

[0111]

[0112] In some embodiments, the compounds disclosed herein are used in different isotopically enriched forms, such as 2 H. 3 H. 11 C. 13 C and / or 14In a specific embodiment, the compound is deuterated at at least one position. Such deuterated forms can be prepared by the methods described in U.S. Patent Nos. 5,846,514 and 6,334,997. As described in U.S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve metabolic stability and / or therapeutic efficacy, thereby extending the duration of action of the drug.

[0113] Unless otherwise stated, structures depicted herein are intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, except for the replacement of hydrogen by deuterium or tritium, or by enriched 13 C or 14 Compounds having the present structure in which the carbon of C is substituted for the carbon of C are within the scope of this disclosure.

[0114] The compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, isotopes such as deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C) Label the compound. 2 H. 11 C. 13 C. 14 C. 15 C. 12 N. 13 N. 15 N. 16 N. 16 O. 17 O. 14 F. 15 F. 16 F. 17 F. 18 F. 33 S. 34 S. 35 S. 36 S. 35 Cl, 37 Cl, 79 Br, 81 Br, 125 Isotopic substitutions of I are all contemplated. In some embodiments, it is contemplated to use 18 Isotopic substitution of F. All isotopic variations of the compounds of the present invention, whether radioactive or not, are encompassed within the scope of the present invention.

[0115] In certain embodiments, some or all of the compounds disclosed herein 1 H atoms are 2Synthetic methods for deuterium-containing compounds are known in the art and include the following synthetic methods which are provided by way of non-limiting example only.

[0116] Deuterium-substituted compounds can be synthesized using various methods such as those described in Dean, Dennis C.; Editors. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6(10)] 2000, 110pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0117] Deuterated starting materials are readily available and can be subjected to the synthetic methods described herein to provide the synthesis of deuterium-containing compounds. A large number of deuterium-containing reagents and molecular building blocks are commercially available from chemical suppliers (eg, Aldrich Chemical Co.).

[0118] Deuterium transfer reagents suitable for nucleophilic substitution reactions (e.g., iodomethane-d3 (CD3I)) are readily available and can be used to transfer a deuterated carbon atom to a reaction substrate under nucleophilic substitution reaction conditions. The use of CD3I is illustrated in the following reaction schemes as an example only.

[0119]

[0120] Deuterium transfer reagents such as lithium aluminum deuteride (LiAlD4) can be used to transfer deuterium to the reaction substrate under reducing conditions. By way of example only, the use of LiAlD4 is illustrated in the following reaction schemes.

[0121]

[0122] Deuterium gas and palladium catalysts can be used to reduce unsaturated carbon-carbon bonds and to perform reductive substitution of aryl carbon-halogen bonds, by way of example only, as shown in the following reaction schemes.

[0123]

[0124] In one embodiment, the compounds disclosed herein contain one deuterium atom. In another embodiment, the compounds disclosed herein contain two deuterium atoms. In another embodiment, the compounds disclosed herein contain three deuterium atoms. In another embodiment, the compounds disclosed herein contain four deuterium atoms. In another embodiment, the compounds disclosed herein contain five deuterium atoms. In another embodiment, the compounds disclosed herein contain six deuterium atoms. In another embodiment, the compounds disclosed herein contain more than six deuterium atoms. In another embodiment, the compounds disclosed herein are completely substituted with deuterium atoms and do not contain non-exchangeable deuterium atoms. 1 H hydrogen atoms. In one embodiment, the level of deuterium incorporation is determined by a synthesis method in which deuterated synthetic molecular building blocks are used as starting materials.

[0125] "Pharmaceutically acceptable salts" include acid addition salts and base addition salts. Pharmaceutically acceptable salts of any of the RAF-inhibiting compounds described herein are intended to include any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

[0126] "Pharmaceutically acceptable acid addition salts" refers to those salts which retain the biological effectiveness and properties of the free bases and which are not biologically or otherwise undesirable and which can be formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like, including, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Thus, exemplary salts include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, trifluoroacetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzenesulfonate, toluenesulfonate, phenylacetate, citrate, lactate, malate, tartrate, methanesulfonate, etc. Salts of amino acids, such as arginine, gluconate, and galacturonate, are also contemplated (see, e.g., Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66: 1-19 (1997)). In some embodiments, the acid addition salts of basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt according to methods and techniques familiar to skilled artisans.

[0127] "Pharmaceutically acceptable base addition salts" refers to salts that retain the biological effectiveness and properties of the free acid and are not biologically or otherwise undesirable. These salts are prepared by adding inorganic or organic bases to the free acid. In some embodiments, pharmaceutically acceptable base addition salts are formed with metals or amines (e.g., alkali metals and alkaline earth metals or organic amines). Salts derived from inorganic bases include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenediphenylamine, N-methylglucamine, glucamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-methylpiperidine, polyamine resins, and the like. See Berge et al., supra.

[0128] "Pharmaceutically acceptable solvate" refers to a composition of matter in the form of a solvent addition. In some embodiments, the solvate contains a stoichiometric or non-stoichiometric amount of solvent and can be formed in processes prepared with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is an alcohol. Solvates of the compounds described herein can be conveniently prepared or formed in the methods described herein. The compounds provided herein optionally exist in unsolvated and solvated forms.

[0129] The term "subject" or "patient" includes mammals. Examples of mammals include, but are not limited to, any member of the class mammalia: humans, non-human primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents such as rats, mice, and guinea pigs, etc. In one aspect, the mammal is a human.

[0130] As used herein, "treatment" or "treating," "alleviate," or "improve" are used interchangeably. These terms refer to an approach for obtaining beneficial or desired results, including, but not limited to, a therapeutic benefit and / or a prophylactic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying condition being treated. Furthermore, therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying condition, such that improvement is observed in the patient, although the patient still suffers from the underlying condition. For prophylactic benefit, in some embodiments, the composition is administered to a patient at risk for developing a particular disease, or to a patient reporting one or more physiological symptoms of a disease, although a diagnosis of such disease has not yet been made.

[0131] RAF kinase family

[0132] RAF kinases are a family of serine / threonine protein kinases that form core components of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signaling cascade (also known as the MAPK / ERK pathway, which mediates signals from cell surface receptors to the nucleus to regulate cell growth, differentiation, and survival). RAF proteins are related to retroviral oncogenes and are structurally conserved from metazoans to mammals, as is the MAPK / ERK pathway. Their dysregulation leads to uncontrolled cell proliferation, survival, and dedifferentiation. Consequently, RAF kinases are altered or inappropriately activated in most cancers.

[0133] The MAPK / ERK signaling pathway is a network of proteins in cells that transmits signals from receptors on the cell surface to DNA in the cell nucleus. Signaling is initiated when signaling molecules bind to cell surface receptors, and terminated when proteins are expressed from the DNA in the nucleus, causing changes in the cell (e.g., cell division). The pathway involves numerous proteins that transmit information by adding phosphate groups to neighboring proteins (which act as molecular "on" or "off" switches). Generally speaking, the pathway can be divided into three steps: (i) Ras activation, (ii) the kinase signaling cascade, and (iii) regulation of translation and transcription. Briefly, extracellular mitogens, or signaling molecules, bind to membrane receptors. This allows Ras (a small GTPase) to convert its GDP to GTP and become activated. Activated Ras activates the protein kinase activity of RAF kinases. RAF kinases phosphorylate and activate MEKs (MEK1 and MEK2). MEKs then phosphorylate and activate MAPKs (also known as ERKs). MAPK activation regulates the activity of several transcription factors and also alters the translation of mRNA into protein. By altering the levels and activity of transcription factors, MAPKs cause transcriptional changes in genes important for the cell cycle.

[0134] There are three known mammalian RAF isoforms: C-RAF (also known as RAF-1 or c-RAF-1), B-RAF and A-RAF. All RAF kinases share a common modular structure composed of three conserved regions (CR1, CR2 and CR3) with different functions. CR1 contains: (i) a Ras binding domain (RBD), which is required for interaction with Ras and with membrane phospholipids required for membrane recruitment; and (ii) a cysteine-rich domain (CRD), which is a secondary Ras binding site and is also required for interaction of CR1 with the kinase domain for RAF autoinhibition. CR2 contains an important inhibitory phosphorylation site that is involved in the negative regulation of Ras binding and RAF activation. CR3 is characterized by a kinase domain that includes an activation segment, the phosphorylation of which is critical for kinase activation.

[0135] Functionally, the RAF structure can be divided into a regulatory N-terminal region containing the RBD (which is essential for activation) and inhibitory phosphorylation sites, and a catalytic C-terminal region including phosphorylation sites required for kinase activation. The regulatory domain inhibits the activity of the kinase domain, and its removal leads to constitutive oncogenic activation. However, the activity of the isolated C-RAF kinase domain is further regulated and can be stimulated by phorbol esters, v-Src, and phosphorylation.

[0136] A key step common to the activation of all three RAF kinase isoforms is the membrane recruitment of Ras family proteins. When bound to 14-3-3 proteins, RAF kinases are located in the cytosol in an inactive state. In the presence of active Ras, they translocate to the plasma membrane. Membrane translocation triggers further activation events, such as PP2A binding, which dephosphorylates the inhibitory pS259 site in RAF-1 (and potentially corresponding sites in A-RAF and B-RAF), and colocalizes with kinases responsible for multiple activating phosphorylations. The sequences forming the binding interface are highly conserved among the RAF and Ras families, indicating that several members of the Ras family have the ability to bind to RAF kinases. H-Ras, N-Ras, and K-Ras can stimulate all three RAF isoforms and are the only Ras proteins that can activate B-RAF. In contrast, A-RAF can also be activated by R-Ras3, while C-RAF responds equally weakly to R-Ras3, Rit, and TC21. However, all RAF kinases share MEK1 / 2 kinases as substrates. MEK1 / 2 in turn activate ERK1 / 2, a pathway that regulates many cellular functions, such as cell proliferation, differentiation, migration, or apoptosis.

[0137] C-RAF

[0138] C-RAF was the first to be identified and is the ubiquitously expressed isoform. In humans, C-RAF is encoded by the RAF1 gene. C-RAF also has a known splice variant that is preferentially expressed in muscle and brain. C-RAF plays a key role in mediating the cellular effects of growth factor signaling. In its inactive state, C-RAF exists in a closed conformation, in which the N-terminal regulatory region folds and blocks the catalytic region. This conformation is stabilized by binding of a 14-3-3 dimer to the N-terminal site phospho-S259 (pS259) and the C-terminal site pS621. Dephosphorylation of pS259 at the cell membrane by specific phosphatases (PP2A, PP1) releases 14-3-3 from the N-terminal binding site in C-RAF, allowing for conformational changes that unmask the RBD and CRD domains in the CR1 region, enabling Ras binding and membrane recruitment.

[0139] B-RAF

[0140] B-RAF is encoded by the BRAF gene (also known as proto-oncogene B-RAF and v-RAF murine sarcoma viral oncogene homolog B) in humans. Alternative splicing produces a variety of B-RAF isoforms, which are differentially expressed in various tissues. The activation of A-RAF and C-RAF requires phosphorylation and dephosphorylation of certain residues and the combination with other proteins, while B-RAF is activated immediately after translocation to the plasma membrane. B-RAF exhibits a higher basal kinase activity than A-RAF and C-RAF. B-RAF requires Ras and 14-3-3 to be combined for its activation, and is inhibited or activated by PKA according to the level of 14-3-3-3 expression, wherein high levels of 14-3-1 expression are required to allow activation. B-RAF activity is also regulated by splicing. B-RAF isoforms containing exon 8b are more highly phosphorylated at the inhibitory S365 site, resulting in increased interaction with 14-3-3 and enhanced inhibitory interaction between the N-terminal regulatory domain and the kinase domain, together leading to lower kinase activity.

[0141] A-RAF

[0142] The serine / threonine protein kinase A-RAF, or A-RAF, is an enzyme encoded by the ARAF gene in humans. A-RAF exists in two known splice isoforms: DA-RAF1 and D-RAF2. These lack the kinase domain and act as dominant inhibitory mutants of the Ras and ARF GTPases. DA-RAF1 acts as a positive regulator of myogenic differentiation by inhibiting the ERK pathway, which is required for differentiation. A-RAF differs from other RAF kinases in several ways. A-RAF is the only RAF isoform regulated by steroid hormones. Furthermore, the A-RAF protein possesses amino acid substitutions in a negatively charged region upstream of the kinase domain (N region), resulting in low basal activity. A-RAF is also only weakly activated by oncogenic H-Ras and Src and exhibits low kinase activity against MEK (the lowest kinase activity against MEK proteins among the RAF kinase family). In addition to phosphorylating MEK, A-RAF also inhibits MST2, a tumor suppressor and pro-apoptotic kinase not found in the MAPK pathway. By inhibiting MST2, A-RAF prevents apoptosis. However, this inhibition only occurs when the splicing factor heterogeneous nuclear ribonucleoprotein H (hnRNP H) maintains full-length A-RAF protein expression. Tumor cells often overexpress hnRNP H, which leads to full-length A-Raf expression. A-Raf then inhibits apoptosis, allowing cancer cells that should be destroyed to remain alive. A-RAF also binds to pyruvate kinase M2 (PKM2), also outside the MAPK pathway. PKM2 is an isoenzyme of pyruvate kinase that is responsible for the Warburg effect in cancer cells. A-RAF upregulates PKM2 activity by promoting conformational changes in PKM2. This causes PKM2 to transform from its less active dimer form to a more active tetramer form. This results in more glucose carbons being converted to pyruvate and lactate, generating energy for the cell, thereby linking A-Raf to energy metabolism regulation and cellular transformation, both of which are very important in tumorigenesis.

[0143] BRAF-targeted therapy for CNS tumors and / or brain metastases

[0144] Patients with brain involvement have a poor prognosis, and their treatment is an unmet medical need. In the case of melanoma, brain metastases are usually the first site of disease progression (Cohn-Cedermark, G. et al., Central nervous system metastases of cutaneous malignant melanoma—A population-based study. Acta Oncol. 1998, 37, 463-470). Metastatic CNS invasion is a multi-step process. Primary tumor cells initially enter the blood circulation and then spread hematogenously until they stop in the capillary bed of the organ, where they proliferate and form metastases (Redmer, T. Deciphering mechanisms of brain metastasis in melanoma—The gist of the matter. Mol. Cancer 2018, 17, 106; Tawbi, HA et al., New era in the management of melanoma brain metastases. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 741-750). One drawback of current therapies is the inability of small molecule RAF kinase inhibitors to cross the blood-brain barrier, thereby preventing the delivery of therapeutically effective amounts of the inhibitors to the site of CNS tumors and / or brain metastases.

[0145] Determination of blood-brain barrier permeability of small molecules

[0146] In drug development, CNS drug candidates have lower success rates and longer development times than drug candidates in other therapeutic areas. (Di, L. et al., Expert Opinion on Drug Discovery (2008) 3:6, 677-687. DOI: 10.1517 / 17460441.3.6.677) The low brain penetration of small molecules may be attributed to several factors, including but not limited to low blood-brain barrier (BBB) ​​permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding.

[0147] There are multiple mechanisms that influence the brain permeability of molecules. Compounds can enter the brain by passive diffusion across cells, which is driven by the concentration gradient between the blood and the brain. The brain permeability of compounds can be enhanced by influx transporters such as the large neutral amino acid transporter 1 (LAT1) for levodopa and gabapentin (Ohtsuki et al., Pharm. Res. 2007, 24, 1745-58; Gynther et al., J. Med. Chem. 2008, 51(4), 932-936). This requires that the compound has certain structural motifs to bind to the transporter. Only a few examples have been reported where this pathway has been specifically used to increase brain permeability. Efflux transporters move molecules out of cells. The efflux transporter Pgp is crucial for brain permeability. Plasma protein binding (which reduces the free drug concentration available for BBB penetration) as well as metabolism and renal excretion (which reduce the total blood concentration) also affect brain permeability. In general, passive diffusion is the primary driving force for the movement of most molecules into the brain; however, depending on the structure and properties of the compound, other mechanisms discussed above may reduce brain permeability.

[0148] Bioanalytical methods and screening strategies provide a theoretical basis for designing and evaluating compounds with desired BBB distribution properties. (Di, L. et al., Expert Opinion on Drug Discovery (2008) 3:6, 677-687; Summerfield et al., J. Pharmacol. Exp. Ther. (2016) 358:294-305) A good proxy for brain distribution is based on the ratio of unbound compound in brain extracellular fluid to unbound blood concentration, which is expressed as Kp,uu (Liu and Chen, Blood-Brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs (2015), p.42-65, Wiley & Sons). Kp,uu is a steady-state distribution term that represents the unbound concentration gradient across the BBB. If Kp,uu is less than 1, the drug's passage through the BBB is limited by some factor. If Kp,uu is greater than 1, then drug passage across the BBB is assisted in some way. A Kp,uu value of approximately 1 indicates that passive diffusion across the BBB is dominant, or that active pathways (e.g., influx and efflux) are balanced (Summerfield et al., supra).

[0149] RAF kinase inhibitors

[0150] Aberrant activation of the MAPK / ERK pathway is frequently found in various cancers and is a target for cancer therapy. In particular, B-RAF has become one of the most attractive molecular targets for cancer therapy because somatic mutations in B-RAF are frequently found in human tumors. Approximately 20% of all cancer samples tested to date carry B-RAF mutations. B-RAF-V600E (a missense mutation in the kinase domain resulting from the substitution of glutamic acid at position 600 for valine) is the most common B-RAF mutation. C-RAF mutations occur in approximately 1% of the various tumor types tested, while the mutation rate for A-RAF is even lower. B-RAF and C-RAF form homodimers and heterodimers as part of their activation mechanism, with A-RAF stabilizing the B-RAF:C-RAF complex to maintain signaling efficiency. Furthermore, it is C-RAF, not B-RAF, that transmits the signal from oncogenic RAS to MEK. Therefore, each RAF isoform serves as a potential therapeutic target in different contexts.

[0151] Sorafenib was the first RAF inhibitor to enter clinical trials. Sorafenib is a broadly specific drug that inhibits other kinases, including the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3), the platelet-derived growth factor receptor family (PDGFR-b and KIT), and FLT3. Clinical trials have shown no correlation between clinical response and B-RAF mutation status, indicating that it is a poor inhibitor of B-RAF. This has led to the development of a new generation of B-RAF inhibitors, including but not limited to vemurafenib, SB-590885, and dabrafenib (GSK2118436). Although preliminary results from clinical studies of B-RAF-mutant melanomas are encouraging, as clinical trials of other B-RAF-mutant cancers (such as thyroid cancer and colorectal cancer) begin, it has become apparent that tumors of different cell types carrying B-RAF mutations have different responses to selective B-RAF inhibition. In addition, the existence of primary and secondary resistance to RAF inhibition is one of the biggest challenges in the advancement of RAF kinase inhibitor therapy. Resistance mechanisms are divided into two major categories. Approximately 50% of patients exhibit intrinsic / primary resistance. The other 50% initially respond to RAF inhibitors (>30% tumor shrinkage) but subsequently develop progressive disease associated with acquired / secondary resistance to RAF inhibitors. These two categories are not mutually exclusive, as nearly all responders have residual disease and therefore may exhibit intrinsic resistance. Determinants of primary RAF inhibitor resistance appear to vary by tumor type and also involve alterations in RTK signaling. Potential mechanisms of secondary B-RAF inhibitor resistance include, but are not limited to, reactivation of the ERK1 / 2 pathway, upregulation of RTK signaling, upregulation of receptor tyrosine kinases, mutations in RAS, and upregulation of COT. B-Raf alternative splicing and amplification of B-RAF-V600E are also implicated in approximately 30% and 20% of patients, respectively. Furthermore, RAF kinase inhibitors can cause paradoxical activation of the MAPK pathway, which in some cases leads to the development of malignancies driven by secondary RAS mutations. Therefore, there is a need in the art for new RAF kinase inhibitors that can overcome the existing deficiencies and challenges posed by existing inhibitors.

[0152] RAF inhibitory compounds

[0153] In one aspect, provided herein is a RAF inhibiting compound.

[0154] One embodiment provides a compound having the structure of formula (I) or a pharmaceutically acceptable salt or solvate thereof:

[0155]

[0156] in,

[0157] A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N;

[0158] X is N or CR 1 ;

[0159] Y is N or CR 2 ;

[0160] Z is N or CR 3 ;

[0161] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0162] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0163] One embodiment provides a compound having the structure of Formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:

[0164]

[0165] in,

[0166] X is N or CR 1 ;

[0167] Y is N or CR 2 ;

[0168] Z is N or CR 3 ;

[0169] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0170] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0171] One embodiment provides a compound having the structure of Formula (Ib) or a pharmaceutically acceptable salt or solvate thereof:

[0172]

[0173] in,

[0174] X is N or CR 1 ;

[0175] Y is N or CR 2 ;

[0176] Z is N or CR 3 ;

[0177] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted cycloalkylalkyl; and

[0178] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0179] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 .

[0180] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N and Z is N.

[0181] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is N.

[0182] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N, and Z is CR 3 .

[0183] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is CR 3 .

[0184] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , Y is N, and Z is N.

[0185] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , Y is CR 2 , and Z is N.

[0186] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , Y is N, and Z is CR 3 .

[0187] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , Y is CR 2 , and Z is CR 3 .

[0188] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 .

[0189] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is N.

[0190] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is N.

[0191] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is CR 3 .

[0192] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is CR 3 .

[0193] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR2 , X is N, and Z is N.

[0194] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , X is CR 1 , and Z is N.

[0195] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , X is N, and Z is CR 3 .

[0196] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , X is CR 1 , and Z is CR 3 .

[0197] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 .

[0198] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Y is N.

[0199] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is N.

[0200] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Y is CR 2 .

[0201] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is CR 2 .

[0202] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 , X is N, and Y is N.

[0203] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 , X is CR 1 , and Y is N.

[0204] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 , X is N, and Y is CR 2 .

[0205] One embodiment provides a compound of formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 , X is CR 1 , and Y is CR 2 .

[0206] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For H.

[0207] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 It is a halogen.

[0208] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For fluorine.

[0209] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

[0210] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl.

[0211] One embodiment provides a compound of Formula (I), (Ia) or (Ib), or a pharmaceutically acceptable salt or solvate thereof, wherein R 2Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0212] One embodiment provides a compound having the structure of formula (II) or a pharmaceutically acceptable salt or solvate thereof:

[0213]

[0214] in,

[0215] X is N or CR 1 ;

[0216] Z is N or CR 3 ;

[0217] R 1 and R 3 independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl;

[0218] R 4 is selected from optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and

[0219] W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted with an optionally substituted cycloalkyl group.

[0220] One embodiment provides a compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is N.

[0221] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is N.

[0222] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is CR 3 .

[0223] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is CR 3 .

[0224] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups. Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

[0225] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl. One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0226] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For H.

[0227] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is a halogen.

[0228] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For fluorine.

[0229] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

[0230] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl.

[0231] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0232] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 For H.

[0233] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a halogen.

[0234] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 For fluorine.

[0235] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

[0236] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl.

[0237] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0238] One embodiment provides a compound of formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic group. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from optionally substituted pyrrolidine, optionally substituted 2,5-dihydro-1H-pyrrole, optionally substituted piperidine or optionally substituted 1,2,3,6-tetrahydropyridine. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0239]

[0240] and

[0241] where R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF3, -CH2CHF2 or -C(CH3)2CF3.

[0242] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heteroaryl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted pyridyl, an optionally substituted pyrimidyl, an optionally substituted triazinyl or an optionally substituted pyrrolyl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0243] and

[0244] where R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF3, -CH2CHF2 or -C(CH3)2CF3.

[0245] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazyl, optionally substituted imidazolyl, optionally substituted triazolyl or optionally substituted tetrazolyl.

[0246] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazin-3-yl, optionally substituted pyrazin-4-yl, optionally substituted pyrazin-5-yl, optionally substituted imidazol-4-yl or optionally substituted imidazol-5-yl.

[0247] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted 1,2,3-triazol-4-yl, optionally substituted 1,2,3-triazol-5-yl or optionally substituted 1,2,4-oxadiaz-5-yl.

[0248] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted oxazol-2-yl, optionally substituted oxazol-4-yl or optionally substituted oxazol-5-yl.

[0249] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted thiazol-2-yl, optionally substituted thiazol-4-yl or optionally substituted thiazol-5-yl.

[0250] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclyl further substituted with an optionally substituted cycloalkyl or an optionally substituted nitrogen-containing heteroaryl further substituted with an optionally substituted cycloalkyl.

[0251] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0252]

[0253] And R 5 It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

[0254] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0255] And R 5It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

[0256] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0257]

[0258] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0259]

[0260] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0261]

[0262] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted aryl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted phenyl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is And R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF3, -CH2CHF2 or -C(CH3)2CF3.

[0263] One embodiment provides a compound of Formula (I), (Ia), (Ib) or (II), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted aryl further substituted with optionally substituted cycloalkyl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is And R 5 Selected from 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

[0264] One embodiment provides a compound having the structure of formula (III) or a pharmaceutically acceptable salt or solvate thereof:

[0265]

[0266] in,

[0267] L is -CO-NH- or -NH-CO-;

[0268] A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N;

[0269] X is N or CR 1 ;

[0270] Y is N or CR 2 ;

[0271] Z is N or CR 3 ;

[0272] R 1 、R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; or optionally, R 1 and R 2 can be connected to form a ring; or optionally, R 2 and R 3 Can be connected to form a ring;

[0273] R 4 is selected from H, halogen or optionally substituted C1-C3 alkyl;

[0274] K is N or CH;

[0275] E is N or CH;

[0276] M is N or CR 5 ;

[0277] Q is N or CR 5 ;

[0278] T is N or CR 5 ;

[0279] Each R 5 independently selected from H, halogen or optionally substituted C1-C3 alkyl;

[0280]

[0281] G is selected from and

[0282] W is selected from:

[0283] an optionally substituted nitrogen-containing heterocyclic group;

[0284] an optionally substituted nitrogen-containing heteroaryl group;

[0285] optionally substituted carbocyclyl;

[0286] optionally substituted aryl;

[0287] an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group or an optionally substituted cycloalkylalkyl group;

[0288] optionally substituted nitrogen-containing heteroaryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl;

[0289] optionally substituted carbocyclyl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and

[0290] Optionally substituted aryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl.

[0291] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein A is N and B is C.

[0292] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein A is C and B is N.

[0293] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein L is -CO-NH-.

[0294] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein L is -NH-CO-.

[0295] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein G is

[0296] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 .

[0297] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N and Z is N.

[0298] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is N.

[0299] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N and Z is CR 3 .

[0300] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is CR 3 .

[0301] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 .

[0302] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is N.

[0303] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is N.

[0304] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Z is CR 3 .

[0305] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is CR 3 .

[0306] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 .

[0307] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Y is N.

[0308] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is N.

[0309] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Y is CR 2 .

[0310] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is CR 2 .

[0311] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein K is N; and E is CH.

[0312] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein K is CH; and E is N.

[0313] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein M is CR 5 ; Q is CR 5 ; and T is N.

[0314] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein M is CR 5 ; Q is N; and T is CR 5 .

[0315] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein M is N; Q is CR 5 ; and T is CR 5 .

[0316] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is H. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 1Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0317] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is H. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0318] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is H. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkyl is selected from C3-C4 optionally substituted cycloalkyl. Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 Another embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein the optionally substituted cycloalkylalkyl is selected from C4-C7 optionally substituted cycloalkylalkyl.

[0319] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 It is fluorine or CH3.

[0320] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein M is CH.

[0321] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein Q is CF.

[0322] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein T is CH.

[0323] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic group.

[0324] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from optionally substituted pyrrolidine, optionally substituted 2,5-dihydro-1H-pyrrole, optionally substituted piperidine, or optionally substituted 1,2,3,6-tetrahydropyridine.

[0325] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heteroaryl.

[0326] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted triazinyl, or optionally substituted pyrrolyl.

[0327] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazinyl, optionally substituted imidazolyl, optionally substituted triazolyl, or optionally substituted tetrazolyl.

[0328] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazin-3-yl, optionally substituted pyrazin-4-yl, optionally substituted pyrazin-5-yl, optionally substituted imidazol-4-yl or optionally substituted imidazol-5-yl.

[0329] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted 1,2,3-triazol-4-yl, optionally substituted 1,2,3-triazol-5-yl or optionally substituted 1,2,4-oxadiazol-5-yl.

[0330] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted oxazol-2-yl, optionally substituted oxazol-4-yl, or optionally substituted oxazol-5-yl.

[0331] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted thiazol-2-yl, optionally substituted thiazol-4-yl, or optionally substituted thiazol-5-yl.

[0332] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic group further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl.

[0333] Another embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted nitrogen-containing heteroaryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl.

[0334] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic radical. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from optionally substituted pyrrolidine, optionally substituted 2,5-dihydro-1H-pyrrole, optionally substituted piperidine or optionally substituted 1,2,3,6-tetrahydropyridine. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0335]

[0336] and

[0337] where R 5Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF3, -CH2CHF2 or -C(CH3)2CF3.

[0338] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heteroaryl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted pyridyl, an optionally substituted pyrimidyl, an optionally substituted triazinyl or an optionally substituted pyrrolyl. One embodiment provides a compound or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0339] and

[0340] where R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF3, -CH2CHF2 or -C(CH3)2CF3.

[0341] One embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazinyl, optionally substituted imidazolyl, optionally substituted triazolyl, or optionally substituted tetrazolyl.

[0342] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazin-3-yl, optionally substituted pyrazin-4-yl, optionally substituted pyrazin-5-yl, optionally substituted imidazol-4-yl or optionally substituted imidazol-5-yl.

[0343] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted 1,2,3-triazol-4-yl, optionally substituted 1,2,3-triazol-5-yl or optionally substituted 1,2,4-oxadiazol-5-yl.

[0344] One embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted oxazol-2-yl, optionally substituted oxazol-4-yl, or optionally substituted oxazol-5-yl.

[0345] One embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted thiazol-2-yl, optionally substituted thiazol-4-yl, or optionally substituted thiazol-5-yl.

[0346] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group or an optionally substituted nitrogen-containing heteroaryl group further substituted with an optionally substituted cycloalkyl group.

[0347] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0348]

[0349] And R 5 It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

[0350] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0351] And R 5 It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

[0352] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0353]

[0354] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0355]

[0356] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from:

[0357]

[0358] In some embodiments, a RAF kinase inhibiting compound as described herein has the structure provided in Table 1.

[0359] Table 1

[0360]

[0361]

[0362]

[0363]

[0364]

[0365]

[0366]

[0367]

[0368]

[0369]

[0370]

[0371]

[0372]

[0373]

[0374]

[0375]

[0376]

[0377]

[0378]

[0379]

[0380]

[0381]

[0382]

[0383]

[0384]

[0385]

[0386]

[0387]

[0388]

[0389]

[0390]

[0391]

[0392]

[0393]

[0394]

[0395]

[0396]

[0397]

[0398]

[0399]

[0400]

[0401]

[0402]

[0403]

[0404]

[0405]

[0406]

[0407]

[0408]

[0409]

[0410]

[0411]

[0412]

[0413]

[0414]

[0415]

[0416]

[0417]

[0418]

[0419]

[0420]

[0421]

[0422]

[0423]

[0424]

[0425]

[0426]

[0427]

[0428]

[0429]

[0430]

[0431]

[0432]

[0433]

[0434] Preparation of compounds

[0435] The compounds used in the reactions described herein are prepared according to organic synthesis techniques known to those skilled in the art starting from commercially available chemicals and / or compounds described in the chemical literature. “Commercially available chemicals” were obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, UK), BDH Inc. (Toronto, Canada), Bionet (Cornwall, UK), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals Inc. (Costa Mesa, CA), Key Organics (Cornwall, UK), Lancaster Synthesis (Wyndham, NH), Maybridge Chemical Co. Ltd. (Cornwall, UK), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hannover, Germany), Spectrum Quality Product Inc. (New Brunswick, NJ), TCI America (Portland, OR), Trans World Chemicals Inc. (Rockville, MD), and Wako Chemicals USA Inc. (Richmond, VA).

[0436] Suitable reference books and treatises that detail the synthesis of reactants that can be used to prepare the compounds described herein, or provide citations to articles describing such preparations, include, for example: "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; SR Sandler et al., "Organic Functional Group Preparations", 2nd ed., Academic Press, New York, 1983; H.O. House, "Modern Synthetic Reactions", 2nd ed., WA Benjamin, Inc. Menlo Park, Calif. 1972; T.L. Gilchrist, "Heterocyclic Chemistry", 2nd ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed., Wiley-Interscience, New York, 1992. Other suitable reference books and papers that detail the synthesis of reactants that can be used to prepare the compounds described herein or provide references to articles describing such preparations include, for example: Fuhrhop, J. and Penzlin G. "Organic Synthesis: Concepts, Methods, Starting Materials", Second Revised and Supplemented Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, RV "Organic Chemistry, An Intermediate Text" (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, RC "Comprehensive Organic Transformations: A Guide to Functional Group Preparations" Second Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. "Advanced Organic Chemistry: Reactions, Mechanisms, and Structure" Fourth Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J.(editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992 Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG "Organic Chemistry" 7th edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, "Intermediate Organic Chemistry" 2nd edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "IndustrialOrganic Chemicals: Starting Materials and Intermediates: An Ullmann'sEncyclopedia"(1999)John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942-2000) John Wiley & Sons, in more than 55 volumes; and "Chemistry of Functional Groups" John Wiley & Sons, in 73 volumes.

[0437] Specific analogous reactants are optionally identified by indexes of known chemicals prepared by the Chemical Abstracts service of the American Chemical Society, which are available in most public university libraries or through online databases (for more detailed information, contact the American Chemical Society, Washington, D.C.). Chemicals known in the catalog but not commercially available are optionally prepared by custom chemical synthesis companies, many of which standard chemical supply companies (such as those listed above) provide custom synthesis services. A reference that can be used to prepare and select pharmaceutically acceptable salts of the compounds described herein is P.H. Stahl & C.G. Wermuth, "Handbook of Pharmaceutical Salts", Verlag Helvetica Chimica Acta, Zurich, 2002.

[0438] Pharmaceutical composition

[0439] In certain embodiments, the RAF kinase inhibitory compounds described herein are administered as the pure chemical. In other embodiments, the RAF kinase inhibitory compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier), which is selected based on the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st ed., Mack Pub. Co., Easton, PA (2005)).

[0440] Provided herein is a pharmaceutical composition comprising at least one RAF kinase inhibitory compound as described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, and one or more pharmaceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other ingredients of the composition and is not harmful to the recipient of the composition (i.e., the subject or patient).

[0441] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

[0442] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ia) or a pharmaceutically acceptable salt or solvate thereof.

[0443] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (Ib) or a pharmaceutically acceptable salt or solvate thereof.

[0444] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof.

[0445] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof.

[0446] One embodiment provides a method for preparing a pharmaceutical composition comprising mixing a compound of Formula (I), (Ia), (Ib), (II) or (III), or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable carrier.

[0447] In certain embodiments, the RAF kinase inhibiting compound as described in Formula (I), (Ia), (Ib), (II) or (III), or a pharmaceutically acceptable salt or solvate thereof, is substantially pure in that it contains less than about 5% or less than about 1% or less than about 0.1% of other small organic molecules, such as unreacted intermediates or synthesis by-products produced, for example, during one or more steps of the synthetic method.

[0448] Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose, or other suitable materials that are readily soluble in the digestive tract. In some embodiments, suitable non-toxic solid carriers are used, including, for example, pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, etc. (see, for example, Remington: The Science and Practice of Pharmacy (Gennaro, 21st edition, Mack Pub. Co., Easton, PA (2005)).

[0449] In some embodiments, the RAF kinase inhibitory compound of Formula (I), (Ia), (Ib), (II) or (III), or a pharmaceutically acceptable salt or solvate thereof, is formulated for administration by injection. In some cases, the injection formulation is an aqueous formulation. In some cases, the injection formulation is a non-aqueous formulation. In some cases, the injection formulation is an oil-based formulation, such as sesame oil.

[0450] The dosage of the composition comprising at least one RAF kinase inhibitory compound as described herein varies depending on the condition of the subject or patient (eg, human). In some embodiments, such factors include general health, age, and other factors.

[0451] Pharmaceutical composition is used in a manner suitable for disease to be treated (or prevented). Suitable dosage and suitable duration of application and frequency will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of active ingredient and the method of application. Generally, the amount of the composition provided by suitable dosage and treatment regimen is enough to provide treatment and / or prevention benefit, for example, improved clinical outcome, such as more frequent complete or partial remission, or longer disease-free and / or total survival period, or the symptom severity of alleviation. Conventionally, experimental models and / or clinical trials are used to determine optimal dose. Optimal dose depends on the patient's constitution, body weight or blood volume.

[0452] Oral dosages generally range from about 1.0 mg to about 1000 mg, one to four or more times a day.

[0453] Treatment

[0454] One embodiment provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0455] One embodiment provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or tumor disease.

[0456] One embodiment provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, for use in a method for treating cancer or tumor disease.

[0457] One embodiment provides the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor disease.

[0458] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0459] One embodiment provides a compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0460] One embodiment provides a compound of formula (Ia) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or tumor disease.

[0461] One embodiment provides a pharmaceutical composition comprising a compound of formula (Ia) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, for use in a method for treating cancer or tumor disease.

[0462] One embodiment provides use of a compound of formula (Ia) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor disease.

[0463] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of Formula (Ia) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0464] One embodiment provides a compound of formula (Ib), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0465] One embodiment provides a compound of formula (Ib) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or tumor disease.

[0466] One embodiment provides a pharmaceutical composition comprising a compound of formula (Ib) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, for use in a method for treating cancer or tumor disease.

[0467] One embodiment provides the use of a compound of formula (Ib) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor disease.

[0468] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of Formula (Ib) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (Ib) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0469] One embodiment provides a compound of formula (II), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0470] One embodiment provides a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or tumor disease.

[0471] One embodiment provides a pharmaceutical composition comprising a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, for use in a method for treating cancer or tumor disease.

[0472] One embodiment provides the use of a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor disease.

[0473] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0474] One embodiment provides a compound of formula (III), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

[0475] One embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof for use in a method of treating cancer or tumor disease.

[0476] One embodiment provides a pharmaceutical composition comprising a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient, for use in a method for treating cancer or tumor disease.

[0477] One embodiment provides the use of a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for treating cancer or tumor disease.

[0478] In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method of treating cancer in a patient in need thereof is provided, comprising administering to the patient a pharmaceutical composition comprising a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

[0479] In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) partition across the blood-brain barrier (BBB) ​​with a Kp,uu greater than 1. In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) exhibit a Kp,uu greater than 0.3. In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) exhibit a Kp,uu greater than 0.4. In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) exhibit a Kp,uu greater than 0.6. In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) exhibit a Kp,uu greater than 0.8. In some embodiments described herein, the compounds of Formula (I), (Ia), (Ib), (II), or (III) exhibit a Kp,uu greater than 1.0. In some embodiments described herein, the compound of Formula (I), (Ia), (Ib), (II), or (III) exhibits a Kp,uu greater than 1.2. In some embodiments described herein, the compound of Formula (I), (Ia), (Ib), (II), or (III) exhibits a Kp,uu greater than 1.4. In some embodiments described herein, the compound of Formula (I), (Ia), (Ib), (II), or (III) exhibits a Kp,uu greater than 1.6. In some embodiments described herein, the compound of Formula (I), (Ia), (Ib), (II), or (III) exhibits a Kp,uu greater than 1.8. In some embodiments described herein, the compound of Formula (I), (Ia), (Ib), (II), or (III) exhibits a Kp,uu greater than 2.0. In some embodiments, the Kp,uu values ​​are determined in rats. In some embodiments, the Kp,uu values ​​are determined in mice. In some embodiments, the Kp,uu values ​​are determined in rodents. In some embodiments, the Kp,uu value is determined in dogs. In some embodiments, the Kp,uu value is determined in primates. In some embodiments, the Kp,uu value is determined in humans.

[0480] Provided herein are methods of administering pharmaceutical compositions orally. Provided herein are methods of administering pharmaceutical compositions by injection.

[0481] Other embodiments and uses will be apparent to those skilled in the art in light of this disclosure.The following examples are provided merely as illustrations of various embodiments and should not be construed as limiting the invention in any way.

[0482] Example

[0483] I. Chemical Synthesis

[0484] In some embodiments, the RAF kinase inhibitory compounds disclosed herein are synthesized according to the following examples. As used below, throughout the description of the present invention, unless otherwise indicated, the following abbreviations should be understood to have the following meanings:

[0485] ℃ degrees Celsius

[0486] δ H Chemical shift in parts per million downfield from tetramethylsilane

[0487] DCM dichloromethane (CH2Cl2)

[0488] DMF dimethylformamide

[0489] DMSO dimethyl sulfoxide

[0490] EA Ethyl acetate

[0491] ESI electrospray ionization

[0492] Et ethyl

[0493] g grams

[0494] h hour

[0495] HPLC high-performance liquid chromatography

[0496] Hz Hertz

[0497] J coupling constant (NMR spectrum)

[0498] LCMS liquid chromatography mass spectrometry

[0499] μ micro

[0500] m multiplet (spectrum); meter; millimeter

[0501] M Moore

[0502] M + Parent molecular ion

[0503] Me methyl

[0504] MHz Megahertz

[0505] min

[0506] mol mole; molecule (measured by molar weight)

[0507] mL milliliters

[0508] MS

[0509] nm nanometer

[0510] NMR Nuclear Magnetic Resonance

[0511] pH Acidity or alkalinity; a measure of the acidity or alkalinity of an aqueous solution

[0512] PE petroleum ether

[0513] RT Room temperature

[0514] s singlet (spectrum)

[0515] t triplet (spectrum)

[0516] T temperature

[0517] TFA trifluoroacetic acid

[0518] THF Tetrahydrofuran.

[0519] Intermediate 1: (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0520]

[0521] Step 1. 2-Fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline

[0522] To a stirred mixture of 5-bromo-2-fluoro-4-methylaniline (10 g, 49.01 mmol), 4,4,5,5-tetramethyl-2-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (14.93 g, 58.81 mmol) and Pd(dppf)Cl2C2Cl2 (2.00 g, 2.45 mmol) in 1,4-dioxane (120 mL) was added KOAc (14.43 g, 147.03 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 100° C. for 16 hours. The resulting mixture was diluted with water (300 mL) at room temperature. The resulting mixture was extracted with CHCl (3 x 200 mL). The combined organic layers were washed with brine (3 x 200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (4 / 1) as eluent. The fractions containing the desired product were combined and concentrated to give 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (11.6 g, 94%) as a green solid. MS ESI: C 13 H19 BFNO2[M+H] + , calculated value 252.15, measured value 252.10; 1 H NMR (400 MHz, chloroform-d) δ 7.24 (d, J = 10.0 Hz, 1H), 6.82 (d, J = 12.0 Hz, 1H), 3.60 (s, 2H), 2.45 (s, 3H), 1.35 (s, 12H); 19 F NMR (376 MHz, chloroform-d) δ -131.47 (1F).

[0523] Step 2. (S)-N-(2-Fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0524] Under nitrogen atmosphere, to the stirred solution of 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.50g, 1.99mmol) and DIEA (1.28g, 9.96mmol) in THF (42mL) was added triphosgene (236mg, 0.796mmol) at room temperature. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 0.5 hour. To the above mixture was added a solution of (3S)-3-(2,2,2-trifluoroethyl)pyrrolidine hydrochloride (0.38g, 1.99mmol) in THF (5mL). The reaction mixture was stirred at room temperature for another 2 hours. The resulting mixture was quenched by adding methanol (50mL) at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with petroleum ether / ethyl acetate (2 / 1). Fractions containing the desired product were combined and concentrated to give (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (0.70 g, 82%) as an off-white solid. MS ESI: C 20 H 27 BF4N2O3[M+H] + , calculated value 431.21, measured value 431.30; 1H NMR (400 MHz, chloroform-d) δ 8.39 (d, J = 9.2 Hz, 1H), 6.88 (d, J = 12.8 Hz, 1H), 6.19 (s, 1H), 3.86-3.82 (m, 1H), 3.68-3.63 (m, 1H), 3.50-3.44 (m, 1H), 3.17-3.12 (m, 1H), 2.62-2.54 (m, 1H), 2.49 (s, 3H), 2.33-2.23 (m, 3H), 1.82-1.72 (m, 1H), 1.34 (s, 12H). 19 F NMR (376 MHz, chloroform-d) δ -64.97 (3F), -128.85 (1F).

[0525] Intermediate 2: N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide

[0526]

[0527] Step 1. tert-Butyl 3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxylate

[0528] To a mixture of stirred cesium carbonate (19.87 g, 60.98 mmol), tris (dibenzylideneacetone) dipalladium (0)-chloroform adduct (1.58 g, 1.52 mmol) and XantPhos (3.00 g, 5.18 mmol) in dioxane (30 mL) was added 3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester (4.5 g, 15.24 mmol) and 1,1,1-trifluoro-2-iodoethane (12.80 g, 60.98 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 100 ° C for 16 hours. The resulting mixture was filtered and the filter cake was washed with dichloromethane (3 x 200 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using petroleum ether / ethyl acetate (5 / 1) as eluent. The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxylate (0.30 g, 8%) as a light brown oil. MS ESI: C 11 H 16 F3NO2[M-C4H8+H] + , calculated value 196.05, measured value 195.90; 1H NMR (400 MHz, chloroform-d) δ 5.77 (d, J = 20.0 Hz, 1H), 4.17-4.12 (m, 4H), 3.00-2.91 (m, 2H), 1.50 (s, 9H); 19 F NMR (376 MHz, chloroform-d) δ -64.94 (3F).

[0529] Step 2. 3-(2,2,2-Trifluoroethyl)-2,5-dihydro-1H-pyrrole hydrochloride

[0530] To a stirred solution of tert-butyl 3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxylate (0.30 g, 1.19 mmol) in dichloromethane (3 mL) was added dropwise HCl (gas) (3 mL, 4 M) in 1,4-dioxane at 0 ° C. The resulting mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure to give 3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole hydrochloride (0.20 g, crude product) as a brown oil. MS ESI: C6H9ClF3N[M-HCl+H] + , calculated values ​​152.06, 154.06, measured values ​​152.00, 154.00; 1 H NMR (400MHz, DMSO-d6) δ9.60 (s, 2H), 5.84 (d, J = 62.0Hz, 1H), 3.98-3.91 (m, 4H), 3.41-3.32 (m, 2H); 19 F NMR(376MHz,DMSO-d6)δ-63.32(3F).

[0531] Step 3. N-[2-Fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxamide

[0532] Under a nitrogen atmosphere, triphosgene (47.01 mg, 0.16 mmol) was added to a stirred solution of 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (0.10 g, 0.40 mmol) and N,N-diisopropylethylamine (0.26 g, 1.99 mmol) in tetrahydrofuran (5.00 mL) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 0.5 hours. 3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole hydrochloride (67.00 mg, 0.36 mmol) was added to the above mixture at 0 ° C. The reaction mixture was stirred at room temperature for another 2 hours. The resulting mixture was quenched by adding methanol (20 mL) at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with petroleum ether / ethyl acetate (1 / 1). The fractions containing the desired product were combined and concentrated to give N-[2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)-2,5-dihydropyrrole-1-carboxamide (0.10 g, 59%) as an off-white solid. MS ESI: C 20 H 25 BF4N2O3[M+H] + , calculated value 429.19, measured value 429.20; 1 H NMR (400 MHz, CHLOROFORM-d) δ 8.41 (d, J = 9.6 Hz, 1H), 6.89 (d, J = 12.4 Hz, 1H), 6.19 (d, J = 2.8 Hz, 1H), 5.88 (s, 1H), 4.34-4.32 (m, 4H), 3.07-2.99 (m, 2H), 2.50 (s, 3H), 1.34 (s, 12H). 19 F NMR (376 MHz, chloroform-d) δ -64.84 (3F), -128.78 (1F).

[0533] Intermediate 3: 5-chloro-7-(morpholin-4-yl)-2H-indazole

[0534]

[0535] Under nitrogen atmosphere, to the chloro-2H-indazole (6g, 25.92mmol) of 7-bromo-5-and 1-chloro-1-[dicyclohexyl ([2-[2,4,6-tri-(propane-2-yl)phenyl]phenyl])-1N-[S]-phosphino]-2H, 3H, 4H-benzo [c] 1-aza-2-palladium heterocyclohexane (0.77g, 1.04mmol) in morpholine (2.26g, 25.92mmol) solution of was added dropwise bis(trimethylsilyl)amide lithium (LiHMDS, 1M solution in tetrahydrofuran) (90.7mL, 90.72mmol) at 0 DEG C. Under nitrogen atmosphere, reaction mixture was stirred at 65 DEG C for 3 hours. Gained mixture was quenched with saturated NH4Cl aqueous solution (200mL). Gained mixture was extracted with ethyl acetate (3x 200mL). The combined organic layers were washed with brine (100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with petroleum ether / ethyl acetate (1 / 1). The fractions containing the desired product were combined and concentrated to give 5-chloro-7-(morpholin-4-yl)-2H-indazole (4.1 g, 67%) as a light grey solid. MS ESI: C 11 H 12 ClN3O[M+H] + , calculated values ​​238.07, 240.07, measured values ​​237.90, 239.90. 1 H NMR (400MHz, chloroform-d) δ 8.79 (s, 1H), 8.04 (s, 1H), 7.44 (d, J = 1.6Hz, 1H), 6.85 (d, J = 1.6Hz, 1H), 3.98-3.95 (m, 4H), 3.21-3.19 (m, 4H).

[0536] The compounds in Table 2 below were prepared using procedures analogous to those described in Intermediate 3 and using appropriate starting materials.

[0537] Table 2

[0538]

[0539] Intermediate 5: 4-(5-chloro-2-methyl-2H-indazol-7-yl)morpholine

[0540]

[0541] Under nitrogen atmosphere, trimethyloxonium tetrafluoroborate (0.80g, 5.43mmol) is added to the solution of 5-chloro-7-(morpholine-4-yl)-1H-indazole (1.00g, 4.21mmol) in EA (14mL) stirred at room temperature. Under nitrogen atmosphere, the reaction mixture is stirred at room temperature for 16 hours. The resulting mixture is quenched by adding saturated NaHCO (aqueous solution) (40mL) at 0°C. The resulting mixture is extracted with EtOAc (3x 60mL). The combined organic layer is washed with salt water (1x 40mL) and dried over anhydrous Na2SO4. After filtration, the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography and eluted with PE / EtOAc / EtOH (=4 / 3 / 1). Fractions containing the desired product were combined and concentrated to give 5-chloro-2-methyl-7-(morpholin-4-yl)indazole (0.84 g, 79%) as an off-white solid. MS ESI: C 12 H 14 ClN3O[M+H] + , calculated values ​​252.08, 254.08, measured values ​​252.10, 254.10; 1 H NMR (400 MHz, chloroform-d) δ 7.80 (s, 1H), 7.22 (d, J = 1.6 Hz, 1H), 6.54 (s, 1H), 4.19 (s, 3H), 4.02-4.00 (m, 4H), 3.56-3.54 (m, 4H).

[0542] Intermediate 6: 4-(5-chloro-2-(2-methoxyethyl)-2H-indazol-7-yl)morpholine

[0543]

[0544] Under nitrogen atmosphere, sodium hydride (0.13g, 3.16mmol, 60%) was added to a solution of 5-chloro-7-(morpholine-4-yl)-2H-indazole (0.50g, 2.10mmol) in N,N-dimethylformamide (5mL) at 0°C. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 0.5 hours. 1-iodo-2-methoxyethane (0.47g, 2.53mmol) was added to the above mixture. The reaction mixture was stirred at room temperature for another 2 hours. The resulting mixture was quenched with saturated NH4Cl aqueous solution (100mL). The resulting mixture was extracted with ethyl acetate (3x 100mL). The combined organic layer was washed with saturated brine (100mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with petroleum ether / ethyl acetate (1 / 1). Fractions containing the desired product were combined and concentrated to give 4-(5-chloro-2-(2-methoxyethyl)-2H-indazol-7-yl)morpholine (0.22 g, 35%) as a light brown solid. MS ESI: C 14 H 18 ClN3O2[M+H] + , calculated values ​​296.11, 298.11, measured values ​​295.95, 297.95; 1 H NMR (400 MHz, chloroform-d) δ 7.93 (s, 1H), 7.22 (d, J = 1.6 Hz, 1H), 6.49 (s, 1H), 4.55 (t, J = 1.2 Hz, 2H), 3.88-3.86 (m, 4H), 3.86 (t, J = 4.8 Hz, 2H), 3.56-3.54 (m, 4H), 3.40 (s, 3H).

[0545] 4-(5-chloro-1-(2-methoxyethyl)-1H-indazol-7-yl)morpholine (0.34 g, 55%) was obtained as a light brown solid. MS ESI: C 14 H 18 ClN3O2[M+H] + , calculated value 296.11,298.11, measured value 296.00,298.00; 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.98 (s, 1H), 7.46 (d, J = 1.6 Hz, 1H), 7.04 (d, J = 1.6 Hz, 1H), 4.90 (t J = 5.6 Hz, 2H), 4.02-3.99 (m, 2H), 3.89-3.84 (m, 4H), 3.31 (s, 3H), 3.16-3.13 (m, 2H), 3.06-3.00 (m, 2H).

[0546] The compounds in Table 3 below were prepared using procedures analogous to those described in Intermediate 6 and using appropriate starting materials.

[0547] Table 3

[0548]

[0549] Intermediate 9: 4-(5-chloro-2-cyclopropyl-2H-indazol-7-yl)morpholine

[0550]

[0551] To a stirred mixture of 5-chloro-7-(morpholine-4-yl)-1H-indazole (0.15g, 0.63mmol), cyclopropylboronic acid (0.11g, 1.26mmol) and bipyridine (0.10g, 0.63mmol) in DCE (3mL) was added Cu(OAc)2(0.11g, 0.63mmol) and Na2CO3(0.13g, 1.26mmol) in batches at room temperature. The reaction mixture was degassed with oxygen and stirred at 60°C for 1.5 hours. The resulting mixture was filtered and the filter cake was washed with DCM (3x 20mL). The filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (PE / EA=1 / 1). The fractions containing the desired product were combined and concentrated to give 4-(5-chloro-2-cyclopropyl-2H-indazole-7-yl)morpholine (128mg, 73%) as an off-white solid. MS ESI:C 14 H 16 ClN3O[M+H] + , calculated values ​​278.10, 280.10, measured values ​​278.00, 280.00. 1 H NMR (400 MHz, chloroform-d) δ 7.89 (s, 1H), 7.18 (d, J = 1.6 Hz, 1H), 6.46 (s, 1H), 4.00-3.98 (m, 4H), 3.93-3.89 (m, 1H), 3.55-3.53 (m, 4H), 1.36-1.32 (m, 2H), 1.18-1.14 (m, 2H). 5-Chloro-1-cyclopropyl-7-(morpholin-4-yl)indazole (101 mg, 57%) was obtained as an off-white solid. MS ESI: C 14 H 16 ClN3O[M+H] + , calculated values ​​278.10, 280.10, measured values ​​278.00, 280.00; 1H NMR (400 MHz, CHLOROFORM-d) δ 7.83 (s, 1H), 7.42 (d, J = 1.6 Hz, 1H), 6.96 (d, J = 2.0 Hz, 1H), 4.58-4.53 (m, 1H), 3.94 (s, 4H), 3.15 (m, 4H), 1.43-1.37 (m, 2H), 1.10-1.05 (m, 2H).

[0552] Intermediate 10: 5-chloro-2-(difluoromethyl)-7-(morpholin-4-yl)indazole

[0553]

[0554] Under nitrogen atmosphere, difluoro(sulfo)acetic acid (0.45g, 2.53mmol) was added dropwise to a solution of 5-chloro-7-(morpholine-4-yl)-2H-indazole (0.50g, 2.10mmol) and potassium carbonate (0.87g, 6.31mmol) in ethyl acetate (5mL) at 0°C. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was quenched with water (100mL). The resulting mixture was extracted with ethyl acetate (3x 100mL). The combined organic layer was washed with saturated brine (100mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with ether / ethyl acetate (1 / 1). The fractions containing the desired product were combined and concentrated to give 5-chloro-2-(difluoromethyl)-7-(morpholine-4-yl) indazole (380mg, 63%) as a light yellow solid. MS ESI:C 12 H 12 ClF2N3O[M+H] + , calculated values ​​288.06, 290.06, measured values ​​287.90, 289.90; 1 H NMR (400MHz, DMSO-d6) δ8.81(s,1H),8.14(t,J=55.8Hz,1H),7.34(d,J=1.6Hz,1H),6.46(d,J=1.6Hz,1H),3.63-3.60(m,4H),3.51-3.49(m,4H); 19 F NMR(376MHz,DMSO-d6)δ-94.76(2F).

[0555] Intermediate 11: 4-{6-bromo-2-isopropylimidazo[1,2-a]pyridin-8-yl}morpholine

[0556]

[0557] Step 1. 4-{6-Bromo-2-isopropylimidazo[1,2-a]pyridin-8-yl}morpholine

[0558] To a stirred solution of 5-bromo-3-(morpholin-4-yl)pyridin-2-amine (400 mg, 1.55 mmol) in EtOH (5 mL) was added 1-bromo-3-methylbutan-2-one (511 mg, 3.10 mmol). The reaction mixture was stirred at 80 ° C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA / EtOH (8 / 3 / 1) to give 4-{6-bromo-2-isopropylimidazo[1,2-a]pyridin-8-yl}morpholine (180 mg, 36%) as a gray solid. MS ESI: C 14 H 18 BrN3O[M+H] + , calculated values ​​324.22, 326.22, measured values ​​324.05, 326.05; 1 H NMR (400MHz, chloroform-d) δ7.84 (d, J = 1.6Hz, 1H), 7.21 (s, 1H), 6.44–6.39 (m, 1H), 4. 00-3.97(m,4H),3.63-3.56(m,4H),3.13-3.06(m,1H),1.35(d,J=7.2Hz,6H).

[0559] The compounds in Table 4 below were prepared using procedures analogous to those described in Intermediate 11 and using appropriate starting materials.

[0560] Table 4

[0561]

[0562] Example 1: (3S)-N-[2-fluoro-4-methyl-5-[2-methyl-7-(morpholin-4-yl)indazol-5-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0563]

[0564] To the stirred 5-chloro-2-methyl-7-(morpholin-4-yl)indazole (0.12 g, 0.48 mmol), (3S)-N-[2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (0.21 g, 0.48 mmol) and K PO (0.20 g, 0.95 mmol) in a mixture of THF (2.00 mL) and H O (0.20 mL) was added XPhos palladium (II) biphenyl-2-amine chloride (31 mg, 0.05 mmol) in batches at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 3 hours. The resulting mixture was diluted with water (20 mL). The resulting mixture was extracted with EtOAc (3x 20 mL). The combined organic layers were washed with brine (2 x 20 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC (PE / EtOAc / EtOH=3 / 1) (1 / 1) to give a crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 40 g; Eluent A: water (added with 10 mmol / L NH4HCO3); Eluent B: ACN; Gradient: 25%-80% B over 20 minutes; Flow rate: 30 mL / min; Detector: 220 / 254 nm. The fractions containing the desired product were combined and concentrated to give (3S)-N-[2-fluoro-4-methyl-5-[2-methyl-7-(morpholin-4-yl)indazol-5-yl]phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (132.3 mg, 53%) as a white solid. MS ESI: C 26 H 29 F4N5O2[M+H] + , calculated value 520.23, measured value 520.25; 1 H NMR(300MHz,DMSO-d6)δ8.27(s,1H),7.84(s,1H),7.37-7.35(m,1H),7.12-7.06(m,2H),6.02(s,1H),4.16(s,3H),3.81-3.7 9(m,4H),3.69-3.63(m,1H),3.55-3.32(m,6H),3.05-2.99(m,1H),2.49-2.40(m,3H),2.21-2.08(m,4H),1.71-1.67(m,1H); 19 F NMR(282MHz,DMSO-d6)δ-63.39(3F),-126.58(1F).

[0565] The compounds in Table 5 below were prepared using procedures analogous to those described in Example 1 and using appropriate starting materials.

[0566] Table 5

[0567]

[0568]

[0569] Example 7: (S)-N-(2-fluoro-5-(2-isopropyl-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0570]

[0571] To a stirred mixture of 4-{6-bromo-2-isopropylimidazo[1,2-a]pyridin-8-yl}morpholine (75 mg, 0.23 mmol) and (3S)-N-[2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (100 mg, 0.23 mmol) in dioxane (0.8 mL) and water (0.2 mL) was added KCO (96 mg, 0.69 mmol) and Pd(dppf)ClCHCl (19 mg, 0.02 mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 3 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (petroleum ether / ethyl acetate / ethanol=20 / 3 / 1) to give a crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 40 g; Eluent A: Water (plus 10 mmol / L NH4HCO3); Eluent B: ACN; Gradient: 25% to 80% B over 20 minutes; Flow rate: 30 mL / min; Detector: 220 / 254 nm. Fractions containing the desired product were combined and concentrated to give (S)-N-(2-fluoro-5-(2-isopropyl-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (70.2 mg, 55%) as a white solid. MS ESI: C 28 H 33 F4N5O2[M+H] + , calculated value 548.59 measured value 548.30; 1H NMR (400 MHz, chloroform-d) δ 8.08 (d, J = 8.4 Hz, 1H), 7.66 (s, 1H), 7.25 (s, 1H), 7.00 (d, J = 12.0 Hz, 1H), 6.32 (d, J = 15.2 Hz, 2H), 3.99 (d, J = 5.6 Hz, 4H), 3.86-3.82 (m, 1H), 3.72-3. 62(m,1H),3.58(s,4H),3.52-3.45(m,1H),3.18-3.10(m,2H),2.60-2.56(m,1H),2. 36-2.25(m,2H),2.28(s,1H),2.24(s,3H),1.84-1.74(m,1H),1.38(d,J=6.9Hz,6H). 19 F NMR (376 MHz, chloroform-d) δ -64.96 (3F), -134.62 (1F).

[0572] The compounds in Table 6 below were prepared using procedures analogous to those described in Example 7 and using appropriate starting materials.

[0573] Table 6

[0574]

[0575]

[0576] Example 16: (S)-N-(5-(2,3-dimethyl-7-morpholinyl-2H-indazol-5-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0577]

[0578] Step 1: 2-Ethyl-6-fluoroaniline

[0579] Under N2, a mixture of 2-bromo-6-fluoroaniline (20.0 g, 105.3 mmol), triethylborane (15.7 g, 160.0 mmol), Cs2CO3 (102.9 g, 315.8 mmol) and Pd(dppf)Cl2 (7.7 g, 10.5 mmol) in DMF (500 mL) was stirred at 55 ° C for 1 hour. The reaction mixture was cooled, water (1000 mL) was added thereto, and extracted with EtOAc (500 mL * 3). The combined organic layer was washed with water (500 mL * 2) and brine (500 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA = 20 / 1) to give 2-ethyl-6-fluoroaniline (9.5 g, 64%) as a colorless liquid. MS ESI: C8H 10 FN[M+H] + , calculated value 140.08, measured value 140.00.

[0580] Step 2: 4-Bromo-2-ethyl-6-fluoroaniline

[0581] To a mixture of 2-ethyl-6-fluoroaniline (9.5 g, 68.3 mmol) in DMF (200 mL) was added NBS (9.7 g, 54.6 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. Water (500 mL) was added to the resulting mixture and extracted with EA (200 mL * 2). The combined organic layers were washed with water (200 mL * 2) and brine (200 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA = 20 / 1) to give 4-bromo-2-ethyl-6-fluoroaniline (11.0 g, 74%) as a light brown oil. MS ESI: C8H9BrFN [M + H] + , calculated value 217.99, measured value 218.00.

[0582] Step 3: 5-Bromo-1-ethyl-3-fluoro-2-nitrobenzene

[0583] To a mixture of H2O2 (158.5 g, 30%, 276.5 mmol) in DCM (120 mL) was added TFAA (30.7 mL, 222.0 mmol) at 0°C. The reaction mixture was stirred at 0°C for 10 minutes. A solution of 4-bromo-2-ethyl-6-fluoroaniline (10.0 g, 46.0 mmol) in DCM (30 mL) was then added to the reaction mixture at 0°C. The reactants were stirred at 40°C for 10 hours. Water (100 mL) was added to the resulting mixture and extracted with EA (200 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=20 / 1) to give 5-bromo-1-ethyl-3-fluoro-2-nitrobenzene (6.0 g, 52%) as a light brown solid. MS ESI: C8H7BrFNO2[M+H] + , calculated value 247.96, measured value 247.90.

[0584] Step 4: 4-(5-Bromo-3-ethyl-2-nitrophenyl)morpholine

[0585] To a mixture of 5-bromo-1-ethyl-3-fluoro-2-nitrobenzene (6.0 g, 24.1 mmol) in DMSO (100 mL) was added morpholine (3.1 g, 36.2 mmol) and K2CO3 (6.6 g, 48.3 mmol) at room temperature. The reactant was stirred at 60 ° C for 16 hours. The resulting mixture was cooled to room temperature, water (200 mL) was added thereto, and extracted with EA (200 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=5 / 1) to give 4-(5-bromo-3-ethyl-2-nitrophenyl)morpholine (4.3 g, 56.4%) as a brown oil. MS ESI: C 12 H 15 BrN2O3[M+H] + , calculated value 315.03, measured value 315.00.

[0586] Step 5: 4-Bromo-2-ethyl-6-morpholinaniline

[0587] To a mixture of 4-(5-bromo-3-ethyl-2-nitrophenyl)morpholine (4.3 g, 13.6 mmol) in EtOH / H2O (70 / 70 mL) was added Fe (7.6 g, 136.5 mmol) and NH4Cl (7.3 g, 136.5 mmol) at room temperature. The reactant was stirred at 70°C for 2 hours. The resulting mixture was cooled to room temperature, water (100 mL) was added thereto, filtered and washed with EA (100 mL). The organic layer was concentrated. The residue was diluted with water (100 mL) and extracted with EA (200 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=10 / 1) to give 4-bromo-2-ethyl-6-morpholineaniline (3.1 g, 80%) as a brown oil. MS ESI:C 12 H 17 BrN2O[M+H] + , calculated value 285.05, measured value 285.00.

[0588] Step 6: 4-(5-Bromo-3-methyl-1H-indazol-7-yl)morpholine

[0589] To a mixture of 4-bromo-2-ethyl-6-morpholineaniline (1.5 g, 5.2 mmol) in AcOH (35 mL) was added NaNO2 (0.39 g, 5.78 mmol) at 0 ° C. The reaction mixture was stirred at room temperature for 4 hours. The resulting mixture was concentrated. The residue was diluted with EtOAc (100 mL) and the pH was adjusted to 7 with saturated NaHCO3. The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=2 / 1) to give 4-(5-bromo-3-methyl-1H-indazole-7-yl)morpholine (340 mg, 22%) as a brown solid. MS ESI: C 12 H 14 BrN3O[M+H] + , calculated value 296.03, measured value 296.00.

[0590] Step 7: 4-(5-Bromo-2,3-dimethyl-2H-indazol-7-yl)morpholine

[0591] To a mixture of 4-(5-bromo-3-methyl-1H-indazole-7-yl)morpholine (290 mg, 0.97 mmol) in EtOAc (35 mL) was added trimethyloxonium tetrafluoroborate (188 mg, 1.27 mmol) at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered and washed with EA (100 mL). The filtrate was evaporated. The residue was diluted with water (100 mL) and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=2 / 1) to give 4-(5-bromo-2,3-dimethyl-2H-indazole-7-yl)morpholine (195 mg, 64%) as a brown solid. MS ESI:C 13 H 16 BrN3O[M+H] + , calculated value 310.05, measured value 310.00.

[0592] Example 16: (S)-N-(5-(2,3-dimethyl-7-morpholinyl-2H-indazol-5-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0593] A mixture of 4-(5-bromo-2,3-dimethyl-2H-indazol-7-yl)morpholine (50 mg, 0.16 mmol), (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (69 mg, 0.16 mmol), CsCO (104 mg, 0.32 mmol) and Pd(dppf)Cl (11 mg, 0.01 mmol) in dioxane / HO (10 mL / 2 mL) was stirred at 80° C. for 3 hours under N2. The reaction mixture was cooled, water (30 mL) was added thereto, and extracted with EtOAc (30 mL). The organic layer was washed with brine (40 mL), dried over anhydrous NaSO, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC (HCOOH) to give (S)-N-(5-(2,3-dimethyl-7-morpholinyl-2H-indazol-5-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (23.3 mg, 27.1%) as a white solid. MS ESI: C27H31F4N5O2 [M+H] + , calculated value 534.24, measured value 534.20. 1H NMR (400MHz, DMSO-d6), δ7.83 (s, 1H), 7.35 (d, J = 8.4Hz, 1H), 7.10 (d, J = 12.0Hz, 1H),7.02(d,J=0.8Hz,1H),6.29(d,J=0.8Hz,1H),4.03(s,3H),3.80-3.78(m,4H) ,3.58-3.52(m,1H),3.52-3.44(m,1H),3.41-3.42(m,4H),3.04-3.01(m,1H),2. 56(s,3H),2.49-2.41(m,4H),2.20(s,3H),2.10-2.02(m,1H),1.68-1.63(m,1H).

[0594] Example 17: (S)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0595]

[0596] Step 1: 4-(6-chloroimidazo[1,2-a]pyridin-8-yl)morpholine

[0597] Under a nitrogen atmosphere, a mixture of 8-bromo-6-chloroimidazo[1,2-a]pyridine (1.0 g, 4.33 mmol), morpholine (753 mg, 8.66 mmol), Pd2dba3 (394 mg, 0.43 mmol), Binap (280 mg, 0.43 mmol) and Cs2CO3 (2.82 g, 8.66 mmol) in dioxane (30 mL) was stirred at 100 ° C for 5 hours. The resulting mixture was cooled, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EtOAc=2 / 1) to give 4-(6-chloroimidazo[1,2-a]pyridin-8-yl)morpholine (750 mg, 75%) as a yellow solid. MS ESI: C 11 H 12 ClN3O[M+H] + , calculated value 238.07, measured value 238.1.

[0598] Example 17: (S)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0599] Under a nitrogen atmosphere, a mixture of 4-(6-chloroimidazo[1,2-a]pyridin-8-yl)morpholine (100 mg, 0.42 mmol), (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (180 mg, 0.42 mmol), Xphos G2 (32 mg, 0.04 mmol) and K3PO4 (178 mg, 0.84 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred at 85°C for 2 hours. The resulting mixture was cooled, water (20 mL) was added thereto, and extracted with EA (50 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by prep-HPLC to give (S)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (113.4 mg, 53%) as a white solid. MSESI: C 25 H 27 F4N5O2[M+H] + , calculated value 506.21, measured value 506.10. 1 H NMR (400MHz, DMSO-d6), δ8.12(s,1H),7.90(s,2H),7.52(s,1H),7.43(d,J=8.0Hz,1H),7.17(d,J=11.6Hz,1H),6.35(br s,1H),3.80(t,J=4.4Hz,4H),3.68-3.64(m,1H),3.53(s,5H),3.03(t,J=9.2H z,1H),2.50-2.41(m,4H),2.25(s,3H),2.14-2.07(m,1H),1.71-1.61(m,1H).

[0600] Example 18: (S)-N-(5-(2-cyclopropyl-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0601]

[0602] Step 1: 8-Bromo-6-chloro-2-cyclopropylimidazo[1,2-a]pyridine

[0603] A suspension of 3-bromo-5-chloropyridin-2-amine (5.0 g, 24.2 mmol) and 2-bromo-1-cyclopropylethyl-1-one (2.6 mL, 76.6 mmol) in EtOH (100 mL) was stirred at 95 ° C for 16 hours. The reaction mixture was cooled and concentrated. The residue was slurried with EA (30 mL) to give 8-bromo-6-chloro-2-cyclopropylimidazo[1,2-a]pyridine (5.2 g, 79%) as a gray solid. MS ESI: C 10 H8BrClN2[M+H] + , calculated value 270.96, measured value 271.00.

[0604] Step 2: 4-(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine

[0605] Under a nitrogen atmosphere, a mixture of 8-bromo-6-chloro-2-cyclopropylimidazo[1,2-a]pyridine (500 mg, 1.85 mmol), morpholine (241 mg, 2.77 mmol), Xphos G2 (145 mg, 0.18 mmol) and t-BuONa (354 mg, 3.69 mmol) in toluene (20 mL) was stirred at 90 ° C for 16 hours. The resulting mixture was cooled, water (50 mL) was added thereto, and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (PE / EA=1 / 1) to give 4-(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine (115 mg, 23%) as a brown oil. MS ESI: C 14 H 16 ClN3O[M+H] + , calculated value 278.10, measured value 278.10.

[0606] Example 18: (S)-N-(5-(2-cyclopropyl-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0607] Under a nitrogen atmosphere, a mixture of 4-(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-8-yl)morpholine (64 mg, 0.23 mmol), (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (100 mg, 0.23 mmol), Xphos G2 (18 mg, 0.02 mmol) and K3PO4 (99 mg, 0.46 mmol) in dioxane (15 mL) and H2O (3 mL) was stirred at 85°C for 1 hour. The resulting mixture was cooled, water (50 mL) was added thereto, and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude residue. The residue was purified by Prep-HPLC to give (S)-N-(5-(2-cyclopropyl-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-2-fluoro-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (67.9 mg, 54%) as a white solid. MS ESI: C 28 H 31 F4N5O2[M+H] + , calculated value 546.24, measured value 546.30. 1 H NMR (400MHz, DMSO-d6) δ7.95 (d, J=1.2Hz, 1H), 7.89 (s, 1H), 7.61 (s, 1H), 7.40 (d, J= 8.0Hz,1H),7.14(d,J=11.2Hz,1H),6.27(s,1H),3.80-3.78(m,4H),3.68-3.64(m,1H ),3.52-3.49(m,5H),3.30-3.33(m,1H),3.05-3.00(m,1H),2.50-2.40(m,3H),2.22 (s,3H),2.07-1.99(m,2H),1.66-1.64(m,1H),0.92-0.88(m,2H),0.80-0.75(m,2H).

[0608] Example 19: 5-(tert-butyl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide

[0609]

[0610] Step 1: 3-(tert-Butyl)pyridine

[0611] Under a hydrogen balloon atmosphere, a mixture of 5-(tert-butyl)-2-chloropyridine (5.0 g, 29.5 mmol), Pd / C (1.5 g, 5%) and NaHCO 3 (2.5 g, 29.5 mmol) in MeOH (50 mL) was stirred at room temperature for 5 hours. The resulting mixture was filtered and concentrated under reduced pressure to give 3-(tert-butyl)pyridine (3.4 g, 85%) as a white solid. MS ESI: C 9 H 13 N[M+H] + , calculated value 136.10, measured value 136.10.

[0612] Step 2: 3-(tert-Butyl)-1-(4-methoxybenzyl)pyridin-1-ium bromide

[0613] Under nitrogen atmosphere, a mixture of 3-(tert-butyl)pyridine (3.4 g, 25.2 mmol) and PMBBr (3.7 mL, 25.2 mmol) in acetonitrile (50 mL) was stirred at room temperature for 3 hours. The resulting mixture was evaporated. The residue was stirred with EA (50 mL) and the solvent was poured off to give 3-(tert-butyl)-1-(4-methoxybenzyl)pyridin-1-ium bromide (5.5 g, 65%) as a brown oil. MS ESI: C 17 H 22 BrNO[M+H-79] + , calculated value 336.09, measured value 257.2.

[0614] Step 3: 5-(tert-Butyl)-1-(4-methoxybenzyl)-1,2,3,6-tetrahydropyridine

[0615] A mixture of 3-(tert-butyl)-1-(4-methoxybenzyl)pyridin-1-ium bromide (5.5 g, 21.5 mmol) in MeOH (50 mL) was cooled to 0 ° C. NaBH4 (1.6 g, 42.9 mmol) was then slowly added to the mixture at 0 ° C. The reaction mixture was stirred at room temperature for 5 hours. The resulting mixture was quenched with NaHCO3 solution and the pH was adjusted to 9, and extracted with EA (100 mL * 2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by FCC (DCM / MeOH=20 / 1) to give 5-(tert-butyl)-1-(4-methoxybenzyl)-1,2,3,6-tetrahydropyridine (4.5 g, 81%) as a light yellow oil. MS ESI: C 17 H 25 NO[M+H] + , calculated value 260.19, measured value 260.1.

[0616] Step 4: 5-(tert-Butyl)-1,2,3,6-tetrahydropyridine

[0617] Under a nitrogen atmosphere, a mixture of 5-(tert-butyl)-1-(4-methoxybenzyl)-1,2,3,6-tetrahydropyridine (4.5 g, 17.3 mmol) and 1-chloroethyl chloroformate (2.2 mL, 20.8 mmol) in DCE (60 mL) was stirred at 70 ° C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was then cooled, MeOH (60 mL) was added thereto, and stirred at 70 ° C for 2 hours under a nitrogen atmosphere. The resulting mixture was cooled and concentrated under reduced pressure. The residue was used directly in the next step.

[0618] Step 5: tert-Butyl 3-(tert-Butyl)-5,6-dihydropyridine-1(2H)-carboxylate

[0619] A mixture of 5-(tert-butyl)-1,2,3,6-tetrahydropyridine (17.3mmol, crude product) in DCM (30mL) was cooled to 0 ° C. DIEA (8.4mL, 51.6mmol) was then added to the mixture, followed by di-tert-butyl dicarbonate (4.5g, 20.7mmol), and then stirred at room temperature for 5 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by FCC (PE / EA=10 / 1) to give tert-butyl 3-(tert-butyl)-5,6-dihydropyridine-1(2H)-carboxylate (3.0g, 73%) as a light yellow oil. MSESI: C 14 H 25 NO2[M+H] + , calculated value 240.19, measured value 240.2.

[0620] Step 6: 5-(tert-Butyl)-1,2,3,6-tetrahydropyridine hydrochloride

[0621] A mixture of tert-butyl 3-(tert-butyl)-5,6-dihydropyridine-1(2H)-carboxylate (3.0 g, 12.5 mmol) in EA / HCl (20 mL, 2N) was stirred at room temperature for 3 hours. The resulting mixture was concentrated under reduced pressure. The residue was used directly in the next step.

[0622] Step 7: 5-(tert-Butyl)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide

[0623] Under a nitrogen atmosphere, BTC (1.1 g, 3.6 mmol) was added to a solution of 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.3 g, 9.1 mmol) and DIEA (7.5 mL, 45.8 mmol) in THF (50 mL) at -78°C. The reaction mixture was stirred at -78°C for 30 minutes. The HCl salt of 5-(tert-butyl)-1,2,3,6-tetrahydropyridine (12.5 mmol) was then added to the mixture at -78°C. The mixture was stirred at 0°C for an additional hour. The resulting mixture was diluted with H₂O (50 mL). The resulting mixture was extracted with EtOAc (50 mL*2). The combined organic layers were washed with brine (40 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue was purified by FCC (PE / EA=10 / 1) to give 5-(tert-butyl)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide (2.6 g, 68%) as a white solid. MS ESI: C 23 H 34 BFN2O3[M+H] + , calculated value 417.26, measured value 417.20.

[0624] Example 19: 5-(tert-butyl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide

[0625] Under a nitrogen atmosphere, a mixture of 4-(6-chloroimidazo[1,2-a]pyridin-8-yl)morpholine (60 mg, 0.25 mmol), 5-(tert-butyl)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide (104 mg, 0.25 mmol), Xphos G2 (16 mg, 0.02 mmol) and K3PO4 (106 mg, 0.50 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred at 85 ° C for 1 hour. The resulting mixture was cooled, water (20 mL) was added thereto, and extracted with EA (50 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by prep-HPLC to give 5-(tert-butyl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3,6-dihydropyridine-1(2H)-carboxamide (19.0 mg, 15%) as a white solid. MSESI: C 28 H 34 FN5O2[M+H] + , calculated value 492.27, measured value 492.1. 1 H NMR(400MHz, DMSO-d6), δ8.27(s,1H),8.10(s,1H),7.88(s,1H),7.49(s,1H),7.33(d,J=8.0Hz,1H),7.16(d,J=7.6Hz,1H),6.33(s,1H),5.62-5.6 0(m,1H),3.95(d,J=1.6Hz,2H),3.79(t,J=4.4Hz,4H),3.53(t,J=4.4Hz, 4H), 3.43 (t, J = 6.0Hz, 2H), 2.24 (s, 3H), 2.11-2.10 (m, 2H), 1.06 (s, 9H).

[0626] Example 20: N-(2-fluoro-5-(2-fluoro-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide

[0627]

[0628] Step 1: 4-(6-chloro-2-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine

[0629] To a mixture of 4-(6-chloroimidazo[1,2-a]pyridin-8-yl)morpholine (1.0 g, 4.20 mmol) in THF (30 mL) was added NaH (250 mg, 60%, 6.3 mmol) at 0°C. The reaction mixture was stirred at 0°C for 15 minutes. Selective fluorine reagent (selectfluor) (2.98 g, 8.40 mmol) was then added to the reaction mixture at 0°C. The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (100 mL). The resulting mixture was extracted with EtOAc (100 mL*2). The combined organic layers were washed with brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase column chromatography (PE / EA=2 / 1) to give 4-(6-chloro-2-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine (90 mg, 8%) and 4-(6-chloro-3-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine (150 mg, 14%) as a yellow semisolid.

[0630] 4-(6-chloro-2-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine 1 H NMR (400MHz, CDCl3) δ7.88 (d, J = 6.0 Hz, 1H), 7.55 (d, J = 0.9 Hz, 1H), 7.44 (d, J = 0.9 Hz, 1H), 3.92-3.90 (m, 4H), 3.64-3.61 (m, 4H). MSESI:C 11 H 11 ClFN3O[M+H] + , calculated value 256.06, measured value 256.00.

[0631] 4-(6-chloro-3-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine 1 H NMR (400MHz, CDCl3) δ7.61 (s, 2H), 6.40 (d, J = 6.8Hz, 1H), 3.97-3.95 (m, 4H), 3.49-3.47 (m, 4H). MSESI:C 11 H 11 ClFN3O[M+H] + , calculated value 256.06, measured value 256.00.

[0632] Example 20: N-(2-fluoro-5-(2-fluoro-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide

[0633] Under a nitrogen atmosphere, a mixture of 4-(6-chloro-2-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine (40 mg, 0.16 mmol), N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide (67 mg, 0.16 mmol), Xphos G2 (12 mg, 0.02 mmol) and K3PO4 (67 mg, 0.31 mmol) in dioxane (15 mL) and H2O (3 mL) was stirred at 85 ° C for 1 hour. The resulting mixture was cooled, water (50 mL) was added thereto, and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude residue. The residue was purified by Prep-HPLC to give N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide (27.2 mg, 34%) as a white solid. MS ESI: C 25 H 24 F5N5O2[M+H] + , calculated value 522.19, measured value 522.00. 1 H NMR (400MHz, DMSO-d6) δ8.20(d,J=6.4Hz,1H),8.03(s,1H),7.86(s,1H),7.51(d,J=0.8Hz,1H),7.44(d,J=8.0Hz,1H),7 .20(d,J=11.6Hz,1H),5.92(s,1H),4.20(s,4H),3.76-3.74(m,4H),3.52-3.50(m,4H),3.31-3.29(m,2H),2.16(s,3H).

[0634] Example 21: (S)-N-(2-fluoro-5-(3-fluoro-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0635] Under a nitrogen atmosphere, a mixture of 4-(6-chloro-3-fluoroimidazo[1,2-a]pyridin-8-yl)morpholine (32 mg, 0.13 mmol), (S)-N-(2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (54 mg, 0.13 mmol), Xphos G2 (10 mg, 0.01 mmol) and K3PO4 (53 mg, 0.25 mmol) in dioxane (10 mL) and H2O (2 mL) was stirred at 85°C for 1 hour. The resulting mixture was cooled, water (50 mL) was added thereto, and extracted with EA (100 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give a crude residue. The residue was purified by Prep-HPLC to give (S)-N-(2-fluoro-5-(3-fluoro-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (30.5 mg, 46%) as a white solid. MS ESI: C 25 H 26 F5N5O2[M+H] + , calculated value 524.20, measured value 524.20. 1 H NMR(400MHz,DMSO-d6)δ7.96-7.93(m,2H),7.63(d,J=0.8Hz,1H),7.46(d,J =8.0Hz,1H),7.22(d,J=11.6Hz,1H),6.34(d,J=6.8Hz,1H),3.81-3.79(m,4H ),3.68-3.64(m,1H),3.54-3.45(m,5H),3.34-3.30(m,1H),3.03(t,J=9.2Hz ,1H),2.50-2.41(m,3H),2.17(s,3H),2.10-2.07(m,1H),1.67-1.65(m,1H).

[0636] The compounds in Table 7 below were prepared using procedures analogous to those described in Examples 17, 18 or 20 and using appropriate starting materials.

[0637] Table 7

[0638]

[0639]

[0640]

[0641]

[0642]

[0643] Example 33: N-(4-methyl-3-(6-morpholinyl-3,4-dihydro-1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridin-8-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

[0644]

[0645] Step 1: Under nitrogen atmosphere, to a stirred mixture of 3,5-dibromopyridin-2-amine (20 g, 79.39 mmol) and 1-chloro-1-[dicyclohexyl([2-[2,4,6-tri(propane-2-yl)phenyl]phenyl])-1N-[S]-phosphino]-2H,3H,4H-benzo[c]1-aza-2-palladiumheterocyclohexane (0.59 g, 0.79 mmol) in THF (200 mL) was added morpholine (6.9 mL, 79.39 mmol) and LiHMDS (1 M in THF) (198.50 mL, 198.50 mmol) at room temperature. Under nitrogen atmosphere, the reaction mixture was stirred at 65 ° C for 16 hours. The reaction mixture can be cooled to room temperature. The resulting mixture was quenched at room temperature by adding saturated NH4Cl (aqueous solution) (300 mL). The resulting mixture was extracted with EA (3 x 200 mL). The combined organic layers were washed with brine (2 x 150 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc / EtOH=4 / 3 / 1. The fractions containing the desired product were combined and concentrated to give 5-bromo-3-morpholinopyridine-2-amine (9 g, 44%) as a light yellow solid. MS ESI: C9H 12 BrN3O[M+H] + , calculated value 258.02, measured value 258.00. 1 H NMR (300MHz, CDCl3) δ7.88 (d, J = 2.1 Hz, 1H), 7.24 (d, J = 2.1 Hz, 1H), 4.77 (s, 2H), 3.86-3.82 (m, 4H), 2.93-2.90 (m, 4H).

[0646] Step 2: To a stirred mixture of 5-bromo-3-(morpholin-4-yl)pyridin-2-amine (200.00 mg, 0.78 mmol) in EtOH (5.00 mL) was added 3-bromooxan-4-one (277.41 mg, 1.56 mmol). The reaction mixture was stirred at 80° C. for 48 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: Column: C18 column 120 g; Mobile phase A: water (plus 10 mmol / L NH4HCO3), Mobile phase B: MeCN; Flow rate: 60 mL / min; Gradient: 30% B to 60% B over 30 minutes; 254 / 220 nm. The fractions containing the desired product were combined and concentrated to give 8-bromo-6-morpholino-3,4-dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine (66 mg, 25%) as a brown solid. MSESI: C 14 H 16 BrN3O2[M+H] + , calculated value 338.21, measured value 338.05; 1 H NMR (400MHz, DMSO-d6) δ7.49(d,J=1.6Hz,1H),6.50(d,J=1.6Hz,1H),4.89(t,J=1.4Hz, 2H), 4.08 (t, J = 5.5Hz, 2H), 4.03-3.95 (m, 4H), 3.64-3.53 (m, 4H), 2.99 (t, J = 5.6Hz, 2H).

[0647] Step 3: Under nitrogen atmosphere, TEA (2.38mL, 23.57mmol) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1g, 4.29mmol) were added to a solution of 2-(trifluoromethyl)pyridine-4-carboxylic acid (1.23g, 6.43mmol) and HATU (3.26g, 8.58mmol) in DMF (10mL) at 0°C. The reaction mixture was stirred at room temperature for 1.5 hours. The resulting mixture was diluted with water (30mL) and extracted with EA (3x 80mL). The combined organic layers were washed with brine (5x40mL), dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (3 / 1). The fractions containing the desired product were combined and concentrated to give N-(4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-2-(trifluoromethyl)isonicotinamide (1.45 g, 83%) as an off-white solid. MS ESI: C 20 H22 BF3N2O3[M+H] + , calculated value 407.17, measured value 406.90; 1 H NMR (400MHz, DMSO-d6) δ10.63 (s, 1H), 8.98 (d, J = 5.0Hz, 1H), 8.43-8.39 (m, 1H), 8.22 (dd ,J=5.1,1.6Hz,1H),7.98-7.88(m,2H),7.21(d,J=8.3Hz,1H),2.46(s,3H),1.32(s,12H).

[0648] Step 4: to the stirred 8-bromo-6-morpholinyl-3,4-dihydro-1H-pyrano[4',3':4,5]imidazo[1,2-a]pyridine (66.00mg, 0.20mmol) and N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-(trifluoromethyl)pyridine-4-carboxamide (87.20mg, 0.22mmol) in dioxane (4.00mL) and H2O (1.00mL) mixture was added Pd(dppf)Cl2.CH2Cl2 (15.94mg, 0.02mmol) and K2CO3 (80.91mg, 0.59mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC using PE / EA / EtOH (4 / 3 / 1) as eluent to afford the crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: Column: C18 column 120 g; Mobile phase A: Water (added with 10 mmol / L NH4HCO3), Mobile phase B: MeCN; Flow rate: 60 mL / min; Gradient: 35% B to 65% B over 25 minutes; 254 / 220 nm. Fractions containing the desired product were combined and concentrated to afford the title compound (45 mg, 42%) as a white solid. MS ESI: C 28 H 26 F3N5O3[M+H] + , calculated value 538.54, measured value 538.20; 1H NMR (400MHz, DMSO-d6) δ10.71(s,1H),9.00(d,J=5.0Hz,1H),8.38(s,1H),8.20(d,J=5.0Hz,1H),7.85-7.68(m,3H),7.35(d,J=8.3Hz ,1H),6.41(s,1H),4.89(s,2H),3.99(t,J=5.4Hz,2H),3.90-3.74(m,4H),3.54(t,J=4.5Hz,4H),2.83(t,J=5.4Hz,2H),2.27(s,3H).

[0649] Examples 34 and 35: N-(2-Fluoro-5-(8-hydroxy-4-morpholinyl-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-2-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide

[0650]

[0651] Step 1 & 2: Under a nitrogen atmosphere, at -78 ° C, to a stirred mixture of 1,4-dioxaspiro [4.5] decane-8-one (6.00 g, 38.42 mmol) in THF (100.00 mL), LiHMDS (1 M in THF) (76.8 mL, 76.83 mmol) was added dropwise. Under a nitrogen atmosphere, the reaction mixture was stirred at -78 ° C for 30 minutes. At -78 ° C, TMSCl (6.60 mL, 51.64 mmol) was added dropwise to the above mixture over 20 minutes. The reaction mixture was stirred for another 30 minutes at -78 ° C. The resulting mixture was quenched with NaHCO at 0 ° C and extracted with EA (3 x 200 mL). The combined organic layer was washed with brine (2 x 50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was then dissolved in THF (50.00 mL) and H2O (50.00 mL). NaOAc (0.32 g, 3.91 mmol) and NBS (6.84 g, 38.43 mmol) were added to the above solution in batches at 0 ° C. The reaction mixture was stirred at room temperature for 3 hours. The resulting mixture was quenched with NaHCO3 (aqueous solution) and extracted with EtOAc (3 x 300 mL). The combined organic layer was washed with salt water (2 x 100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to obtain 7-bromo-1,4-dioxaspiro [4.5] decane-8-one (crude product). To a stirred mixture of 7-bromo-1,4-dioxaspiro[4.5]decane-8-one (819.66 mg, 3.49 mmol) in EtOH (10.00 mL) was added 5-bromo-3-(morpholin-4-yl)pyridin-2-amine (600.00 mg, 2.33 mmol) in batches at room temperature. The reaction mixture was stirred at 80 ° C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EtOAc (1 / 1). The fractions containing the desired product were combined and concentrated to give 2-bromo-4-morpholino-6,9-dihydro-7H-spiro[benzo[4,5]imidazo[1,2-a]pyridine-8,2'-[1,3]dioxolane] (0.60 g, 65%) as a brown oil. MS ESI: C 17 H 20 BrN3O3[M+H] + , calculated value 394.07, measured value 394.10.

[0652] Step 3: A solution of 12-bromo-10-(morpholin-4-yl)-1,8-diazaspiro[1,3-dioxolane-2,4-tricyclo[7.4.0.0^[2,7]]tridecane]-2(7),8,10,12-tetraene (500 mg, 1.53 mmol) in HCl (6M) (8 mL) was stirred at 60 °C for 1 hour. The resulting mixture was concentrated under reduced pressure. The resulting mixture was basified with saturated NaHCO3 (aq.) to pH 9. The combined organic layers were washed with brine (2 x 100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The aqueous layer was extracted with EtOAc (3 x 50 mL). The residue was purified by Prep-TLC eluting with PE / (EtOAc / EtOH) (1 / (3 / 1)). The fractions containing the desired product were combined and concentrated to give 2-bromo-4-morpholino-6,9-dihydrobenzo[4,5]imidazo[1,2-a]pyridin-8(7H)-one (0.35 g, 65%) as a dark green oil. MS ESI: C 15 H 16 BrN3O2[M+H] + , calculated values ​​350.04, 352.04, measured values ​​350.05, 352.05.

[0653] Step 4: To a stirred mixture of 2-bromo-4-morpholino-6,9-dihydrobenzo[4,5]imidazo[1,2-a]pyridine-8(7H)-one (300.00 mg, 0.86 mmol) in MeOH (5.00 mL) was added NaBH4 (38.89 mg, 1.03 mmol) in portions at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC and eluted with PE / EtOAc (1 / 1). The fractions containing the desired product were combined and concentrated to give 2-bromo-4-morpholino-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridine-8-ol (200 mg, 66%) as a light brown solid. MS ESI:C 15 H 18 BrN3O2[M+H] + , calculated values ​​352.06, 354.06, measured values ​​352.10, 354.10; 1 H NMR(300MHz, CDCl3) δ7.62(d,J=1.7Hz,1H),6.51(d,J=1.7Hz,1H),4.43(s,1H),4.11-3 .97(m,4H),3.56-3.52(m,4H),3.14-2.86(m,3H),2.81-2.28(m,2H),2.07-1.76(m,2H).

[0654] Step 5: To a stirred mixture of N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-(trifluoromethyl)pyridine-4-carboxamide (230.65 mg, 0.57 mmol) and 2-bromo-4-morpholino-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-8-ol (200.00 mg, 0.57 mmol) in dioxane (6.00 mL) and H2O (1.00 mL) was added Pd(dppf)Cl2.CH2Cl2 (46.37 mg, 0.06 mmol) and Na2CO3 (180.54 mg, 1.70 mmol) in portions at room temperature. The reaction mixture was degassed with nitrogen three times and stirred at 80°C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC using PE / (EtOAc / EtOH) (1 / (3 / 1)) as eluent to give the crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: column: Spherical C18, 20-40 μm, 120 g; mobile phase A: water (with 10 mmol / L NH4HCO3); mobile phase B: ACN; flow rate: 60 mL / min; gradient of B: 35% to 75% over 20 minutes; detector: 220 nm. Fractions containing the desired product were combined and concentrated to give N-(3-(8-hydroxy-4-morpholino-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-2-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (200 mg, 64%) as a light yellow solid. MS ESI: C 29 H 28 F3N5O2[M+H] + , calculated value 552.21, measured value 552.15.

[0655] Step 6: N-(3-(8-Hydroxy-4-morpholino-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-2-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide (200.00 mg) was purified by Prep-chiral-HPLC using the following conditions: Column: CHIRALPAK-AD-H-UL001, 20 x 250 mm, 5 μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, Mobile phase B: IPA--HPLC; Flow rate: 20 mL / min; Gradient: 20B to 20B over 18 minutes; 220 / 254 nm; RT1 (peak 1): 10.805 min; Injection volume: 0.5 mL.

[0656] Peak 1 (Example 34, N-(2-fluoro-5-(8-hydroxy-4-morpholinyl-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-2-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide): Fractions (RT: 10.8 min) were combined and concentrated to give the title compound (76.8 mg, 38%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 29 H 28 F3N5O3[M+H] + , calculated value 552.21, measured value 552.20; 1 H NMR (300MHz, DMSO-d6) δ10.70(s,1H),8.99(d,J=5.1Hz,1H),8.37(d,J=1.5H z,1H),8.20(d,J=5.2Hz,1H),7.74-7.70(m,3H),7.34(d,J=8.3Hz,1H),6.37 (s,1H),4.97(d,J=4.2Hz,1H),4.14(s,1H),3.81-3.77(m,4H),3.55-3.51(m ,4H),3.06-3.02(m,1H),2.86-2.51(m,3H),2.28(s,3H),2.07-1.76(m,2H).

[0657] Peak 2 (Example 35, N-(2-fluoro-5-(8-hydroxy-4-morpholinyl-6,7,8,9-tetrahydrobenzo[4,5]imidazo[1,2-a]pyridin-2-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide): Fractions (RT: 14.2 min) were combined and concentrated to give the title compound (75.6 mg, 38%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 29 H 28 F3N5O3[M+H] + , calculated value 552.21, measured value 552.20; 1H NMR (300MHz, DMSO-d6) δ10.70(s,1H),8.99(d,J=5.0Hz,1H),8.38(s,1H),8.24-8.16(m,1H),7.81-7.67(m,3H),7.35(d,J=8.3Hz,1H),6.37(s,1H ),4.97(d,J=4.2Hz,1H),4.14(s,1H),3.81-3.77(m,4H),3.55-3.51(m,4 H),3.06-3.02(m,1H),2.88-2.53(m,3H),2.28(s,3H),2.05-1.74(m,2H).

[0658] Example 36: N-(4-methyl-3-(9-morpholinyl-3,4-dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridin-7-yl)phenyl)-2-(trifluoromethyl)isonicotinamide

[0659]

[0660] Step 1: Under a nitrogen atmosphere, sulfur (6.36 g, 198.49 mmol) was added to a stirred mixture of 3,5-dibromopyridin-2-amine (10 g, 39.69 mmol) and oxane-3-one (7.95 g, 79.39 mmol) in dioxane (100 mL) at room temperature. The reaction mixture was stirred at 100 ° C for 48 hours under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give a crude product. The crude product was purified by Prep-HPLC using the following conditions: Column: XBridge Shield RP18 OBD column, 30 x 150 mm, 5 μm; Mobile phase A: Water (plus 10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 30% B to 40% B, 40% B over 10 minutes; Wavelength: 254 nm; RT1: 8.5 min. Fractions containing the desired product were combined and concentrated to give 7,9-dibromo-3,4-dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine (200 mg, 2%) as a light yellow solid. MS ESI: C 10 H8Br2N2O[M+H] + , calculated values ​​330.90, 332.90, measured values ​​330.80 332.80; 1H NMR (300MHz, CDCl3) δ 8.01 (d, J = 1.6 Hz, 1H), 7.56 (d, J = 1.6 Hz, 1H), 4.93 (d, J = 1.4 Hz, 2H), 4.13 (t, J = 5.5 Hz, 2H), 2.93 (t, J = 5.5 Hz, 2H).

[0661] Step 2: Under a nitrogen atmosphere, to a stirred mixture of 7,9-dibromo-3,4-dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine (185 mg, 0.56 mmol), morpholine (50.98 mg, 0.56 mmol) and 1-chloro-1-[dicyclohexyl([2-[2,4,6-tri(propane-2-yl)phenyl]phenyl])-1^[S]-phosphino]-2H,3H,4H-benzo[c]1-aza-2-palladiumheterocyclohexane (20.58 mg, 0.03 mmol) in THF (2 mL) was added dropwise LiHMDS (2.5 M in THF) (0.56 mL, 1.39 mmol) at 65 ° C. Under a nitrogen atmosphere, the resulting mixture was stirred at 65 ° C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (1 / 4) as eluent. The fractions containing the desired product were combined and concentrated to afford 7-bromo-9-morpholino-3,4-dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine (60 mg, 31.84%) as an off-white solid. MS ESI: C 14 H 16 BrN3O2[M+H] + , calculated values ​​338.04, 340.04, measured values ​​337.95, 339.95; 1 H NMR(300MHz, CDCl3) δ7.67(d,J=1.6Hz,1H),6.53(d,J=1.6Hz,1H),4.89(s,2H), 4.11(t,J=5.5Hz,2H),4.00-3.96(m,4H),3.56-3.52(m,4H),2.96-2.83(m,2H).

[0662] Step 3: to 7-bromo-9-morpholinyl-3,4-dihydro-1H-pyrano[3',4':4,5]imidazo[1,2-a]pyridine (50mg, 0.15mmol) and N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-(trifluoromethyl)pyridine-4-carboxamide (72mg, 0.18mmol) in dioxane (5mL) and H2O (1mL) solution in add K2CO3 (40mg, 0.30mmol) and Pd(dppf)Cl2.CH2Cl2 (12mg, 0.02mmol). The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC, eluted with PE / EtOAc (1 / 5). The fractions containing the desired product were combined and concentrated to give the title compound as a white solid (19.2 mg, 24%). MS ESI: C 28 H 26 F3N5O3[M+H] + , calculated value 538.20, measured value 538.10; 1 H NMR (300MHz, DMSO-d6) δ10.70(s,1H),8.99(d,J=5.1Hz,1H),8.38(d,J=1.4H z,1H),8.20(d,J=5.1Hz,1H),7.85(d,J=1.3Hz,1H),7.81-7.68(m,2H),7.35 (d,J=8.3Hz,1H),6.42(d,J=1.5Hz,1H),4.74(s,2H),4.01(t,J=5.4Hz,2H), 3.81-3.77(m,4H),3.55-3.51(m,4H),2.91-2.86(m,2H),2.28-2.17(m,3H).

[0663] Example 38: (3S)-N-[4-methyl-3-(8-[8-oxa-3-azabicyclo[3.2.1]octan-3-yl]imidazo[1,2-a]pyridin-6-yl)phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0664]

[0665] Step 1: To a stirred mixture of 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (2.00 g, 8.58 mmol) and DIEA (5.54 g, 42.89 mmol) in THF (100.00 mL) was added triphosgene (1.02 g, 3.44 mmol). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 30 minutes. To the above mixture was added (3S)-3-(2,2,2-trifluoroethyl)pyrrolidine·HCl salt (1.63 g, 8.58 mmol) dropwise at room temperature. The reaction mixture was stirred at room temperature for an additional 3 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1). The fractions containing the desired product were combined and concentrated to give (3S)-N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (3.1 g, 88%) as an off-white solid. MS ESI: C 20 H 28 BF3N2O3[M+H] + , calculated value 413.21, measured value 413.15; 1 H NMR (300MHz, DMSO-d6) δ8.14(s,1H),7.67(d,J=2.3Hz,1H),7.62-7.59(m,1H),7.03(d,J=8.3Hz,1H),3.69-3.65(m,1H),3.55-3.51 (m,1H),3.31-3.27(m,1H),3.04-3.00(m,1H),2.51-2.43(m,3H),2.38(s,3H),2.10-2.06(m,1H),1.70-1.63(m,1H),1.31(s,12H).

[0666] Step 2: To a stirred mixture of 8-bromo-6-chloroimidazo[1,2-a]pyridine (500 mg, 2.16 mmol), Cs2CO3 (2.1 g, 6.48 mmol) and 8-oxa-3-azabicyclo[3.2.1]octane HCl salt (0.48 g, 3.24 mmol) in dioxane (6.00 mL) was added RuPhos-PdCl-2nd G (0.17 g, 0.22 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 3 hours. The resulting mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give 3-[6-chloroimidazo[1,2-a]pyridin-8-yl]-8-oxa-3-azabicyclo[3.2.1]octane (140 mg, 23%) as a pale yellow solid; MS ESI: C 13 H 14 ClN3O[M+H] + , calculated values ​​264.08, 266.08, measured values ​​264.20, 266.20.

[0667] Step 3: To a stirred mixture of 3-[6-chloroimidazo[1,2-a]pyridin-8-yl]-8-oxa-3-azabicyclo[3.2.1]octane (120 mg, 0.46 mmol), (3S)-N-[4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide (187 mg, 0.46 mmol) and KCO (188 mg, 1.36 mmol) in THF (2.00 mL) and H0 (0.20 mL) was added XPhosPdG (38 mg, 0.05 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 16 hours. The resulting mixture was diluted with water (10 mL) and extracted with EA (3 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by prep-TLC using PE / EA / EtOH (4 / 3 / 1) as eluent to give the crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: column: Spherical C18, 20-40 μm, 120 g; mobile phase A: water (with 10 mmol / L NH4HCO3); mobile phase B: ACN; flow rate: 60 mL / min; gradient of B: 35% to 75% in 20 minutes; detector: 220 nm. The fractions containing the desired product were combined and concentrated to give the title compound (88.9 mg, 37%) as a white solid; MS ESI: C 27 H 30 F3N5O2[M+H] + , calculated value 514.24, measured value 514.30; 1 H NMR (300MHz, CDCl3) δ7.73-7.69(m,1H),7.63-7.61(m,1H),7.54-7.50(m,1H),7.42-7.38( m,1H),7.32-7.30(m,1H),7.22(d,J=8.2Hz,1H),6.36-6.33(m,1H),6.14(s,1H),4.52-4.48 (m,2H),4.14-4.10(m,2H),3.89-3.77(m,1H),3.66(t,J=8.4Hz,1H),3.47-3.42(m,1H),3.1 6-3.12(m,3H),2.65-2.51(m,1H),2.32-2.23(m,8H),2.07-2.03(m,2H),1.85-1.71(m,1H).

[0668] Example 43: 1-tert-Butyl-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrrole-3-carboxamide

[0669]

[0670] Step 1: Under a nitrogen atmosphere, 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (100 mg, 0.31 mmol) was added to a stirred solution of 1-tert-butylpyrrole-3-carboxylic acid (76.85 mg, 0.46 mmol), HATU (174.75 mg, 0.46 mmol) and TEA (155.03 mg, 1.53 mmol) in THF (1 mL) at room temperature. The reaction mixture was stirred at 60° C. for 1 hour under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-HPLC using the following conditions: Column: XBridge Shield RP18 OBD column, 30 x 150 mm, 5 μm; Mobile phase A: Water (plus 10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 42% B to 52% B, 52% B over 10 minutes; Wavelength: 254 nm; RT1: 8.02 min. Fractions containing the desired product were combined and concentrated to give the title compound (39.3 mg, 26%) as an off-white solid. MS ESI: C 27 H 30 FN5O2[M+H] + , calculated value 476.24, measured value 476.15; 1 H NMR (400MHz, DMSO-d6) δ9.32 (s, 1H), 8.14 (d, J = 1.4Hz, 1H), 7.89 (d, J = 1.2Hz, 1 H),7.70(t,J=2.1Hz,1H),7.54(d,J=8.0Hz,1H),7.50(d,J=1.2Hz,1H),7.24(d ,J=11.5Hz,1H),7.01(t,J=2.7Hz,1H),6.59(dd,J=3.0,1.8Hz,1H),6.36(d,J= 1.5Hz,1H),3.83-3.77(m,4H),3.55(t,J=4.8Hz,4H),2.28(s,3H),1.51(s,9H).

[0671] Example 46: (R)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxamide

[0672]

[0673] Step 1: to the mixture of (3R)-pyrrolidine-3-carboxylic acid methyl ester HCl salt (1.00g, 6.04mmol) and potassium carbonate (2.50g, 18.11mmol) in N, N-dimethylformamide (10.00mL) of stirring, add 1,1,1-trifluoro-2-iodoethane (1.90g, 9.06mmol). Under nitrogen atmosphere, the reaction mixture was stirred at 100 ° C for 16 hours. The gained mixture was diluted with water (80.00mL) and extracted with ethyl acetate (3x50mL). The combined organic layer was washed with salt water (2x 50mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (5 / 1). The fractions containing the desired product were combined and concentrated to give (R)-methyl 1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxylate (800 mg, 62%) as a yellow liquid. MS ESI: C8H 12 F3NO2[M+H] + , calculated value 212.08, measured value 212.05.

[0674] Step 2: To a stirred mixture of (3R)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxylic acid methyl ester (850 mg, 4.03 mmol) in THF (3.00 mL) and MeOH (3.00 mL) was added LiOH·H2O (506.66 mg, 12.08 mmol) in water (3.00 mL). The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was acidified to pH 6 with HCl (aqueous solution). The resulting mixture was extracted with ethyl acetate (3x40 mL). The combined organic layers were washed with brine (3x 20 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure to give (R)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxylic acid (0.63 g, 79%) as a yellow oil. MS ESI: C7H 10 F3NO2[M+H] + , calculated value 198.07, measured value 198.00.

[0675] Step 3: To a stirred mixture of (R)-1-(2,2,2-trifluoroethyl)pyrrolidine-3-carboxylic acid (100 mg, 0.51 mmol), HATU (289.29 mg, 0.76 mmol), and trimethylamine (256.63 mg, 2.54 mmol) in acetonitrile (1.00 mL) was added 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (165.54 mg, 0.51 mmol). The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase: ACN in water (plus 10 mmol / L NH4HCO3), gradient from 10% to 50% over 10 minutes; detector, UV 254 nm. The fractions containing the desired product were combined and concentrated to give the title compound as an off-white solid (23.2 mg, 9%). MS ESI: C 25 H 27 F4N5O2[M+H] + , calculated value 506.21, measured value 506.20; 1 H NMR (400MHz, DMSO-d6) δ9.74(s,1H),8.13(d,J=1.5Hz,1H),7.90(d,J=1.2Hz,1H) ,7.79(d,J=8.1Hz,1H),7.53(s,1H),7.24(d,J=11.8Hz,1H),6.36(s,1H),3.81(t, J=4.7Hz,4H),3.54(t,J=4.7Hz,4H),3.32-3.13(m,2H),3.18-3.12(m,1H),3.07-3 .03(m,1H),2.88-2.74(m,2H),2.69-2.62(m,1H),2.25(s,3H),2.05-1.96(m,2H).

[0676] Example 50: 2-(tert-Butyl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)morpholine-4-carboxamide

[0677]

[0678] Step 1: Under a nitrogen atmosphere, to a stirred solution of 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (200 mg, 0.61 mmol) and DIEA (0.53 mL, 3.06 mmol) in THF (12.71 mL) was added dropwise a solution of triphosgene (72.73 mg, 0.25 mmol) in THF (1 mL) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 30 minutes. 2-tert-butylmorpholine HCl (110.11 mg, 0.61 mmol) in THF (1 mL) was added dropwise to the above mixture at room temperature. The reaction mixture was stirred for another 2 hours at room temperature. The resulting mixture was quenched with MeOH at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with DCM / MeOH (10 / 1). The fractions containing the desired product were combined and concentrated to give 2-tert-butyl-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}morpholine-4-carboxamide (185 mg, 61%) as an off-white solid. MS ESI: C 27 H 34 FN5O3[M+H] + , calculated value 496.26, measured value 496.20.

[0679] Step 2: 2-tert-Butyl-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}morpholine-4-carboxamide (230 mg, 0.46 mmol) was purified by Prep-chiral-HPLC using the following conditions: Column: CHIRAL ART Amylose-SA, 2 x 25 cm, 5 μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, Mobile phase B: MeOH:DCM=1:1--HPLC; Flow rate: 20 mL / min; Gradient: 20% B to 20% B over 10 minutes; Wavelength: 220 / 254 nm; RT1: 8.00 min; RT2: 9.37 min; Sample solvent: MeOH--HPLC; Injection volume: 0.3 mL.

[0680] Peak 1 (Example 50, 2-(tert-butyl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)morpholine-4-carboxamide): Fractions (RT: 8.0 min) were combined and concentrated to give the title compound (71.8 mg, 31%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 34 FN5O3[M+H]+ , calculated value 496.26, measured value 496.25; 1 H NMR (400MHz, DMSO-d6) δ8.34(s,1H),8.11(d,J=1.4Hz,1H),7.88(d,J=1.2Hz,1H),7.50(d ,J=1.2Hz,1H),7.33(d,J=8.2Hz,1H),7.17(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),4.01- 3.97(m,1H),3.95-3.84(m,2H),3.80(t,J=4.7Hz,4H),3.54(t,J=4.7Hz,4H),3.42-3.36( m,1H),2.99-2.97(m,1H),2.91-2.79(m,1H),2.66-2.64(m,1H),2.25(s,3H),0.91(s,9H).

[0681] Examples 60 and 61: N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1-methylcyclopropyl)pyrrolidine-1-carboxamide

[0682]

[0683] Step 1: Add in batches to a stirred mixture of 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (100 mg, 0.31 mmol) and triethylamine (124 mg, 1.22 mmol) in tetrahydrofuran (1.5 mL) at room temperature. Triphosgene (36 mg, 0.12 mmol) was added in batches over 30 minutes at room temperature to the above mixture. 2,2,2-trifluoro-113-ethan-1-one compound was added dropwise to the above mixture along with 3-(1-(trifluoromethyl)cyclopropyl)pyrrolidine 2,2,2-trifluoroacetate (134 mg, 0.46 mmol) at room temperature. The reaction mixture was stirred for another 2 hours at room temperature. The resulting mixture was quenched with methanol and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 120 g; Mobile phase A: Water (plus 10 mmol / L NH4HCO3); Mobile phase B: Acetonitrile; Gradient: 40% to 60% B over 20 minutes; Flow rate: 60 mL / min; Detector: 220 / 254 nm. Fractions containing the desired product were combined and concentrated to afford N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}-3-[1-(trifluoromethyl)cyclopropyl]pyrrolidine-1-carboxamide as an off-white solid. MS ESI: C 27 H 29 F4N5O2[M+H] + , calculated value 532.23, measured value 532.15.

[0684] Step 2: N-{2-Fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}-3-[1-(trifluoromethyl)cyclopropyl]pyrrolidine-1-carboxamide (112 mg, 0.21 mmol) was purified by chiral-Prep-HPLC using the following conditions: Column: Lux 5 μm Cellulose-4, 2.12 x 25 cm, 5 μm; Mobile phase A: Hex-HPLC, Mobile phase B: MeOH:EtOH=1:1-HPLC; Flow rate: 20 mL / min; Gradient: 20% B to 20% B over 25 minutes; Wavelength: 220 / 254 nm; RT1: 19.36 min; RT2: 22.26 min; Sample solvent: MeOH-HPLC; Injection volume: 0.3 mL.

[0685] Peak 1 (Example 60, N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1-methylcyclopropyl)pyrrolidine-1-carboxamide): Fractions (RT 19.36 min) were combined and concentrated to give the title compound (29 mg, 25%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 29 F4N5O2[M+H] + , calculated value 532.23, measured value 532.30; 1 H NMR(400MHz,DMSO-d6)δ8.19(s,1H),7.97-7.96(m,1H),7.91-7.89(m,1H),7.63-7.5 9(m,1H),7.44(d,J=8.1Hz,1H),7.18(d,J=11.6Hz,1H),6.50(s,1H),3.81(t,J=4.6Hz ,4H),3.65-3.63(m,1H),3.49-3.47(m,4H),3.36-3.32(m,2H),2.93-2.91(m,1H),2.7 4-2.68(m,1H),2.25(s,3H),1.93-1.86(m,1H),1.49-1.44(m,1H),0.91-0.85(m,4H).

[0686] Peak 2 (Example 61, N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1-methylcyclopropyl)pyrrolidine-1-carboxamide): Fractions (RT 22.26 min) were combined and concentrated to give the title compound (32 mg, 28%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 29 F4N5O2[M+H] + , calculated value 532.23, measured value 532.30; 1H NMR(400MHz,DMSO-d6)δ8.19(s,1H),7.97-7.96(m,1H),7.91-7.89(m,1H),7.63-7.5 9(m,1H),7.44(d,J=8.1Hz,1H),7.18(d,J=11.6Hz,1H),6.50(s,1H),3.81(t,J=4.6Hz ,4H),3.65-3.63(m,1H),3.57-3.44(m,4H),3.33-3.32(m,2H),2.93-2.91(m,1H),2.7 4-2.68(m,1H),2.25(s,3H),1.93-1.86(m,1H),1.47-1.45(m,1H),0.91-0.85(m,4H).

[0687] Example 66: 1-tert-Butyl-4-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrrole-3-carboxamide

[0688]

[0689] Step 1: 2,5-dimethoxyoxacyclopentane (50g, 378.33mmol) was added dropwise to a stirred solution of 2-methylpropane-2-amine (50g, 683.63mmol) in AcOH (150mL) at 0°C. The reaction mixture was stirred at 80°C for 48 hours. The mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was diluted with water and basified to pH 8 with NaOH (aqueous solution). The resulting mixture was extracted with diethyl ether (2x 200mL). The combined organic layers were washed with brine (1x 200mL) and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The resulting mixture was concentrated under reduced pressure. The crude product was purified by distillation at 2Mpa, and fractions were collected at 80°C to obtain 1-tert-butylpyrrole (5g, 10%) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ6.84 (t, J = 2.0 Hz, 2H), 6.16 (t, J = 2.0 Hz, 2H), 1.53 (s, 9H).

[0690] Step 2: To a stirred solution of 1-tert-butylpyrrole (3.5 g, 28.41 mmol) in tetrahydrofuran (40 mL) was added dropwise N-bromosuccinimide (10.11 g, 56.82 mmol) in tetrahydrofuran (140 mL) at -80 ° C. The reaction mixture was stirred at -80 ° C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with ethyl acetate. The fractions containing the desired product were combined and concentrated to give 3,4-dibromo-1-tert-butylpyrrole (7.71 g, 96%) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ6.80 (d, J=1.2Hz, 2H), 1.49 (s, 9H).

[0691] Step 3: Under a nitrogen atmosphere, 2.5M n-BuLi (4.48mL, 11.21mmol) in hexane was added dropwise to a stirred solution of 3,4-dibromo-1-tert-butyl pyrrole (3g, 10.68mmol) in tetrahydrofuran (30mL) at -78°C. After stirring for 30 minutes, N-fluorobenzenesulfonimide (5.05g, 16.01mmol) in tetrahydrofuran (30mL) was added dropwise at -78°C. The reaction mixture was stirred at -78°C for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE as eluent. The fractions containing the desired product were combined and concentrated to give 3-bromo-1-tert-butyl-4-fluoropyrrole (1.5g, 63%) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ6.59-6.55 (m, 2H), 1.47 (s, 9H).

[0692] Step 4: Under a nitrogen atmosphere, butyl lithium (1.05 mL, 2.62 mmol) was added dropwise to a stirred solution of 3-bromo-1-tert-butyl-4-fluoropyrrole (550 mg, 2.50 mmol) in tetrahydrofuran (5.5 mL) at -78 ° C. Under a nitrogen atmosphere, the reaction mixture was stirred at -78 ° C for 30 minutes. Propyl chloroformate (336.88 mg, 2.75 mmol) was added dropwise to the above mixture at -78 ° C. The reaction mixture was stirred for another hour at -78 ° C. The resulting mixture was quenched at 0 ° C by adding saturated ammonium chloride (aqueous solution) (20 mL). The resulting mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with brine (1 x 100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (8 / 1). The fractions containing the desired product were combined and concentrated to give 1-tert-butyl-4-fluoropyrrole-3-carboxylic acid propyl ester (360 mg, 63%) as a yellow oil. MS ESI: C12 H 18 FNO2[M+H] + , calculated value 228.13, measured value 228.10; 1 H NMR (400MHz, CDCl3) δ7.18-7.16(m,1H),6.56-6.54(m,1H),4.19(t,J=6.4Hz,2H),1.78-1.69(m,2H),1.50(s,9H),1.00(t,J=7.2Hz,3H).

[0693] Step 5: To a stirred solution of 1-tert-butyl-4-fluoropyrrole-3-carboxylic acid propyl ester (320 mg, 1.41 mmol) in methanol (3.2 mL), tetrahydrofuran (3.2 mL) and water (3.2 mL) was added lithium hydroxide (134.88 mg, 5.63 mmol) dropwise at room temperature. The reaction mixture was stirred at 50°C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (plus 10 mmol / L NH4HCO3), 10% to 50% gradient over 10 minutes; detector, UV 254 nm. The fractions containing the desired product were combined and concentrated to give 1-tert-butyl-4-fluoropyrrole-3-carboxylic acid (200 mg, 76%) as a white solid. MS ESI: C9H 12 FNO2[M+H] + , calculated value 186.09, measured value 186.05; 1 H NMR (400MHz, DMSO-d6) δ7.06 (dd, J = 4.2, 3.2Hz, 1H), 6.85-6.83 (m, 1H), 1.43 (s, 9H).

[0694] Step 6: To a stirred mixture of 1-tert-butyl-4-fluoropyrrole-3-carboxylic acid (60.15 mg, 0.32 mmol), 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (53 mg, 0.16 mmol), EDCI (46.70 mg, 0.24 mmol), and HOBt (32.91 mg, 0.24 mmol) in N,N-dimethylformamide (0.3 mL) was added triethylamine (65.73 mg, 0.65 mmol) dropwise at room temperature. The reaction mixture was stirred at 80°C for an additional 48 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 10% to 50% over 10 minutes; detector, UV 254 nm. The fractions containing the desired product were combined and concentrated to give the title compound as an off-white solid (12.1 mg, 15%). MS ESI: C 27 H 29 F2N5O2[M+H] + , calculated value 494.23, measured value 494.20; 1 H NMR(400MHz, DMSO-d6)δ9.01(s,1H),8.13(d,J=1.2Hz,1H),7.89(d,J=1.2Hz,1H),7.69(d,J=8.0Hz,1H),7.53-7.46(m,2H),7.25(d, J=11.6Hz,1H),7.07(t,J=2.8Hz,1H),6.35(d,J=1.2Hz,1H),3.80(t,J=4.0Hz,4H),3.55(t,J=3.6Hz,4H),2.28(s,3H),1.48(s,9H).

[0695] Example 67: 1-tert-Butyl-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}imidazole-4-carboxamide

[0696]

[0697] Step 1: Under nitrogen atmosphere, DMF-DMA (6.46 g, 88.40 mmol) was added dropwise to a stirred solution of ethyl 2-isocyanoacetate (5 g, 44.20 mmol) in EtOH (50 mL) at 0 ° C. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (100 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layer was washed with brine (3 x 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give (2Z)-3-(dimethylamino)-2-isocyanoprop-2-enoic acid ethyl ester (5.26 g, 71%) as a yellow solid. MS ESI: C8H 12 N2O2[M+H] + , calculated value 169.19, measured value 169.10; 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.20 (s, 1H), 4.24-4.13 (m, 2H), 3.25 (s, 6H), 1.32 (t, J = 4.2 Hz, 3H).

[0698] Step 2: A solution of ethyl (2Z)-3-(dimethylamino)-2-isocyanoprop-2-enoate (100 mg, 0.60 mmol) in 2-methylpropane-2-amine (1 mL) was stirred at 140° C. for 24 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA / EtOH (4 / 3 / 1) to give a crude product. The crude product was further purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 40 g; Eluent A: water (plus 10 mmol / L NH4HCO3); Eluent B: ACN; Gradient: 40% to 60% B over 25 minutes; Flow rate: 30 mL / min; Detector: 220 / 254 nm. The fractions containing the desired product were combined and concentrated to give ethyl 1-tert-butylimidazole-4-carboxylate (80 mg, 69%) as a yellow solid. MS ESI: C 10 H 16 N2O2[M+H] + , calculated value 197.25, measured value 197.10; 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.76 (d, J = 1.6 Hz, 1H), 7.66 (d, J = 1.6 Hz, 1H), 4.42-4.36 (m, 2H), 1.61 (s, 9H), 1.41 (t, J = 4.2 Hz, 3H).

[0699] Step 3: To a stirred solution of ethyl 1-tert-butylimidazole-4-carboxylate (80 mg, 0.41 mmol) in MeOH (1 mL) and THF (1 mL) was added LiOH·H2O (51.31 mg, 1.22 mmol) in H2O (1 mL). The reaction mixture was stirred at 60 ° C for 1 hour. The resulting mixture was concentrated under reduced pressure to give 1-tert-butylimidazole-4-carboxylic acid (50 mg, crude). MS ESI: C8H 12 N2O2[M+H] + , calculated value 169.19, measured value 169.10.

[0700] Step 4: To a stirred solution of 1-tert-butylimidazole-4-carboxylic acid (50 mg, 0.29 mmol) in pyridine (1 mL) was added T3P (233.98 mg, 0.38 mmol, 50% in EA) and 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (80 mg, 0.25 mmol) at room temperature. The reaction mixture was stirred at 60°C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 40 g; Eluent A: water (plus 10 mmol / L NH4HCO3); Eluent B: ACN; Gradient: 40% to 60% B over 25 minutes; Flow rate: 30 mL / min; Detector: 220 / 254 nm. The fractions containing the desired product were combined and concentrated to give the title compound as a white solid (4.8 mg, 4%). MS ESI: C 26 H 29 FN6O2[M+H] + , calculated value 477.55 measured value 477.30; 1 H NMR (400MHz, DMSO-d6) δ9.44(s,1H),8.16(d,J=1.2Hz,1H),8.05-7.97(m,3H),7.91(d,J=1.2Hz,1H),7.52(d,J=1.2Hz,1 H), 7.30 (d, J = 11.8Hz, 1H), 6.37 (d, J = 1.6Hz, 1H), 3.80 (d, J = 4.8Hz, 4H), 3.56 (d, J = 5.2Hz, 4H), 2.29 (s, 3H), 1.56 (s, 9H).

[0701] Example 69: N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1-methylcyclopropyl)-2,5-dihydro-1H-pyrrole-1-carboxamide

[0702]

[0703] Step 1: Under a nitrogen atmosphere, bis(trimethylsilyl)amide lithium (100mL, 100.00mmol) was added dropwise to a solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (10g, 53.99mmol) in tetrahydrofuran (1L) at -78°C. Under a nitrogen atmosphere, the reaction mixture was stirred at -78°C for 0.5 hours. 1,1,1-trifluoro-N-phenyl-N-trifluoromethanesulfonyl methanesulfonamide (21.22g, 59.39mmol) was added dropwise to the above mixture at -78°C. The reaction mixture was stirred for another 2 hours at -45°C. The resulting mixture was quenched with saturated ammonium chloride (aqueous solution) and extracted with EtOAc (2x 200mL). The combined organic layers were washed with brine (1x 100mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EA (20 / 1) as eluent. The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(trifluoromethanesulfonyloxy)-2,5-dihydropyrrole-1-carboxylate (15 g, 87%) as a brown oil. MS ESI: C 10 H 14 F3NO5S[M+H] + , calculated value 318.05, measured value 318.00.

[0704] Step 2: To a stirred solution of tert-butyl 3-(trifluoromethanesulfonyloxy)-2,5-dihydropyrrole-1-carboxylate (4 g, 12.61 mmol), 1,1'-bis(diphenylphosphino)ferrocene-dichloropalladium(II) dichloromethane complex (1.03 g, 1.26 mmol) and cesium carbonate (8.22 g, 25.21 mmol) in dioxane (40 mL) and water (10 mL) was added 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3-dioxolane (2.58 g, 15.13 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 100 ° C for 1 hour. The resulting mixture was diluted with water (200 mL). The resulting mixture was extracted with ethyl acetate (2 x 200 mL). The combined organic layers were washed with brine (2 x 100 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (9 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(prop-1-en-2-yl)-2,5-dihydropyrrole-1-carboxylate (1.3 g, 49%) as a colorless oil. MS ESI: C 12 H19 NO2[M+H] + , calculated value 210.1 measured value 210.1.

[0705] Step 3: Under a nitrogen atmosphere, diethyl zinc (11.87 mL, 69.76 mmol) was added dropwise to a stirred solution of diiodomethane (5.62 mL, 69.76 mmol) in dichloromethane (15 mL) at 0 ° C. Under a nitrogen atmosphere, the reaction mixture was stirred at 0 ° C for 15 minutes. 3- (prop-1-ene-2-yl) -2,5-dihydropyrrole-1-carboxylic acid tert-butyl ester (1.46 g, 6.98 mmol) was added dropwise to the above mixture at 0 ° C. The reaction mixture was stirred for another 16 hours at room temperature. The resulting mixture was quenched by adding saturated ammonium chloride (aqueous solution) (50 mL) at room temperature. The resulting mixture was diluted with water (150 mL) and extracted with ethyl acetate (2 x 200 mL). The combined organic layer was washed with brine (1 x 200 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water (plus 10 mmol / L NH4HCO3), gradient from 40% to 60% over 20 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give tert-butyl 3-(1-methylcyclopropyl)-2,5-dihydropyrrole-1-carboxylate (80 mg, 5%) as a yellow solid. MS ESI: C 13 H 21 NO2[M+H] + , calculated value 224.1, measured value 224.1; 1 H NMR (400MHz, CDCl3) δ5.36-5.34(m,1H),4.09-4.06(m,2H),3.92-3.88(m,2H),1.47(s,9H),1.23(s,3H),0.73-0.71(m,2H),0.52-0.50(m,2H).

[0706] Step 4: To a stirred solution of tert-butyl 3-(1-methylcyclopropyl)-2,5-dihydropyrrole-1-carboxylate (70 mg, 0.31 mmol) in dichloromethane (4 mL) was added 2,2,2-trifluoroacetic acid (0.8 mL) dropwise at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The fractions containing the desired product were combined and concentrated to give 3-(1-methylcyclopropyl)-2,5-dihydro-1H-pyrrole 2,2,2-trifluoroacetate (80 mg, 92%) as a black oil. MS ESI: C 10 H 14 F3NO[M+H]+ , calculated value 124.10, measured value 124.10.

[0707] Step 5: Under a nitrogen atmosphere, to a stirred solution of 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (110.65 mg, 0.34 mmol) and bis(trichloromethyl)carbonate (40.24 mg, 0.14 mmol) in tetrahydrofuran (1 mL) was added dropwise N,N-diisopropylethylamine (0.30 mL, 1.70 mmol) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 15 minutes. 3-(1-methylcyclopropyl)-2,5-dihydro-1H-pyrrole 2,2,2-trifluoroacetate (75 mg, 0.40 mmol) was added dropwise to the above mixture at room temperature. The reaction mixture was stirred at room temperature for another hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with DCM / MeOH (10 / 1) to give a crude product. The crude product was purified by Prep-HPLC using the following conditions: Column: Xselect CSH F-phenyl OBD column, 19 x 250 mm, 5 μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 20 mL / min; Gradient: 20% B to 25% B, 25% B over 8 minutes; Wavelength: 254 nm. Fractions containing the desired product were combined and concentrated to give the title compound as a white solid (20 mg, 12%). MS ESI: C 27 H 30 FN5O2[M+H] + , calculated value 476.24, measured value 476.25; 1 H NMR (400MHz, DMSO-d6) δ8.37(s,1H),8.13(m,1H),7.90(m,2H),7.52(d,J=8.0Hz,1H),7.22(d,J=11.6Hz,1H),6.88(s,1H),5.54-5.52(m,1 H),4.16(s,2H),4.01(s,2H),3.83(t,J=4.6Hz,4H),3.33(t,J=4.6Hz,4H),2.25(s,3H),1.23(s,3H),0.79-0.77(m,2H),0.58-0.51(m,2H).

[0708] Example 70: N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-5-(trifluoromethyl)nicotinamide

[0709]

[0710] Step 1. To the stirred 2-fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (60 mg, 0.18 mmol), 5-(trifluoromethyl)pyridine-3-carboxylic acid (42.16 mg, 0.22 mmol) and 2-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (104.85 mg, 0.28 mmol) in N,N-dimethylformamide (1 mL) was added triethylamine (93.02 mg, 0.92 mmol) dropwise at room temperature. The reaction mixture was stirred for another 16 hours at room temperature. The resulting mixture was diluted with water (20 mL) and extracted with ethyl acetate (3 x 30 mL). The combined organic layer was washed with brine (3 x 30 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 40% to 70% over 30 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}-5-(trifluoromethyl)pyridine-3-carboxamide (67.8 mg, 73%) as a light blue solid. MS ESI: C 25 H 21 F4N5O2[M+H] + , calculated value 500.16, measured value 500.20; 1 H NMR (400MHz, CDCl3) δ9.31 (s, 1H), 9.10 (s, 1H), 8.47 (s, 1H), 8.33 (d, J = 8Hz, 1H), 8.07 (s, 1H), 7.80 (s, 1H), 7.6 5(s,1H),7.59(s,1H),7.15(d,J=11.6Hz,1H),6.40(s,1H),4.03-3.96(m,4H),3.59-3.52(m,4H),2.32(s,3H).

[0711] Example 73: 1-(tert-Butyl)-5-fluoro-N-(4-methyl-3-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-1H-pyrazole-4-carboxamide

[0712]

[0713] Step 1: To a stirred solution of 4-bromo-3-fluoro-1H-pyrazole (1 g, 6.06 mmol) in t-BuOH (10 mL) was added dropwise H2SO4 (0.36 mL, 6.67 mmol, 98%) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at 80°C for 6 hours. The resulting mixture was diluted with water (20 mL). The resulting mixture was extracted with CH2Cl2 (3 x 20 mL). The combined organic layers were washed with brine (3 x 15 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give 4-bromo-1-(tert-butyl)-5-fluoro-1H-pyrazole (1 g, 62%) as a light yellow oil. MS ESI: C7H 10 BrFN2[M+H] + , calculated value 221.00, 223.00, measured value 221.00, 223.00; 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.30 (d, J = 2.4 Hz, 1H), 1.59 (s, 9H).

[0714] Step 2: To a stirred mixture of 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (400 mg, 1.68 mmol) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (431.54 mg, 1.85 mmol), K 3 PO 4 (714.43 mg, 3.37 mmol) in THF (5 mL) and water (0.5 mL) was added the second generation XPhos precatalyst (132.41 mg, 0.17 mmol) in batches at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA / EtOH (4 / 3 / 1). The fractions containing the desired product were combined and concentrated to give 4-methyl-3-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (327 mg, 63%) as a yellow solid. MS ESI: C 18 H 20 N4O[M+H] + , calculated value 309.16, measured value 309.10; 1H NMR (400MHz, chloroform-d) δ7.71(d,J=1.4Hz,1H),7.60(d,J=1.3Hz,1H),7.53(d,J=1.3Hz,1H),7.07(d,J=8.1Hz,1H),6. 66(dd,J=8.0,2.6Hz,1H),6.62(d,J=2.5Hz,1H),6.41(s,1H),4.02-3.95(m,4H),3.57-3.51(m,4H),2.17(s,3H).

[0715] Step 3: To a stirred mixture of 4-methyl-3-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (80 mg, 0.26 mmol), Pd(dppf)Cl2·CHCl2 (42.43 mg, 0.05 mmol) and Co2(CO)8 (26.62 mg, 0.08 mmol) in dioxane (1.5 mL) was added TEA (156.95 mg, 1.55 mmol) and 4-bromo-1-(tert-butyl)-5-fluoro-1H-pyrazole (114.92 mg, 0.52 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 90°C for 16 hours. The resulting mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with CHCl / MeOH (10 / 1) to give the crude product. The crude product was purified by Prep-HPLC using the following conditions: Column: YMC-Actus Triart C18 ExRS, 30 x 150 mm, 5 μm; Mobile Phase A: Water (plus 10 mmol / L NH4HCO3), Mobile Phase B: ACN; Flow rate: 60 mL / min; Gradient: 40% B to 50% B, 50% B over 10 minutes; Wavelength: 254 nm; RT1: 12.3 min. Fractions were combined and concentrated to give the title compound (12.2 mg, 9%) as an off-white solid. MS ESI: C 26 H 29 FN6O2[M+H] + , calculated value 477.23, measured value 477.20; 1 H NMR (400 MHz, CHLOROFORM-d) δ 7.85-7.79 (m, 2H), 7.69-7.59 (m, 3H), 7.54-7.44 (m, 2H), 7.31-7.28 (m, 1H), 6.52 (s, 1H), 4.03 (t, J = 4.6 Hz, 4H), 3.54 (t, J = 4.7 Hz, 4H), 2.29 (s, 3H), 1.67 (d, J = 1.4 Hz, 9H).

[0716] Examples 74 and 75: N-(2-Fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrolidine-1-carboxamide

[0717]

[0718] Step 1: Under a nitrogen atmosphere, to a stirred solution of maleic anhydride (10 g, 101.98 mmol) in acetic acid (50 mL) was added dropwise (4-methoxyphenyl)methylamine (13.32 mL, 101.98 mmol) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at 120 ° C for 6 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (4 / 1). The fractions containing the desired product were combined and concentrated to give 1-[(4-methoxyphenyl)methyl]pyrrole-2,5-dione (8 g, 36%) as a white solid: 1 H NMR (400MHz, CDCl3) δ7.33-7.26(m,2H),6.87-6.79(m,2H),6.68-6.62(m,2H),4.61(s,2H),3.78(s,3H).

[0719] Step 2: Under a nitrogen atmosphere, to a stirred solution of 1-[(4-methoxyphenyl)methyl]pyrrole-2,5-dione (8g, 36.83mmol), 3,3,3-trifluoro-2,2-dimethylpropionic acid (14.37g, 92.07mmol) and ammonium persulfate (21.01g, 92.07mmol) in dimethyl sulfoxide (160mL) and water (80mL) was added tripotassium phosphate (19.54g, 92.07mmol) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at 70°C for 16 hours. The resulting mixture was quenched with saturated sodium bicarbonate (aqueous solution) at room temperature. The resulting mixture was diluted with water (500mL) and extracted with EA (2x 500mL). The combined organic layers were washed with brine (2x 200mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (9 / 1). The fractions containing the desired product were combined and concentrated to give 1-[(4-methoxyphenyl)methyl]-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrole-2,5-dione (3.4 g, 28%) as a yellow oil. 1H NMR (400MHz, CDCl3) δ7.31-7.27(m,2H),6.87-6.82(m,2H),6.48-6.46(m,1H),4.58(s,2H),3.78(s,3H),1.57-1.51(s,6H).

[0720] Step 3: Under a nitrogen atmosphere, 1-[(4-methoxyphenyl)methyl]-3-(1,1,1-trifluoro-2-methylpropane-2-yl)pyrrole-2,5-dione (3.47 g, 10.60 mmol) was added dropwise to a stirred solution of LiAlH4 (3.22 g, 84.82 mmol) in tetrahydrofuran (35 mL) at 0°C. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was quenched at 0°C by adding water (3.2 mL), sodium hydroxide (15%) (3.2 mL) and water (9.6 mL). The resulting mixture was filtered and the filter cake was washed with EA (3 x 300 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1). Fractions containing the desired product were combined and concentrated to give 1-[(4-methoxyphenyl)methyl]-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrolidine (1.6 g, 50%) as a yellow oil. MS ESI: C 16 H 22 F3NO[M+H] + , calculated value 302.17, measured value 302.10; 1 H NMR(400MHz, CDCl3) δ7.26(d,J=8.4Hz,2H),6.86(d,J=8.6Hz,2H),3.80(s,3H),3.71-3.48(m,2H),2 .76(d,J=9.2Hz,2H),2.63-2.26(m,2H),1.89-1.86(m,1H),1.78-1.45(m,2H),1.07(d,J=9.4Hz,6H).

[0721] Step 4: Under a hydrogen atmosphere, Pd / C (2.00 g, 18.78 mmol, 60%) was added to a stirred solution of 1-[(4-methoxyphenyl)methyl]-3-(1,1,1-trifluoro-2-methylpropane-2-yl)pyrrolidine (2 g, 6.64 mmol) in EA (2 mL) at room temperature. The reaction mixture was stirred at room temperature for 48 hours under a hydrogen atmosphere. HCl (g) (10 mL, 40.000 mmol) in EA was added dropwise to the above mixture at room temperature. The resulting mixture was stirred at room temperature for another 5 minutes. The resulting mixture was filtered and the filter cake was washed with EA (2 x 20 mL). The filtrate was concentrated under reduced pressure to give 3-(1,1,1-trifluoro-2-methylpropane-2-yl)pyrrolidine HCl salt (1.5 g, crude product) as a yellow oil. MS ESI: C8H 14 F3N[M+H] + , calculated value 182.11, measured value 182.10.

[0722] Step 5: Under a nitrogen atmosphere, N, N-diisopropylethylamine (0.53 mL, 3.06 mmol) was added dropwise to a stirred solution of 3- (1,1,1-trifluoro-2-methylpropane-2-yl) pyrrolidine HCl salt (250.09 mg, 1.15 mmol) and triphosgene (90.92 mg, 0.31 mmol) in tetrahydrofuran (2.5 mL) at room temperature. The reaction mixture was stirred at room temperature for 15 minutes. 2-fluoro-4-methyl-5- (8-morpholinoimidazo [1,2-a] pyridin-6-yl) aniline (251.09 mg, 0.77 mmol) was added to the above mixture at room temperature. The reaction mixture was stirred at room temperature for another 1 hour. The resulting mixture was diluted with water (20 mL) and extracted with EA (3 x 20 mL). The combined organic layers were washed with brine (1 x 20 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EA to give a crude product. The crude product was purified by Prep-HPLC using the following conditions: column: XBridge Prep OBD C18 column, 30x 150mm, 5μm; mobile phase A: water (plus 10mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60mL / min; gradient: 49% B to 57% B, 57% B over 8 minutes; wavelength: 220nm. The fractions containing the desired product were combined and concentrated to give N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1,1,1-trifluoro-2-methylpropane-2-yl)pyrrolidine-1-carboxamide (0.19g, 46%) as a yellow oil. MS ESI: C 27 H 31F4N5O2[M+H] + , calculated value 534.24, measured value 534.15.

[0723] Step 6: N-(2-Fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrolidine-1-carboxamide (0.19 g) was purified by Prep-chiral-HPLC using the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, Mobile phase B: IPA:DCM=1:1--HPLC; Flow rate: 20 mL / min; Gradient: 30% B to 30% B over 11 minutes; Wavelength: 254 / 220 nm; RT1: 7.70 min; RT2: 8.70 min; Sample solvent: MeOH:DCM=1:1--HPLC; Injection volume: 0.3 mL.

[0724] Peak 1 (Example 74: N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrolidine-1-carboxamide). Fractions (RT 7.7 min) were combined and concentrated to give the title compound (61.3 mg, 15%) as a white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 31 F4N5O2[M+H] + , calculated value 534.24, measured value 534.20; 1 H NMR(400MHz, DMSO-d6)δ8.10(d,J=1.6Hz,1H),7.91-7.86(m,2H),7.50(d,J=1.2H z,1H),7.43(d,J=8.2Hz,1H),7.16(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),3.83- 3.77(m,4H),3.60-3.50(m,6H),3.28-3.26(m,1H),3.16-3.13(m,1H),2.47-2.35 (m,1H),2.25(s,3H),1.95-1.87(m,1H),1.81-1.73(m,1H),1.12(d,J=8.9Hz,6H).

[0725] Peak 2 (Example 75: N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-3-(1,1,1-trifluoro-2-methylpropan-2-yl)pyrrolidine-1-carboxamide). Fractions (RT 8.7 min) were combined and concentrated to give the title compound (61.5 mg, 15%) as a white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 31 F4N5O2[M+H]+, calculated value 534.24, found value 534.20; 1 H NMR(400MHz, DMSO-d6)δ8.10(d,J=1.6Hz,1H),7.91-7.86(m,2H),7.50(d,J=1.2H z,1H),7.43(d,J=8.2Hz,1H),7.16(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),3.83- 3.77(m,4H),3.60-3.50(m,6H),3.28-3.26(m,1H),3.16-3.13(m,1H),2.47-2.35 (m,1H),2.25(s,3H),1.95-1.87(m,1H),1.81-1.73(m,1H),1.12(d,J=8.9Hz,6H).

[0726] Example 84: 5-(1,1-difluoroethyl)-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyridine-3-carboxamide

[0727]

[0728] Step 1: Under a nitrogen atmosphere, a solution of 1-(5-bromopyridin-3-yl)ethanone (3 g, 14.99 mmol) in BAST (4.98 g, 22.49 mmol) was stirred at 80 ° C for 6 hours. The resulting mixture can be cooled to room temperature. The resulting mixture is quenched by adding saturated NaHCO (aqueous solution) (100 mL) and extracted with EA (3 x 100 mL). The combined organic layers are washed with brine (2 x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate is concentrated under reduced pressure. The residue is purified by silica gel column chromatography and eluted with PE / EA (2 / 1). The fractions are combined and concentrated to give 3-bromo-5-(1,1-difluoroethyl)pyridine (1.11 g, 33%) as a yellow oil. MS ESI: C7H6BrF2N[M+H] + , calculated value 221.97, measured value 222.00.

[0729] Step 2: To a solution of 3-bromo-5-(1,1-difluoroethyl)pyridine (1 g, 4.50 mmol) in MeOH (10 mL) was added Pd(dppf)Cl2·CH2Cl2 (366.89 mg, 0.45 mmol) and TEA (1.88 mL, 13.51 mmol). Under a carbon monoxide atmosphere (30 psi), the reaction mixture was stirred at 100 ° C for 16 hours. The resulting mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (2 / 1). The fractions containing the desired product were combined and concentrated to give methyl 5-(1,1-difluoroethyl)pyridine-3-carboxylate (800 mg, 88%) as an off-white oil. MSESI: C9H9F2NO2[M+H] + , calculated value 202.06, measured value 202.10; 1 H NMR (400MHz, DMSO-d6) δ9.30 (d, J = 2Hz, 1H), 8.95 (d, J = 2.4Hz, 1H), 8.45-8.43 (m, 1H), 4.00 (s, 3H), 1.99 (t, J = 18.3Hz, 3H).

[0730] Step 3: under nitrogen atmosphere, at 0 DEG C, to the fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridine-6-yl]aniline (162.24mg, 0.49mmol) of stirring in LiHMDS (1mL, 1M in THF) solution in 5-(1,1-difluoroethyl)pyridine-3-carboxylic acid methyl esters (100mg, 0.49mmol). Under nitrogen atmosphere, reaction mixture was stirred at room temperature for 1 hour. Gained mixture was quenched by adding saturated NH4Cl (aqueous solution) (10mL), and extracted with EtOAc (3x 20mL). The organic layer merged was washed with salt water (2x 20mL), with anhydrous Na2SO4 dried. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC using PE / EA / EtOH (4 / 3 / 1) as eluent to give the crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 5% to 95% over 30 minutes; detector: UV 254 nm. Fractions were combined and concentrated to give the title compound (132.7 mg, 53%) as a white solid. MS ESI: C 26 H 24 F3N5O2[M+H] + , calculated value 496.19, measured value 496.15;1 H NMR (400MHz, DMSO-d6) δ10.52(s,1H),9.23(d,J=2.1Hz,1H),9.00(d,J=2.1Hz,1H),8.49(s,1H),8.17(s,1H),7.90(s,1H),7.58(d,J=7.8Hz,1H ), 7.52 (d, J = 2.4Hz, 1H), 7.33 (d, J = 11.4Hz, 1H), 6.39 (s, 1H), 3.80 (t, J = 4.6Hz, 4H), 3.55 (t, J = 4.6Hz, 4H), 2.31 (s, 3H), 2.09 (t, J = 19.2Hz, 3H).

[0731] Example 86: 1-tert-Butyl-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}-1,2,3-triazole-4-carboxamide

[0732]

[0733] Step 1: To a stirred solution of 1-tert-butyl-1,2,3-triazole-4-carboxylic acid (51.84 mg, 0.306 mmol) in pyridine (1 mL) and propylphosphonic anhydride solution (1 mL, 50% in EA) was added 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (100 mg, 0.306 mmol). The reaction mixture was stirred at room temperature for 16 hours under a nitrogen atmosphere. The resulting mixture was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: Column: WelFlash™ C18-I, 20-40 μm, 40 g; Mobile phase A: water (plus 10 mmol / L NH4HCO3); Mobile phase B: ACN; Gradient: 45% to 55% B over 20 minutes; Flow rate: 30 mL / min; Detector: 254 nm. The fractions were combined and concentrated to give the title compound as an off-white solid (119.9 mg, 81%). MS ESI: C 25 H 28 FN7O2[M+H] + , calculated value 478.23, measured value 478.25; 1H NMR (400MHz, DMSO-d6) δ10.02(s,1H),8.85(s,1H),8.16(d,J=1.5Hz,1H),7.90(d,J=1.4Hz,1H),7.64(d,J=7.8Hz,1H),7.51(d,J=1.1H z, 1H), 7.29 (d, J = 11.5Hz, 1H), 6.37 (d, J = 1.7Hz, 1H), 3.80 (t, J = 4.7Hz, 4H), 3.55 (t, J = 4.8Hz, 4H), 2.30 (s, 3H), 1.67 (d, J = 1.1Hz, 9H).

[0734] Examples 87-90: 3-(1,1-difluoropropane-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide

[0735]

[0736] Step 1: Under nitrogen atmosphere, 1M LiHMDS (20.55mL, 20.55mmol) in THF was added dropwise to a solution of tert-butyl 3-(2-methoxy-2-oxoethyl) pyrrolidine-1-carboxylate (2g, 8.22mmol) in THF (80mL) at -10°C. The reaction mixture was stirred for 1 hour at -10°C. CH3I (1.28mL, 20.55mmol) was added to the above mixture at -10°C. Under nitrogen atmosphere, the reaction mixture was heated to room temperature and stirred for 4 hours. The resulting mixture was quenched with water at room temperature and extracted with EtOAc (3x80mL). The combined organic layer was washed with salt water (2x 60mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (4 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(1-methoxy-1-oxopropan-2-yl)pyrrolidine-1-carboxylate (0.7 g, 33%) as a pale yellow oil. MS ESI: C 13 H 23 NO4[M+H] + , calculated value 258.33, measured value 258.16.

[0737] Step 2: Under a nitrogen atmosphere, to a stirred mixture of LiAlH4 (786 mg, 20.72 mmol) in THF (30 mL) was added 3-(1-methoxy-1-oxopropane-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester (2.6 g, 10.41 mmol) in THF (6 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched with 15% sodium hydroxide solution (0.6 mL). The resulting mixture was filtered and the filter cake was washed with EtOAc (5 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give 3-(1-hydroxypropane-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester (2 g, 83%) as a colorless oil. MS ESI: C 12 H 23 NO3[M+H] + , calculated value 230.32, measured value 230.15.

[0738] Step 3: To a stirred solution of tert-butyl 3-(1-hydroxypropane-2-yl)pyrrolidine-1-carboxylate (2 g, 8.72 mmol) in DCM (40 mL) was added Dess-Martin (7.4 g, 17.44 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(1-oxopropane-2-yl)pyrrolidine-1-carboxylate (1.4 g, 70%) as a colorless oil. MS ESI: C 12 H 21 NO3[M+H] + , calculated value 228.30, measured value 228.30.

[0739] Step 4: Under nitrogen atmosphere, DAST (3971 mg, 24.63 mmol) was added dropwise to a stirred solution of tert-butyl 3-(1-oxopropane-2-yl)pyrrolidine-1-carboxylate (1.4 g, 6.15 mmol) in DCM (20 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched with NaHCO (aqueous solution) at 0 ° C. and extracted with CH Cl (3 x 40 mL). The combined organic layers were washed with brine (2 x 30 mL), dried over anhydrous Na SO , filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (4 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-(1,1-difluoropropane-2-yl)pyrrolidine-1-carboxylate (1.1 g, 71%) as a yellow oil. MS ESI: C12 H 21 F2NO2[M+H] + , calculated value 250.30, measured value 250.15.

[0740] Step 5: To a stirred mixture of tert-butyl 3-(1,1-difluoropropane-2-yl)pyrrolidine-1-carboxylate (1.1 g, 4.41 mmol) in DCM (10 mL) was added HCl (gas) (0.48 g, 13.23 mmol) in EA at room temperature. The reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was concentrated under reduced pressure to give 3-(1,1-difluoropropane-2-yl)pyrrolidine HCl salt (700 mg, crude) as a yellow solid. MS ESI: C7H 13 F2N[M+H] + , calculated value 150.10, measured value 150.15.

[0741] Step 6: Under a nitrogen atmosphere, triphosgene (109 mg, 0.36 mmol) and DIEA (356.41 mg, 2.76 mmol) were added to a stirred mixture of 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (300 mg, 0.91 mmol) in THF (22 mL) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 30 minutes. 3-(1,1-difluoropropane-2-yl)pyrrolidine HCl salt (204.29 mg, 1.10 mmol) was added to the above mixture at room temperature. The reaction mixture was stirred for another 2 hours at room temperature. The resulting mixture was quenched with MeOH (5 mL) and concentrated under reduced pressure. The compound was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 5% to 95% over 30 minutes; detector: UV 254 nm. Fractions containing the desired product were combined and concentrated to provide 3-(1,1-difluoropropan-2-yl)-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrrolidine-1-carboxamide (170 mg, 36%) as a yellow solid. The solid was further purified by Prep-chiral-HPLC using the following conditions: column: CHIRALPAK IE, 2x 25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: IPA:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 40% B to 40% B over 30 minutes; wavelength: 254 / 220 nm; RT1: 20.27 min; RT2: 25.06 min; sample solvent: MeOH:DCM=1:1--HPLC; injection volume: 0.3 mL.

[0742] Peak 1 (Example 87: 3-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (RT 20.27 min) were combined and concentrated to give the title compound (16 mg, 9%) with undetermined absolute stereochemistry. MS ESI: C 26 H 30 F3N5O2[M+H] + , calculated value 502.55, measured value 502.25; 1H NMR(400MHz, DMSO-d6)δ8.11(d,J=1.4Hz,1H),7.91-7.85(m,2H),7.50(d,J=1.2Hz, 1H),7.43(d,J=8.2Hz,1H),7.17(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),6.06-5.9 8(m,1H),3.80(t,J=4.7Hz,4H),3.69-3.48(m,6H),3.28-3.26(m,1H),3.01(t,J=10 .0Hz,1H),2.25(s,3H),2.20-1.86(m,3H),1.71-1.61(m,1H),0.96(d,J=6.9Hz,3H).

[0743] Peak 2 (Example 88: 3-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (RT 25.06 min) were combined and concentrated to give the title compound (17.2 mg, 10%) with undetermined absolute stereochemistry. MS ESI: C 26 H 30 F3N5O2[M+H] + , calculated value 502.55, measured value 502.25; 1 H NMR(400MHz, DMSO-d6)δ8.10(d,J=1.4Hz,1H),7.91-7.84(m,2H),7.50(d,J=1.1Hz,1H), 7.44(d,J=8.2Hz,1H),7.17(d,J=11.6Hz,1H),6.33(s,1H),6.25-5.84(m,1H),3.80(t,J= 4.6Hz,4H),3.70-3.51(m,6H),3.26(dd,J=11.6,8.1Hz,1H),3.01(t,J=10.1Hz,1H),2.2 5(s,3H),2.17-2.15(m,1H),2.12-1.88(m,2H),1.71-1.62(m,1H),0.96(d,J=6.9Hz,3H).

[0744] The solid was further purified by Prep-chiral-HPLC using the following conditions: column: CHIRAL ARTCellulose-SC, 2x 25 cm, 5 μm; mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, mobile phase B: MeOH:DCM=1:1--HPLC; flow rate: 20 mL / min; gradient: 30% B to 30% B over 17 minutes; wavelength: 254 / 220 nm; RT1: 14.45 min; RT2: 16.30 min; sample solvent: MeOH:DCM=1:1--HPLC; injection volume: 0.5 mL.

[0745] Peak 3 (Example 89: 3-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (14.45 min) were combined and concentrated to give the title compound (14.6 mg, 8%) with undetermined absolute stereochemistry. MS ESI: C 26 H 30 F3N5O2[M+H] + , calculated value 502.55, measured value 502.25; 1 H NMR (400MHz, DMSO-d6) δ8.11(d,J=1.4Hz,1H),7.91-7.82(m,2H),7.50(d,J=1.2Hz,1H),7. 45(d,J=8.2Hz,1H),7.16(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),5.99-5.92(m,1H),3.80 (t,J=4.6Hz,4H),3.67(t,J=8.9Hz,1H),3.53(dd,J=10.1,6.2Hz,5H),3.28-3.19(m,1H),3 .05-3.03(m,1H),2.25(s,3H),2.20-1.86(m,3H),1.60-1.52(m,1H),0.99(d,J=6.9Hz,3H).

[0746] Peak 4 (Example 90: 3-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (RT 16.30 min) were combined and concentrated to give the title compound (11.8 mg, 6%) as a white solid with uncertain absolute stereochemistry. MS ESI: C 26 H 30 F3N5O2[M+H] +, calculated value 502.55, measured value 502.25; 1 H NMR (400MHz, DMSO-d6) δ8.10(d,J=1.4Hz,1H),7.88(d,J=1.2Hz,1H),7.83(s,1H),7.50(d,J=1. 2Hz,1H),7.45(d,J=8.2Hz,1H),7.16(d,J=11.6Hz,1H),6.33(d,J=1.5Hz,1H),6.25-5.84(m,1H ),3.83-3.76(m,4H),3.68-3.66(m,1H),3.56-3.52(m,5H),3.25-3.23(m,1H),3.05-3.03(m,1H ), 2.24 (s, 3H), 2.14-2.12 (m, 1H), 2.09-1.82 (m, 2H), 1.71-1.62 (m, 1H), 0.99 (d, J = 6.9Hz, 3H).

[0747] Examples 91 and 92: 3-(tert-Butyl)-3-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide

[0748]

[0749] Step 1: under nitrogen atmosphere, tert-butyl lithium (14.33mL, 18.63mmol, 1.3M in THF) was added dropwise to a solution of tert-butyl 3-oxopyrrolidine-1-carboxylate (3g, 16.20mmol) in THF (30mL) at -78°C. Under nitrogen atmosphere, the reaction mixture was stirred at -78°C for 2 hours. The resulting mixture was quenched at room temperature by adding saturated NH4Cl (aqueous solution) (300mL). The resulting mixture was extracted with EtOAc (3x 300mL). The combined organic layer was washed with salt water (2x 200mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (2 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-tert-butyl-3-hydroxypyrrolidine-1-carboxylate (1.3 g, 16%) as a colorless oil. MS ESI: C 13 H 25 NO3[M+H] + , calculated value 24418, measured value 244.15; 1H NMR (400 MHz, CHLOROFORM-d) δ 3.81-3.77 (m, 2H), 3.59-3.46 (m, 2H), 2.07-1.98 (m, 1H), 1.75-1.64 (m, 1H), 1.49 (s, 9H), 1.03 (s, 9H).

[0750] Step 2: under nitrogen atmosphere, DAST (3.31g, 20.55mmol) in DCM (40mL) was added dropwise to a solution of 3-tert-butyl-3-hydroxypyrrolidine-1-carboxylic acid tert-butyl ester (1g, 4.11mmol) in DCM (40mL) at 0°C. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 1 hour. The resulting mixture was quenched at 0°C by adding saturated NaHCO (aqueous solution) (200mL). The resulting mixture was extracted with EtOAc (3x 300mL). The combined organic layer was washed with salt water (2x 200mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. Residue was purified by silica gel column chromatography and eluted with PE / EA (2 / 1). The fractions containing the desired product were combined and concentrated to give 3-tert-butyl-3-fluoropyrrolidine-1-carboxylic acid tert-butyl ester (560mg, crude product) as a colorless oil. MS ESI:C 13 H 24 FNO2[M+H] + , calculated value 246.18, measured value 246.15.

[0751] Step 3: To a stirred solution of tert-butyl 3-fluoropyrrolidine-1-carboxylate (560 mg, 2.283 mmol) in DCM (6 mL) was added HCl (gas) (6 mL, 2 M in EtOAc). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 16 s. The resulting mixture was concentrated under reduced pressure to give 3-tert-butyl-3-fluoropyrrolidine HCl salt (530 mg, crude) as an off-white solid. MS ESI: CH 16 FN[M+H] + , calculated value 182.10, measured value 182.25.

[0752] Step 4: Under a nitrogen atmosphere, to a stirred solution of 2-fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (300 mg, 0.92 mmol) and DIEA (594 mg, 4.60 mmol) in THF (18 mL) was added dropwise triphosgene (109 mg, 0.37 mmol) in THF (2 mL) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 30 minutes. 3-tert-butyl-3-fluoropyrrolidine HCl salt (250 mg, 1.38 mmol) was added dropwise to the above mixture at room temperature. The resulting mixture was stirred for another 2 hours at room temperature. The reaction mixture was quenched by adding MeOH (10 mL) and concentrated under reduced pressure. The residue was purified by prep-HPLC to give 3-tert-butyl-3-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrrolidine-1-carboxamide (40 mg, 6%) as an off-white solid. MS ESI: C 27 H 33 F2N5O2[M+H] + , calculated value 498.26, measured value 498.25.

[0753] Step 5: 3-tert-Butyl-3-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyrrolidine-1-carboxamide (40 mg, 0.08 mmol) was purified by chiral-Prep-HPLC using the following conditions: Column: CHIRAL ART Cellulose-SB, 2 x 25 cm, 5 μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH)--HPLC, Mobile phase B: IPA:DCM=1:1--HPLC; Flow rate: 20 mL / min; Gradient: 40% B to 40% B over 7 minutes; Wavelength: 254 / 220 nm; RT1: 4.42 min; RT2: 6.49 min; Sample solvent: MeOH:DCM=1:1--HPLC; Injection volume: 0.8 mL.

[0754] Peak 1 (Example 91: 3-(tert-butyl)-3-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (RT 4.42 min) were combined and concentrated to give the title compound (12.3 mg, 27%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 33 F2N5O2[M+H] +, calculated value 498.26, measured value 498.20; 1 H NMR (400MHz, chloroform-d) δ8.12(d,J=8.0Hz,1H),7.77(d,J=1.6Hz,1H),7.63(s,1H),7.54(d,J=0.8Hz,1H),7.02(d,J=11.6 Hz,1H),6.42-6.36(m,2H),4.02-4.00(m,4H),3.75-3.60(m,4H),3.56-3.52(m,4H),2.25-2.12(m,5H),1.09(s,9H).

[0755] Peak 2 (Example 92: 3-(tert-butyl)-3-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide): Fractions (RT 6.49 min) were combined and concentrated to give the title compound (11.5 mg, 29%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 33 F2N5O2[M+H] + , calculated value 498.26, measured value 498.25; 1 H NMR (400MHz, chloroform-d) δ8.13(d,J=8.4Hz,1H),7.77(d,J=1.2Hz,1H),7.64(s,1H),7.54(d,J=1.2Hz,1H),7.02(d,J=11.6Hz,1H), 6.45(s,1H),6.37(d,J=2.4Hz,1H),4.03-4.00(m,4H),3.72-3.61(m,4H),3.56-3.53(m,4H),2.28-2.12(m,5H),1.09(s,9H).

[0756] Example 95: 2-tert-Butyl-5-fluoro-N-{4-methyl-3-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyridine-4-carboxamide

[0757]

[0758] Step 1: m-CPBA (6.67 g, 38.68 mmol) was added to a mixture of 3-fluoropyridine-4-carboxylic acid methyl ester (4 g, 25.79 mmol) in DCM (50 mL) to be stirred. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was quenched with saturated NaHCO aqueous solution (200 mL) and extracted with EtOAc (3x200 mL). The combined organic layer was washed with saturated brine (100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EtOAc / EtOH (4 / 3 / 1). The fractions containing the desired product were combined and concentrated to give 3-fluoro-4-(methoxycarbonyl)pyridin-1-ium-1-ol anion (4.3 g, 97%) as an off-white solid. MS ESI: C7H6FNO3[M+H] + , calculated value 172.03, measured value 172.15; 1 H NMR (400MHz, CDCl3) δ8.18-8.16(m,1H),8.14-8.08(m,1H),7.87-7.85(m,1H),3.97(s,3H).

[0759] Step 2: 2,2-dimethylpropanoyl chloride (1.55g, 12.86mmol) is added to a mixture of 3-fluoro-4-(methoxycarbonyl)pyridin-1-ium-1-ol anion (1g, 5.84mmol) and [Ir(dtbbpy)(ppy)2][PF6] (0.05g, 0.06mmol) in ACN (12mL). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 15 minutes. The reaction mixture was stirred and irradiated with a blue LED lamp (7cm away, with a cooling fan to maintain the reaction temperature at 25°C) for 16 hours. The resulting mixture was quenched with saturated NaHCO3 aqueous solution (100mL) and extracted with DCM (3x 100mL). The combined organic layer was washed with brine (100mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc / EtOH (1 / 1) for elution. The fractions containing the desired product were combined and concentrated to give a mixture of 2-tert-butyl-5-fluoropyridine-4-carboxylic acid methyl ester and 2-tert-butyl-3-fluoropyridine-4-carboxylic acid methyl ester as a light yellow oil. 11 H 14 FNO2[M+H] + ,212.03,measured value 212.15.

[0760] Step 3: To the mixture of the stirred mixture of 2-tert-butyl-5-fluoropyridine-4-carboxylic acid methyl ester and 2-tert-butyl-3-fluoropyridine-4-carboxylic acid methyl ester (mixture) (300mg, 1.42mmol) in MeOH (1mL) and THF (1mL) was added LiOH H O (178.78mg, 4.26mmol) in H O (1mL). The reaction mixture was stirred at room temperature for 2 hours. The obtained mixture was concentrated under reduced pressure. The obtained mixture was acidified to pH 4 with HCl (aqueous solution). The obtained mixture was extracted with EtOAc (3x30mL). The combined organic layer was washed with brine (20mL) and dried over anhydrous Na SO Drying. After filtration, the filtrate was concentrated under reduced pressure to obtain a mixture of 2-tert-butyl-5-fluoropyridine-4-carboxylic acid and 2-tert-butyl-3-fluoropyridine-4-carboxylic acid as a light yellow solid (160mg, crude product). MS ESI:C 10 H 12 FNO2[M+H] + , calculated value 198.09, measured value 198.15.

[0761] Step 4: Under a nitrogen atmosphere, a solution of stirred 2-tert-butyl-5-fluoropyridine-4-carboxylic acid (41.57 mg, 0.211 mmol) in T3P (0.5 mL) was stirred at room temperature for 15 minutes. A solution of 4-methyl-3-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (50 mg, 0.162 mmol) in pyridine (0.5 mL) was added to the above mixture at room temperature. The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 1) to give a crude product. The crude product was purified by Prep-chiral-HPLC using the following conditions: column: DAICEL DC Pak P4VP, 3 x 25 cm, 5 μm; mobile phase A: CO2, mobile phase B: MeOH (0.1% 2M NH3-MEOH); flow rate: 75 mL / min; gradient: isocratic 25% B; column temperature: 35°C; back pressure: 100 bar; wavelength: 254 nm; RT1: 4.58 min; RT2: 5.18 min; sample solvent: MeOH--HPLC; injection volume: 2 mL.

[0762] Peak 2 (5.18 min): Fractions were combined and concentrated to give the title compound as a white solid (7.4 mg, 9%). MS ESI: C 28 H 30 FN5O2[M+H] + , calculated value 488.24, measured value 488.25; 1H NMR (400MHz, DMSO-d6) δ10.68(s,1H),8.65(s,1H),8.16(d,J=1.4Hz,1H),7.91(d,J=1.2Hz,1H),7.70-7.60(m,3H),7.51(d,J=1 .2Hz, 1H), 7.32 (d, J = 8.3Hz, 1H), 6.37 (d, J = 1.5Hz, 1H), 3.81 (t, J = 4.6Hz, 4H), 3.55 (t, J = 4.6Hz, 4H), 2.27 (s, 3H), 1.34 (s, 9H).

[0763] Example 98: 1-(tert-Butyl)-N-(4-chloro-2-fluoro-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-5-fluoro-1H-pyrazole-4-carboxamide

[0764]

[0765] Step 1: To a stirred solution of 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (3 g, 12.62 mmol), bis(pinacolato)diboronate (4.81 g, 18.93 mmol) and KOAc (3.72 g, 37.86 mmol) in dioxane (30 mL) was added the second generation XPhos precatalyst (0.99 g, 1.26 mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 100 ° C for 2 hours. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 x 100 mL). The filtrate was concentrated under reduced pressure to give 4-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-8-yl]morpholine (4 g, crude product) as a black oil. MS ESI: C 17 H 24 BN3O3[M+H] + , calculated value 330.19, measured value 329.85.

[0766] Step 2: To a stirred solution of 5-bromo-4-chloro-2-fluoroaniline (300 mg, 1.33 mmol), Pd(PPh3)2Cl2 (93.81 mg, 0.13 mmol) and Na2CO3 (424.97 mg, 4.01 mmol) in dioxane (3 mL) and H2O (0.6 mL) was added 4-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridin-8-yl]morpholine (1.32 g, 2.00 mmol, 50%) in portions at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 1 hour. The resulting mixture was filtered and the filter cake was washed with EtOAc (3 x 100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA / EtOH (8 / 3 / 1). The fractions of the desired product were combined and concentrated to give 4-chloro-2-fluoro-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (328 mg, 70%) as a yellow solid. MSESI: C 17 H 16 ClFN4O[M+H] + , calculated value 347.10,349.10, measured value 347.10,349.10; 1 H NMR (400MHz, chloroform-d) δ7.82(d,J=1.5Hz,1H),7.62(d,J=1.3Hz,1H),7.56(d,J=1.3Hz,1H),7.17(d,J =10.6Hz, 1H), 6.81 (d, J = 9.3Hz, 1H), 6.47 (d, J = 1.5Hz, 1H), 4.05-3.97 (m, 4H), 3.63-3.50 (m, 4H).

[0767] Step 3: To a stirred mixture of 4-chloro-2-fluoro-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (80 mg, 0.23 mmol) and bis(lambda2-cobalt(2+))octakis(methanidylidyneoxidanium) (23.59 mg, 0.07 mmol) in dioxane (1 mL) was added TEA (69.69 mg, 0.69 mmol) and 4-bromo-1-(tert-butyl)-5-fluoro-1H-pyrazole (101.66 mg, 0.46 mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 90° C. for 16 hours. The resulting mixture was concentrated under reduced pressure. The residual mixture was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 10% to 50% over 10 minutes; detector, UV 254 nm. The fractions containing the desired product were combined and concentrated to give the crude product. The crude product (35 mg) was purified by Prep-HPLC using the following conditions: column: XBridgePrep OBD C18 column, 30 x 150 mm, 5 μm; mobile phase A: water (plus 10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 60 mL / min; gradient: 41% B to 51% B, 51% B over 10 minutes; wavelength: 220 / 254 nm; RT1: 7.88-8.78 min. The fractions were combined and concentrated to give the title compound (16.8 mg, 8%) as an off-white solid. MS ESI: C 25 H 25 ClF2N6O2[M+H] + , calculated value 515.17,517.17, measured value 515.20,517.20; 1 H NMR (400MHz, chloroform-d) δ8.58(d,J=8.4Hz,1H),7.90(d,J=1.4Hz,1H),7.85(d,J=2.6Hz,1H),7.72(s,1H),7.64(s,1H), 7.58(d,J=1.3Hz,1H),7.34(d,J=10.5Hz,1H),6.54(s,1H),4.05-3.98(m,4H),3.59(t,J=4.7Hz,4H),1.68(s,9H).

[0768] Example 99: (3S)-N-{2,4-difluoro-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

[0769]

[0770] Step 1: To a stirred mixture of 5-bromo-2,4-difluoroaniline (2 g, 9.62 mmol), pinacol diboron (2.93 g, 11.54 mmol), and potassium acetate (2.83 g, 28.85 mmol) in dioxane (20 mL) was added portionwise 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (0.39 g, 0.48 mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 100°C for an additional 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (3 / 1). The fractions containing the desired product were combined and concentrated to give 2,4-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.4 g, 57%) as a light yellow oil. MS ESI:C 12 H 16 BF2NO2[M+H] + , calculated value 256.12, measured value 256.15.

[0771] Step 2: To a stirred mixture of 2,4-difluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (800 mg, 3.14 mmol), 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (0.75 g, 3.14 mmol) and tripotassium phosphate (1.33 g, 6.27 mmol) in tetrahydrofuran (8 mL) and water (0.8 mL) was added second generation XPhos Pd (0.25 g, 0.31 mmol) in portions at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 2 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA / EtOH (1 / 3 / 1). The fractions containing the desired product were combined and concentrated to give 2,4-difluoro-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (800 mg, 77%) as a brown solid. MS ESI: C 17 H 16 F2N4O[M+H] + , calculated value 331.13, measured value 331.10.

[0772] Step 3: To a stirred mixture of 2,4-difluoro-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (100 mg, 0.30 mmol) and triphosgene (35.93 mg, 0.12 mmol) in tetrahydrofuran (5.5 mL) was added N,N-diisopropylethylamine (195.63 mg, 1.52 mmol) dropwise at room temperature under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for an additional 30 minutes. To the above mixture was added (3S)-3-(2,2,2-trifluoroethyl)pyrrolidine·HCl salt (57.40 mg, 0.30 mmol) in tetrahydrofuran (1.5 mL) dropwise at room temperature. The reaction mixture was stirred at room temperature for an additional 2 hours. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), 50% to 80% gradient over 20 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give the title compound (52.8 mg, 34%) as a white solid. MS ESI: C 24 H 24 F5N5O2[M+H] + , calculated value 510.19, measured value 510.30; 1 H NMR (400MHz, DMSO-d6) δ8.35(d,J=1.7Hz,1H),8.05(s,1H),7.95(d,J=1.2Hz, 1H),7.68-7.66(m,1H),7.52(d,J=1.2Hz,1H),7.41-7.39(m,1H),6.50(s,1H), 3.81(t,J=4.7Hz,4H),3.73-3.64(m,1H),3.58-3.55(m,5H),3.34-3.28(m,1H ),3.07-3.02(m,1H),2.48-2.43(m,3H),2.10-1.99(m,1H),1.70-1.62(m,1H).

[0773] Example 103: 1-(tert-Butyl)-5-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-1H-pyrazole-4-carboxamide

[0774]

[0775] Step 1: Under nitrogen atmosphere, to a stirred solution of (2E)-2-cyano-3-ethoxyprop-2-enoic acid ethyl ester (7g, 41.37mmol) and EtONa (2.67g, 39.30mmol) in EtOH (50mL) was added tert-butylhydrazine HCl salt (5.16g, 41.37mmol) in batches at room temperature. Under nitrogen atmosphere, the reaction mixture was stirred at 70°C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (5 / 1). The fractions containing the desired product were combined and concentrated to give 5-amino-1-tert-butylpyrazole-4-carboxylic acid ethyl ester (8.4g, crude product) as a yellow oil. MS ESI: C 10 H 17 N3O2[M+H] + , calculated value 212.13, measured value 212.15.

[0776] Step 2: under nitrogen atmosphere, at room temperature to the stirred 5-amino-1-tert-butyl pyrazole-4-carboxylic acid ethyl ester (500mg, 2.36mmol) and CuBr (634.33mg, 2.84mmol) in ACN (5mL) solution, add t-BuONO (317.27mg, 3.07mmol) in batches. Under nitrogen atmosphere, reaction mixture was stirred at 45 ℃ for 2 hours. The gained mixture was quenched with saturated NH4Cl (aqueous solution) and extracted with EtOAc (3x 50mL). The organic layer merged was washed with salt water (2x 50mL), with anhydrous Na2SO4 drying. After filtration, the filtrate was concentrated under reduced pressure. The gained mixture was concentrated under reduced pressure. Residue was purified by silica gel column chromatography, eluted with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give ethyl 5-bromo-1-tert-butylpyrazole-4-carboxylate (490 mg, 75%) as a white solid. MS ESI: C 10 H 15 BrN2O2[M+H] + , calculated values ​​275.03, 277.03, measured values ​​275.00, 277.00; 1 H NMR (400MHz, CDCl3) δ7.87 (s, 1H), 4.34-4.28 (m, 2H), 1.77 (s, 9H), 1.35 (t, J = 7.1Hz, 3H).

[0777] Step 3: Under a nitrogen atmosphere, n-BuLi (0.99 mL, 0.99 mmol, 1 M in hexane) was added dropwise to a stirred solution of ethyl 5-bromo-1-tert-butylpyrazole-4-carboxylate (200 mg, 0.90 mmol) in THF (4 mL) at -78 ° C. Under a nitrogen atmosphere, the reaction mixture was stirred at -78 ° C for 30 minutes. NFSI (427.91 mg, 1.35 mmol) was added to the above mixture at -78 ° C. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was quenched with NH4Cl (aqueous solution) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 30 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give ethyl 1-tert-butyl-5-fluoropyrazole-4-carboxylate (80 mg, 41%) as an off-white oil. MS ESI: C 10 H 15 FN2O2[M+H] + , calculated value 215.11, measured value 215.10; 1 H NMR (400MHz, DMSO-d6) δ7.73 (d, J = 2.5Hz, 1H), 4.34-4.30 (m, 2H), 1.63 (s, 9H), 1.36 (t, J = 7.1Hz, 3H).

[0778] Step 4: under nitrogen atmosphere, at 0 DEG C, to the fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (45.70mg, 0.14mmol) of stirring in LiHMDS (1mL, 1M in THF) solution, 1-tert-butyl-5-fluoropyrazole-4-carboxylic acid ethyl ester (30mg, 0.14mmol) in THF (1mL) is added dropwise. Under nitrogen atmosphere, the resulting mixture is stirred at room temperature for 1 hour. The resulting mixture is quenched by adding saturated NH4Cl (aqueous solution) (15mL), and extracted with EtOAc (2x 20mL). The combined organic layer is washed with salt water (2x 20mL), with anhydrous Na2SO4 drying. After filtration, the filtrate is concentrated under reduced pressure. The residue was purified by Prep-TLC eluting with CH2Cl2 / MeOH (10 / 1) to give a crude product (50 mg). The crude product (50 mg) was purified by Prep-HPLC using the following conditions: Column: XBridgeShield RP18 OBD column, 19 x 250 mm, 10 μm; Mobile phase A: water (plus 10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 20% B to 30% B over 8 minutes; Wavelength: 254 / 220 nm; RT1: 6.48 min. Fractions containing the desired product were combined and concentrated to give the title compound (22.3 mg, 32%) as a white solid. MS ESI: C 26 H 28 F2N6O2[M+H] + , calculated value 495.22, measured value 495.20; 1 H NMR(400MHz, DMSO-d6)δ9.67(s,1H),8.15(d,J=1.4Hz,1H),8.00(d,J=2.5Hz,1H),7.90(d,J=1.2Hz,1H),7.56-7.49(m,2H),7 .28(d,J=11.5Hz,1H),6.36(d,J=1.5Hz,1H),3.84(t,J=4.7Hz,4H),3.55(t,J=4.7Hz,4H),2.29(s,3H),1.58(d,J=1.4Hz,9H).

[0779] Example 110: 1-(tert-Butyl)-N-(4-chloro-3-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-5-fluoro-1H-pyrazole-4-carboxamide

[0780]

[0781] Step 1: Under nitrogen atmosphere, to a stirred solution of 4-chloro-3-iodoaniline (1 g, 3.94 mmol), KOAc (801.49 mg, 7.88 mmol) and pinacol diboronate (1.50 g, 5.91 mmol) in DMF (10 mL) was added portionwise Pd(dppf)Cl2.CH2Cl2 (160.69 mg, 0.19 mmol) at room temperature. Under nitrogen atmosphere, the reaction mixture was stirred at 120°C for 2 hours. The resulting mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with brine (1 x 300 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1). The fractions containing the desired product were combined and concentrated to give 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (1.56 g, crude) as a yellow oil. MS ESI: C 12 H 17 BClNO2[M+H] + , calculated value 254.10, 256.10, measured value 254.10, 256.10.

[0782] Step 2: to the stirred 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (500mg, 2.10mmol) and XPhos palladium (II) biphenyl-2-amine chloride (165.51mg, 0.21mmol) in K PO (10mL, 0.5M) and THF (5mL) solution in batches, add 4-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (533.32mg, 2.10mmol) at room temperature. The reaction mixture is degassed three times with nitrogen and stirred at 40°C for 2 hours. The resulting mixture is diluted with water (40mL) and extracted with EtOAc (3x 50mL). The combined organic layer is washed with brine (1x 200mL) and dried over anhydrous Na SO. After filtration, the filtrate is concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give 4-chloro-3-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (433 mg, 62%) as a white solid. MS ESI: C 17 H 17 ClN4O[M+H] + , calculated values ​​329.11, 331.11, measured values ​​329.05, 331.05; 1H NMR (400MHz, CDCl3) δ7.86(d,J=1.4Hz,1H),7.62(d,J=1.2Hz,1H),7.57(d,J=1.2Hz,1H),7.27(d,J =8.5Hz,1H),6.74-6.63(m,2H),6.52(d,J=1.5Hz,1H),4.00(t,J=5.7Hz,4H),3.62(t,J=5.7Hz,4H).

[0783] Step 3: To a stirred mixture of 4-chloro-3-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (100 mg, 0.30 mmol), bis(λ2-cobalt(2+))octa(oxoniumcarbonate) (31.20 mg, 0.09 mmol) and Pd(dppf)Cl2.CH2Cl2 (24.78 mg, 0.03 mmol) in dioxane (2 mL) was added TEA (92.33 mg, 0.91 mmol) and 4-bromo-1-(tert-butyl)-5-fluoro-1H-pyrazole (100.85 mg, 0.45 mmol) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 90°C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 2) to give the crude product. The crude product (100 mg) was purified by Prep-HPLC using the following conditions: Column: XSelect CSH Prep C 18 OBD column, 19 x 250 mm, 5 μm; mobile phase A: water (added with 10 mmol / L NH4HCO3), mobile phase B: ACN; flow rate: 20 mL / min; gradient: 52% B to 57% B, 57% B over 8 minutes; wavelength: 254 nm; RT1: 9 min. Fractions containing the desired product were combined and concentrated to give the title compound as a white solid (38.5 mg, 24%). MS ESI: C 25 H 26 ClFN6O2[M+H] + , calculated value 497.18 measured value 497.20; 1H NMR (400MHz, DMSO-d6) δ10.02(s,1H),8.28(d,J=1.4Hz,1H),8.03(d,J=2.5Hz,1H),7.95(d,J=1.2Hz,1H),7.85(d,J=2.6Hz,1H), 7.77(dd,J=8.8,2.6Hz,1H),7.59-7.51(m,2H),6.46(d,J=1.5Hz,1H),3.81(t,J=4.6Hz,4H),3.55(t,J=4.7Hz,4H),1.57(s,9H).

[0784] Example 111: 1-tert-Butyl-5-fluoro-N-{2-fluoro-5-[3-fluoro-8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]-4-methylphenyl}pyrazole-4-carboxamide

[0785]

[0786] Step 1: under nitrogen atmosphere, at 0 DEG C, to the solution of 8-bromo-6-chloroimidazo [1,2-a] pyridine (10g, 43.20mmol) and NaH (1.90g, 47.52mmol, 60%) in THF (100mL) of stirring, selective fluorine reagent (15.30g, 43.20mmol) is added in batches. Under nitrogen atmosphere, reaction mixture is stirred at 60 DEG C for 16 hours. Gained mixture is diluted with NH4Cl (20mL) and extracted with EtOAc (3x 50mL). The combined organic layer is washed with brine (3x50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate is concentrated under reduced pressure. Residue is purified by silica gel column chromatography and eluted with PE / EA (6 / 1). The fractions containing the desired product were combined and concentrated to give 8-bromo-6-chloro-3-fluoroimidazo[1,2-a]pyridine (3.3 g, 30%) as a light yellow solid. MS ESI: C7H3BrClF2[M+H] + , calculated value 248.92, measured value 248.85.

[0787] Step 2: Pd (OAc) (27 mg, 0.12 mmol) and Dppf (199 mg, 0.36 mmol) were added to a solution of 8-bromo-6-chloro-3-fluoroimidazo[1,2-a]pyridine (300 mg, 1.21 mmol), morpholine (105.27 mg, 1.21 mmol) and K PO (765 mg, 3.60 mmol) in dioxane (3 mL) at room temperature. The reaction mixture was degassed three times with nitrogen and stirred at 80 ° C for 16 hours under a nitrogen atmosphere. The resulting mixture was diluted with water (30 mL) and extracted with EtOAc (3x30 mL). The combined organic layer was washed with brine (3x 30 mL) and dried over anhydrous Na SO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (5 / 1). The fractions containing the desired product were combined and concentrated to give 4-{6-chloro-3-fluoroimidazo[1,2-a]pyridin-8-yl}morpholine (200 mg, 65%) as an off-white solid. MS ESI: C 11 H 11 ClFN3O[M+H] + , calculated value 256.68, measured value 256.70.

[0788] Step 3: Under nitrogen atmosphere, to a stirred mixture of 4-{6-chloro-3-fluoroimidazo[1,2-a]pyridin-8-yl}morpholine (200 mg, 0.78 mmol) and 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (256.54 mg, 0.86 mmol) in THF (5 mL) and H2O (0.5 mL) at room temperature was added second generation XPhos precatalyst (61 mg, 0.07 mmol) and K3PO4 (332 mg, 1.56 mmol). The mixture was allowed to cool to room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (5 / 1) to give 2-fluoro-5-(3-fluoro-8-morpholinylimidazo[1,2-a]pyridin-6-yl)-4-methylaniline (190 mg, 71%) as a yellow solid. MS ESI: C 18 H 18 F2N4O[M+H] + , calculated value 345.14, measured value 345.10.

[0789] Step 4: To a stirred solution of 2-fluoro-5-[3-fluoro-8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]-4-methylaniline (80 mg, 0.23 mmol), bis(λ2-cobalt(2+))octa(oxoniumcarbonate) (23.83 mg, 0.07 mmol) and Pd(dppf)Cl2.CH2Cl2 (18.92 mg, 0.02 mmol) in dioxane (1 mL) was added TEA (139.38 mg, 1.38 mmol) and 4-bromo-1-(tert-butyl)-5-fluoro-1H-pyrazole (102.79 mg, 0.46 mmol) at room temperature. The reaction mixture was degassed with nitrogen three times and stirred at 90°C for 16 hours. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EA (1 / 1) to give a crude product, which was then purified by Prep-HPLC using the following conditions: Column: XBridge Prep OBD C18 column, 30 x 150 mm, 5 μm; Mobile phase A: water (supplemented with 10 mmol / L NH4HCO3), Mobile phase B: ACN; Flow rate: 60 mL / min; Gradient: 47% B to 57% B, 57% B over 10 minutes; Wavelength: 220 / 254 nm; RT1: 8.73 min. Fractions containing the desired product were combined and concentrated to give the title compound (7.2 mg, 6%). MS ESI: C 26 H 27 F3N6O2[M+H] + , calculated value 513.21, measured value 513.30; 1 H NMR (400MHz, DMSO-d6) δ9.69(s,1H),8.00(d,J=2.5Hz,1H),7.78(d,J=1.4Hz,1H),7.55(d,J=7.9Hz,1H),7.34 -7.24(m,2H),6.36(d,J=1.4Hz,1H),3.83-3.77(m,4H),3.57-3.42(m,4H),2.30(s,3H),1.58(d,J=1.5Hz,9H).

[0790] Example 112: 2-Fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline

[0791]

[0792] Step 1: To a stirred mixture of 8-bromo-6-chloroimidazo[1,2-a]pyridine (1 g, 4.32 mmol), morpholine (0.38 g, 4.36 mmol) and Pd(OAc)2 (0.10 g, 0.43 mmol) in dioxane (10 mL, 118.04 mmol) was added Dppf (0.72 g, 1.29 mmol) and K3PO4 (2.75 g, 12.96 mmol). The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 3 hours. The resulting mixture was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (2 x 80 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to give 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (1.52 g, 76%) as an off-white solid. MS ESI: C 11 H 12 ClN3O[M+H] + , calculated values ​​238.07, 240.07, measured values ​​238.10, 240.10; 1 H NMR (400MHz, CDCl3) δ7.85(d,J=1.6Hz,1H),7.59(d,J=1.6Hz,1H),7.50(d,J=1 .2Hz, 1H), 6.39 (d, J = 1.6Hz, 1H), 3.99 (t, J = 4.8Hz, 4H), 3.59 (t, J = 4.8Hz, 4H).

[0793] Step 2: to the stirred 4-{6-chloroimidazo[1,2-a]pyridin-8-yl}morpholine (180mg, 0.76mmol) and 2-fluoro-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (190mg, 0.76mmol), K PO (321mg, 1.51mmol) in THF (2mL) and H O (0.2mL) mixture was added in batches of second generation XPhos precatalyst (59mg, 0.08mmol). The reaction mixture was degassed three times with nitrogen and stirred at 80°C for 16 hours. The resulting mixture was diluted with water (30mL) and extracted with EtOAc (3x 30mL). The combined organic layer was washed with brine (2x 30mL) and dried over anhydrous Na SO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 5% to 95% over 25 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (178 mg, 72%) as a white solid. MS ESI: C 18 H 19 FN4O[M+H] + , calculated value 327.15, measured value 327.15; 1 H NMR (400MHz, DMSO-d6) δ8.07(d,J=1.2Hz,1H),7.88(d,J=1.2Hz,1H),7.49(d,J=1.2Hz,1H),6.95(d,J=12.4Hz,1H), 6.72 (d, J = 9.2Hz, 1H), 6.31 (d, J = 1.6Hz, 1H), 5.01 (s, 2H), 3.81 (t, J = 4.8Hz, 4H), 3.53 (t, J = 4.8Hz, 4H), 2.12 (s, 3H).

[0794] Examples 113 and 114: 2-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamide

[0795]

[0796] Step 1: Under a nitrogen atmosphere, to a stirred solution of methyl 2-acetylpyridine-4-carboxylate (500 mg, 2.79 mmol) in DMF (6 mL) was added (triphenylphosphonium) difluoroacetic acid inner salt (1.99 g, 5.58 mmol) at room temperature. Under a nitrogen atmosphere, the reaction mixture was stirred at 60 ° C for 3 hours. The resulting mixture was diluted with water (80 mL) and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with brine (50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (1 / 1) to obtain a crude product. The crude product was further purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water, 30% to 70% gradient over 15 minutes; detector, UV 254 / 210 nm. The fractions containing the desired product were combined and concentrated to give methyl 2-(1,1-difluoroprop-1-en-2-yl)pyridine-4-carboxylate (190 mg, 32%) as a pink oil. MSESI: C 10 H9F2NO2[M+H] + , calculated value 214.06, measured value 213.95; 1 H NMR (400MHz, CDCl3) δ8.79 (dd, J = 5.2, 1.2Hz, 1H), 8.07-8.05 (m, 1H), 7.73 (dd, J = 5.2, 1.6Hz, 1H), 3.99 (s, 3H), 2.12 (t, J = 3.6Hz, 3H).

[0797] Step 2: Under a nitrogen atmosphere, Pd / C (170 mg, 1.59 mmol, 10%) was added to a stirred solution of methyl 2-(1,1-difluoroprop-1-ene-2-yl)pyridine-4-carboxylate (170 mg, 0.80 mmol) in THF (3 mL). The reaction mixture was degassed three times with a hydrogen atmosphere and stirred for 5 hours under a hydrogen atmosphere. The resulting mixture was filtered and the filter cake was washed with MeOH (3x10 mL). The filtrate was concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water, 20% to 80% gradient over 20 minutes; detector, UV 210 / 278 nm. The fractions containing the desired product were combined and concentrated to give methyl 2-(1,1-difluoropropane-2-yl)pyridine-4-carboxylate (105 mg, 41%) (67.7% purity) as a light yellow oil. MS ESI:C 10 H 11 F2NO2[M+H] + , calculated value 216.08, measured value 216.05; 1H NMR (400MHz, CDCl3) δ8.76 (dd, J=4.8, 0.8Hz, 1H), 7.81 (t, J=1.2Hz, 1H), 7.78 (dd,J=4.8,1.6Hz,1H),6.27-5.98(m,1H),3.99(s,3H),1.48(d,J=7.2Hz,3H).

[0798] Step 3: To a stirred solution of methyl 2-(1,1-difluoropropan-2-yl)pyridine-4-carboxylate (105 mg, 0.49 mmol) in MeOH (1 mL), H2O (1 mL) and THF (1 mL) was added LiOH·H2O (61 mg, 1.47 mmol) portionwise at 0°C. The reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was acidified to pH 4 with HCl (aq) and concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile in water, gradient from 5% to 95% over 20 minutes; detector, UV 200 / 273 nm. Fractions containing the desired product were combined and concentrated to give 2-(1,1-difluoropropan-2-yl)pyridine-4-carboxylic acid (80 mg, 73%) as an off-white solid (89% purity). MS ESI: C9H9F2NO2[M+H] + , calculated value 202.06, measured value 202.10; 1 H NMR(400MHz, DMSO-d6)δ8.68(dd,J=4.8,0.8Hz,1H),7.80(t,J=1.2Hz,1H),7.71(d d,J=4.8,1.6Hz,1H),6.46-6.16(m,1H),3.61-3.47(m,1H),1.35(d,J=6.8Hz,3H).

[0799] Step 4: To a stirred mixture of 2-(1,1-difluoro-2-methylpropane-2-yl)pyridine-4-carboxylic acid (80 mg, 0.37 mmol) in T3P (1 mL) and pyridine (1 mL) is added 2-fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (110 mg, 0.37 mmol). The reaction mixture is stirred at room temperature for 2 hours. The resulting mixture is diluted with water (50 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic layer is washed with saturated brine (50 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate is concentrated under reduced pressure. The residue is purified by Prep-TLC and eluted with PE / EA / EtOH=8 / 3 / 1 to give a crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, acetonitrile (10 mmol NH4HCO3) in water, gradient from 5% to 95% over 15 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give 2-(1,1-difluoropropan-2-yl)-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyridine-4-carboxamide (70 mg, 41%) as an off-white solid. MS ESI: C 27 H 26 F3N5O2[M+H] + , calculated value 510.20, measured value 510.15; 1 H NMR (400MHz, CDCl3) δ8.86(dd,J=5.2,0.8Hz,1H),8.36(d,J=8.0Hz,1H),8.06(s,1H),7.79(d,J=1.6Hz,1H),7.68-7.61(m,3H),7.58(d,J=1.2Hz,1H) ,7.13(d,J=12.0Hz,1H),6.41(s,1H),6.29-5.99(m,1H),4.03-4.00(m,4H) ,3.60-3.57(m,4H),3.55-3.41(m,1H),2.31(s,3H),1.51(d,J=6.8Hz,3H).

[0800] Step 5: 2-(1,1-Difluoropropane-2-yl)-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}pyridine-4-carboxamide (70 mg, 0.14 mmol) was purified by chiral-Prep-HPLC using the following conditions: Column: CHIRAL ART Cellulose-SC, 2 x 25 cm, 5 μm; Mobile phase A: Hex (0.1% 2M NH3-MeOH)--HPLC, Mobile phase B: MeOH:DCM=1:1--HPLC; Flow rate: 20 mL / min; Gradient: 40% B to 40% B over 13.5 minutes; Wavelength: 220\254 nm; RT1: 8.996 min; RT2: 11.239 min; Sample solvent: EtOH:DCM=1:1--HPLC; Injection volume: 1.3 mL.

[0801] Peak 1 (Example 113: 2-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamide): Fractions (RT 8.996 min) were combined and concentrated to give the title compound (26.9 mg, 38%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 26 F3N5O2[M+H] + , calculated value 510.20, measured value 510.25; 1 H NMR (400MHz, CDCl3) δ8.80(d,J=4.8Hz,1H),8.36(d,J=8.0Hz,1H),8.08(d,J=2.0Hz,1H),7.80(d,J=1.6Hz,1H),7.68-7.54(m,4H),7.13(d, J=11.6Hz,1H),6.42(s,1H),6.29-5.99(m,1H),4.03-4.00(m,4H),3.59-3.57(m,4H),3.53-3.41(m,1H),2.31(s,3H),1.51(d,J=6.8Hz,3H).

[0802] Peak 2 (Example 114: 2-(1,1-difluoropropan-2-yl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)isonicotinamide): Fractions (RT 11.239 min) were combined and concentrated to give the title compound (26.2 mg, 37%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 27 H 26F3N5O2[M+H] + , calculated value 510.20, measured value 510.20; 1 H NMR (400MHz, CDCl3) δ8.80(d,J=4.8Hz,1H),8.35(d,J=8.0Hz,1H),8.08(d,J=3.2 Hz,1H),7.78(d,J=1.6Hz,1H),7.68(d,J=1.6Hz,1H),7.63-7.61(m,2H),7.57(d, J=1.2Hz,1H),7.13(d,J=11.6Hz,1H),6.38(s,1H),6.29-5.99(m,1H),4.02-3.99 (m,4H),3.60-3.57(m,4H),3.54-3.41(m,1H),2.31(s,3H),1.51(d,J=7.2Hz,3H).

[0803] Example 115: 1-tert-Butyl-2-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}imidazole-4-carboxamide

[0804]

[0805] Step 1: to the mixture of stirred 1-tert-butylimidazole-4-carboxylic acid ethyl ester (300mg, 1.53mmol) and sodium bicarbonate (385.25mg, 4.59mmol) in acetonitrile (10mL), selective fluorine reagent (2.71g, 7.65mmol) was added. Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 16 hours. The obtained mixture was diluted with water (10mL) and extracted with ethyl acetate (3x 10mL). The combined organic layer was washed with salt water (3x 20mL) and dried over anhydrous sodium sulfate. After filtering, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (1 / 1). The fractions containing the desired product were combined and concentrated to obtain 1-tert-butyl-2-fluoroimidazole-4-carboxylic acid ethyl ester (100mg, 31%) as a brown oil. MS ESI:C 10 H 15 FN2O2.[M+H] + , calculated value 215.11, measured value 215.05.

[0806] Step 2: Under a nitrogen atmosphere, to a stirred solution of 2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (137.11 mg, 0.42 mmol) in lithium bis(trimethylsilyl)amide (2 mL) was added dropwise 1-tert-butyl-2-fluoroimidazole-4-carboxylic acid ethyl ester (90 mg, 0.42 mmol) dissolved in tetrahydrofuran (1 mL) at 0 ° C. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was quenched with saturated ammonium chloride (aqueous solution) at room temperature. The resulting mixture was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed with brine (3x 15 mL) and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by Prep-TLC and eluted with DCM / MeOH (20 / 1) to give a crude product. The crude product was purified by reverse phase flash chromatography using the following conditions: Column: XBridge Prep OBD C18 column, 30 x 150 mm, 5 μm; Mobile phase A: Water (plus 10 mmol / L NH4HCO3); Mobile phase B: Acetonitrile; Flow rate: 60 mL / min; Gradient: 39% B to 49% B, 49% B over 10 minutes; Wavelength: 254 nm; RT1: 10 min. Fractions containing the desired product were combined and concentrated to give 1-tert-butyl-2-fluoro-N-{2-fluoro-4-methyl-5-[8-(morpholin-4-yl)imidazo[1,2-a]pyridin-6-yl]phenyl}imidazole-4-carboxamide (67.1 mg, 21%) as an off-white solid. MS ESI: C 26 H 28 F2N6O2.[M+H] + , calculated value 495.22, measured value 495.20; 1 H NMR (400MHz, DMSO-d6) δ9.41(s,1H),8.48(s,1H),8.22(s,1H),8.03(s,1H),7.94(d,J=7.9Hz,1H),7.67(s,1H),7. 34(d,J=11.6Hz,1H),7.07(s,1H),3.84(t,J=4.6Hz,4H),3.28(d,J=5.6Hz,4H),2.28(s,3H),1.59(d,J=1.1Hz,9H).

[0807] Examples 119-121: 3-Fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide

[0808]

[0809] Step 1: under nitrogen atmosphere, at -20 ℃ to the solution of 6-oxa-3-azabicyclo [3.1.0] hexane-3-carboxylic acid benzyl ester (5g, 22.80mmol) and copper bromide (I) dimethyl sulfide (0.94g, 4.56mmol) in THF (200mL) that stir, add isopropyl magnesium bromide (13.4g, 91.22mmol). Under nitrogen atmosphere, reaction mixture is stirred at -20 ℃ for 1 hour. Gained mixture is quenched at 0 ℃ by adding saturated NH4Cl (aqueous solution) (300mL). Gained mixture is extracted with EtOAc (3x 300mL). The organic layer merged is washed with salt water (2x 200mL), uses anhydrous Na2SO4 drying. After filtration, the filtrate is concentrated under reduced pressure. The residue was purified by reverse phase flash chromatography using the following conditions: column, C18 silica gel; mobile phase, MeCN in water (plus 10 mmol / L NH4HCO3), gradient from 25% to 95% over 35 minutes; detector, UV 254 nm. Fractions containing the desired product were combined and concentrated to give benzyl 3-hydroxy-4-isopropylpyrrolidine-1-carboxylate (2.05 g, 34%) as a colorless oil. MS ESI: C 15 H 21 NO3[M+H] + , calculated value 264.33, measured value 264.15.

[0810] Step 2: Under a nitrogen atmosphere, at 0 ° C, to a stirred mixture of 3-isopropyl-4-oxopyrrolidine-1-carboxylic acid benzyl ester (700 mg, 2.67 mmol) in DAST (10 mL, 8.03 mmol). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 4 hours. The resulting mixture was quenched by adding NH4HCO3 (aqueous solution) at 0 ° C. The resulting mixture was extracted with EtOAc (3x 50 mL). The combined organic layer was washed with brine (3x 50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (5 / 1). The fractions containing the desired product were combined and concentrated to give 3,3-difluoro-4-isopropylpyrrolidine-1-carboxylic acid benzyl ester (250 mg, 32%) as a yellow oil. MS ESI: C 15 H 20 FNO2[M+H] + , calculated value 266.32, measured value 266.15.

[0811] Step 3: A solution of benzyl 3-fluoro-4-isopropylpyrrolidine-1-carboxylate (300 mg, 1.13 mmol) in TFA (3 mL) was stirred at 60 ° C for 16 hours. The resulting mixture was cooled to room temperature. The resulting mixture was concentrated under reduced pressure to give 3-fluoro-4-isopropylpyrrolidine (100 mg, crude) as a yellow oil. MS ESI: C7H 14 FN[M+H] + , calculated value 132.19, measured value 132.60.

[0812] Step 4: To a stirred mixture of 2-fluoro-4-methyl-5-[8-(morpholine-4-yl)imidazo[1,2-a]pyridin-6-yl]aniline (150 mg, 0.46 mmol) and DIEA (297 mg, 2.30 mmol) in THF (7.6 mL) was added triphosgene (54 mg, 0.18 mmol). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 15 minutes. To the above mixture was added 3-fluoro-4-isopropylpyrrolidine (60 mg, 0.46 mmol). Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was quenched with MeOH (2 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with CH2Cl2 / MeOH (10 / 1). The fractions containing the desired product were combined and concentrated to give 3-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide (100 mg, 45%) as a yellow solid. MS ESI: C 26 H 31 F2N5O2[M+H] + , calculated value 484.56, measured value 484.25.

[0813] Step 5: 3-Fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide (100 mg) was purified by Prep-HPLC using the following conditions: Column: CHIRALPAK IH, 2x 25 cm, 5 μm; Mobile phase A: Hex (0.5% 2M NH3-MeOH)—HPLC, Mobile phase B: MeOH:DCM=1:1—HPLC; Flow rate: 20 mL / min; Gradient: 20% B to 20% B over 15 minutes; Wavelength: 254 / 220 nm; RT1: 8.19 min; RT2: 11.76 min; Sample solvent: MeOH:DCM=1:1—HPLC; Injection volume: 0.5 mL.

[0814] Peak 1 (Example 119: 3-fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide): Fractions (RT 8.19 min) were combined and concentrated to give the title compound (33.3 mg, 14%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 26 H 31 F2N5O2[M+H] + , calculated value 484.56, measured value 484.30; 1 H NMR (400MHz, DMSO-d6) δ8.12(d,J=1.4Hz,1H),8.02(s,1H),7.89(d,J=1.2Hz,1H),7.50(d,J=1. 2Hz,1H),7.42(d,J=8.1Hz,1H),7.18(d,J=11.6Hz,1H),6.34(d,J=1.5Hz,1H),5.23(d,J=53.4H z,1H),3.80(t,J=4.6Hz,4H),3.78-3.59(m,3H),3.53(t,J=4.7Hz,4H),3.10(t,J=10.5Hz,1H), 2.25(s,3H),1.98-1.96(m,1H),1.74-1.70(m,1H),1.01(d,J=6.5Hz,3H),0.92(d,J=6.6Hz,3H).

[0815] Peak 2 (Example 120: 3-Fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide): Fractions (RT 11.76 min) were combined and concentrated to give the title compound (29.7 mg, 13%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 26 H 31 F2N5O2[M+H] + , calculated value 484.56, measured value 484.35; 1H NMR (400MHz, DMSO-d6) δ8.12(d,J=1.4Hz,1H),8.03(s,1H),7.89(d,J=1.2Hz,1H),7.50(d,J=1 .2Hz,1H),7.42(d,J=8.2Hz,1H),7.18(d,J=11.6Hz,1H),6.34(d,J=1.5Hz,1H),5.23(d,J=53. 5Hz,1H),3.83(t,J=4.7Hz,4H),3.76-3.63(m,3H),3.53(t,J=4.7Hz,4H),3.11-3.09(m,1H),2 .25(s,3H),2.15-1.86(m,1H),1.83-1.65(m,1H),1.01(d,J=6.5Hz,3H),0.92(d,J=6.6Hz,3H).

[0816] Peak 3 (Example 121: 3-Fluoro-N-(2-fluoro-4-methyl-5-(8-morpholinylimidazo[1,2-a]pyridin-6-yl)phenyl)-4-isopropylpyrrolidine-1-carboxamide): Fractions (RT 8.2-11.76 min) were combined and concentrated to give the title compound (1.7 mg, 0.56%) as an off-white solid with uncertain absolute stereochemistry. MS ESI: C 26 H 31 F2N5O2[M+H] + , calculated value 484.56, measured value 484.35; 1 H NMR (400MHz, chloroform-d) δ8.10(d,J=8.2Hz,1H),7.76-7.71(m,1H),7.59(d,J=1.7Hz,1H),7.54-7.49(m,1H),7.00(d,J=11.5Hz,1H),6.35(d,J=12.4Hz ,2H),5.18-5.16(m,1H),3.98(t,J=5.0Hz,4H),3.91-3.60(m,3H),3.58- 3.42(m,5H),2.23(d,J=2.0Hz,3H),2.16-1.84(m,2H),1.06-1.04(m,6H).

[0817] Examples 122 and 123: 3-(Cyclopropyldifluoromethyl)-N-(2-fluoro-4-methyl-5-(8-morpholinimidazo[1,2-a]pyridin-6-yl)phenyl)pyrrolidine-1-carboxamide

[0818]

[0819] Step 1: under nitrogen atmosphere, at room temperature to the solution of 1-(tert-butyloxycarbonyl) pyrrolidine-3-carboxylic acid (5g, 23.23mmol) and N, O-dimethylhydroxylamine HCl salt (3.40g, 34.84mmol) in THF (50mL) of stirring, add EDCI (6.68g, 34.84mmol) and TEA (7.05g, 69.69mmol). Under nitrogen atmosphere, the reaction mixture was stirred at room temperature for 2 hours. The gained mixture was diluted with water (300mL) and extracted with EtOAc (3x 200mL). The organic layer merged was washed with salt water (3x 200mL), with anhydrous Na2SO4 drying. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (1 / 3). Fractions containing the desired product were combined and concentrated to give tert-butyl 3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate (3.2 g, 53%) as a yellow oil. 1 H NMR (400 MHz, CHLOROFORM-d) δ 3.74-3.72 (m, 3H), 3.71-3.52 (m, 2H), 3.50-3.30 (m, 3H), 3.22 (s, 3H), 2.23-2.02 (m, 2H), 1.48 (d, J = 1.0 Hz, 9H).

[0820] Step 2: at -78 ℃, cyclopropylmagnesium bromide (10.35g, 71.23mmol) was added dropwise to a solution of tert-butyl 3-[methoxy(methyl)carbamoyl]pyrrolidine-1-carboxylate (4.6g, 17.81mmol) in THF (30mL) to be stirred. Under a nitrogen atmosphere, the reaction mixture was stirred at room temperature for 2 hours. The resulting mixture was quenched at room temperature by adding saturated NH4Cl (aqueous solution) (100mL). The resulting mixture was extracted with EtOAc (3x 150mL). The combined organic layer was washed with brine (3x100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography and eluted with PE / EA (3 / 1). The fractions containing the desired product were combined and concentrated to give tert-butyl 3-cyclopropanecarbonylpyrrolidine-1-carboxylate (3.16g, 74%) as a light yellow oil. 1 H NMR (300 MHz, CHLOROFORM-d) δ 3.70-3.52 (m, 2H), 3.53-3.22 (m, 3H), 2.21-2.06 (m, 2H), 1.99-1.74 (m, 1H), 1.48 (s, 9H), 1.10-1.07 (m, 2H), 1.03-0.88 (m, 2H).

[0821] Step 3: HCl (g) (5mL, 4M in EA) is added to a solution of tert-butyl 3-cyclopropanecarbonylpyrrolidine-1-carboxylate (1g, 4.18mmol) in DCM (5mL) to be stirred. The reaction mixture is stirred at room temperature for 1 hour. The resulting mixture is concentrated under reduced pressure to obtain cyclopropyl (pyrrolidin-3-yl) ketone HCl salt (720mg, crude product). NaHCO (905mg, 10.78mmol) and benzyl chloroformate (1226mg, 7.18mmol) are added dropwise to a solution of cyclopropyl (pyrrolidin-3-yl) ketone HCl salt (720mg, crude product) in ACN (5mL) at 0°C. Under a nitrogen atmosphere, the reaction mixture is stirred at room temperature for 2 hours. The resulting mixture is diluted with water (50mL) and extracted with EtOAc (3x 50mL). The combined organic layer is washed with brine (3x 40mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EA (3 / 1). The fractions containing the desired product were combined and concentrated to give 3-cyclopropanecarbonylpyrrolidine-1-carboxylic acid benzyl ester (650 mg, 57%) as a colorless oil. MS ESI: C 16 H 19 NO3[M+H] + , calculated value 274.33, measured value 274.35.

[0822] Step 4: under nitrogen atmosphere, a solution of 3-cyclopropanecarbonylpyrrolidine-1-carboxylic acid benzyl ester (640mg, 2.34mmol) in BAST (5mL) was stirred at 60 ℃ for 16 hours. The resulting mixture was quenched at room temperature by adding saturated NaHCO (aqueous solution) (10mL). The resulting mixture was diluted with water (30mL) and extracted with EtOAc (3x 50mL). The combined organic layer was washed with brine (3x 50mL) and dried over anhydrous Na2SO4. After filtering, the filtrate was concentrated under reduced p...

Claims

1. A compound having the structure of formula (I) or a pharmaceutically acceptable salt or solvate thereof: in, A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N; X is N or CR 1 ; Y is N or CR 2 ; Z is N or CR 3 ; R 1 , R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted by an optionally substituted cycloalkyl group.

2. A compound having the structure of formula (Ia) or a pharmaceutically acceptable salt or solvate thereof: in, X is N or CR 1 ; Y is N or CR 2 ; Z is N or CR 3 ; R 1 , R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted by an optionally substituted cycloalkyl group.

3. A compound having the structure of formula (Ib) or a pharmaceutically acceptable salt or solvate thereof: in, X is N or CR 1 ; Y is N or CR 2 ; Z is N or CR 3 ; R 1 , R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted by an optionally substituted cycloalkyl group.

4. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 .

5. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is N, and Z is N.

6. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is CR 2 , and Z is N.

7. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is N, and Z is CR 3 .

8. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is CR 2 , and Z is CR 3 .

9. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Y is CR 2 .

10. The compound according to claim 1, 2, 3 or 9, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Z is N.

11. The compound according to claim 1, 2, 3 or 9, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Z is N.

12. The compound according to claim 1, 2, 3 or 9, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Z is CR 3 .

13. The compound according to claim 1, 2, 3 or 9, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Z is CR 3 .

14. The compound according to claim 1, 2 or 3, or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is CR 3 .

15. The compound according to claim 1, 2, 3 or 14, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Y is N.

16. The compound according to claim 1, 2, 3 or 14, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Y is N.

17. The compound according to claim 1, 2, 3 or 14, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Y is CR 2 .

18. The compound according to claim 1, 2, 3 or 14, or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Y is CR 2 .

19. A compound having the structure of formula (II) or a pharmaceutically acceptable salt or solvate thereof: in, X is N or CR 1 ; Z is N or CR 3 ; R 1 and R 3 independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; R 4 is selected from optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and W is an optionally substituted nitrogen-containing heterocyclic group, an optionally substituted nitrogen-containing heteroaryl group, an optionally substituted aryl group, an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group, an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group, or an optionally substituted aryl group further substituted by an optionally substituted cycloalkyl group.

20. The compound according to claim 19 or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Z is N.

21. The compound according to claim 19 or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Z is N.

22. The compound according to claim 19 or a pharmaceutically acceptable salt or solvate thereof, wherein: X is N, and Z is CR 3 .

23. The compound according to claim 19 or a pharmaceutically acceptable salt or solvate thereof, wherein: X is CR 1 , and Z is CR 3 .

24. A compound according to any one of claims 19 to 23 or a pharmaceutically acceptable salt or solvate thereof, wherein: R 4 is selected from optionally substituted alkyl groups.

25. The compound according to any one of claims 19 to 23, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 4 is selected from optionally substituted cycloalkyl.

26. A compound according to any one of claims 19 to 23 or a pharmaceutically acceptable salt or solvate thereof, wherein: R 4 is selected from optionally substituted cycloalkylalkyl.

27. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 For H.

28. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 It is a halogen.

29. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 For fluorine.

30. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 is an optionally substituted alkyl group.

31. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 is an optionally substituted cycloalkyl group.

32. A compound according to any one of claims 1 to 26, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 1 is optionally substituted cycloalkylalkyl.

33. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 For H.

34. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 It is a halogen.

35. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 For fluorine.

36. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 is an optionally substituted alkyl group.

37. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 is an optionally substituted cycloalkyl group.

38. A compound according to any one of claims 1 to 18 or 27 to 32, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 is optionally substituted cycloalkylalkyl.

39. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 For H.

40. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 It is a halogen.

41. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 For fluorine.

42. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 is an optionally substituted alkyl group.

43. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 is an optionally substituted cycloalkyl group.

44. A compound according to any one of claims 1 to 38, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 is optionally substituted cycloalkylalkyl.

45. A compound according to any one of claims 24, 30, 36 or 42, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

46. ​​A compound according to any one of claims 25, 31, 37 or 43, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted cycloalkyl group is selected from C3-C4 optionally substituted cycloalkyl groups.

47. A compound according to any one of claims 26, 32, 38 or 44, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted cycloalkylalkyl group is selected from C4-C7 optionally substituted cycloalkylalkyl groups.

48. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted nitrogen-containing heterocyclic group.

49. The compound according to claim 48 or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from optionally substituted pyrrolidine, optionally substituted 2,5-dihydro-1H-pyrrole, optionally substituted piperidine or optionally substituted 1,2,3,6-tetrahydropyridine.

50. The compound according to claim 48 or a pharmaceutically acceptable salt or solvate thereof, wherein W is selected from: and Among them, R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF 3、 -CH2CHF2 or -C(CH3)2CF3.

51. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted nitrogen-containing heteroaryl group.

52. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted triazinyl or optionally substituted pyrrolyl.

53. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from: and Among them, R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF 3、 -CH2CHF2 or -C(CH3)2CF3.

54. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazinyl, optionally substituted imidazolyl, optionally substituted triazolyl or optionally substituted tetrazolyl.

55. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted pyrazin-3-yl, optionally substituted pyrazin-4-yl, optionally substituted pyrazin-5-yl, optionally substituted imidazol-4-yl or optionally substituted imidazol-5-yl.

56. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted 1,2,3-triazol-4-yl, optionally substituted 1,2,3-triazol-5-yl or optionally substituted 1,2,4-oxadiazol-5-yl.

57. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted oxazol-2-yl, optionally substituted oxazol-4-yl or optionally substituted oxazol-5-yl.

58. The compound according to claim 51 or a pharmaceutically acceptable salt or solvate thereof, wherein W is optionally substituted thiazol-2-yl, optionally substituted thiazol-4-yl or optionally substituted thiazol-5-yl.

59. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group or an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group.

60. The compound according to claim 59 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from: And R 5 It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

61. The compound according to claim 59 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from: And R 5 It is 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

62. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted aryl group.

63. The compound according to claim 62 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted phenyl group.

64. The compound according to claim 62, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is And R 5 Selected from -CH3, -CH2CH3, -CH(CH3)2, -C(CH3)3, -CF3, -CH2CF3, -CH(CH3)CF 3、 -CH2CHF2 or -C(CH3)2CF3.

65. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted aryl further substituted by optionally substituted cycloalkyl.

66. The compound according to claim 65 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is And R 5 Selected from 1-trifluoromethylcyclopropyl or cyclopropyl substituted by at least one fluorine.

67. A compound having the structure of formula (III) or a pharmaceutically acceptable salt or solvate thereof: in, L is -CO-NH- or -NH-CO-; A is N or C; B is N or C; provided that if A is N, then B is C; or if A is C, then B is N; X is N or CR 1 ; Y is N or CR 2 ; Z is N or CR 3 ; R 1 , R 2 and R 3 is independently selected from H, -CN, halogen, optionally substituted alkyl, optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; or optionally, R 1 and R 2 can be connected to form a ring; or optionally, R 2 and R 3 Can be connected to form a ring; R 4 is selected from H, halogen or optionally substituted C1-C3 alkyl; K is N or CH; E is N or CH; M is N or CR 5 ; Q is N or CR 5 ; T is N or CR 5 ; Each R 5 independently selected from H, halogen or optionally substituted C1-C3 alkyl; G is selected from and W is selected from: an optionally substituted nitrogen-containing heterocyclic group; an optionally substituted nitrogen-containing heteroaryl group; optionally substituted carbocyclyl; optionally substituted aryl; an optionally substituted nitrogen-containing heterocyclic group further substituted with an optionally substituted cycloalkyl group or an optionally substituted cycloalkylalkyl group; optionally substituted nitrogen-containing heteroaryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; optionally substituted carbocyclyl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl; and Optionally substituted aryl further substituted with optionally substituted cycloalkyl or optionally substituted cycloalkylalkyl.

68. The compound according to claim 67 or a pharmaceutically acceptable salt or solvate thereof, wherein A is N and B is C.

69. The compound according to claim 67 or a pharmaceutically acceptable salt or solvate thereof, wherein A is C and B is N.

70. A compound according to any one of claims 67 to 69, or a pharmaceutically acceptable salt or solvate thereof, wherein: L is -CO-NH-.

71. A compound according to any one of claims 67 to 69, or a pharmaceutically acceptable salt or solvate thereof, wherein: L is -NH-CO-.

72. A compound according to any one of claims 67 to 71 or a pharmaceutically acceptable salt or solvate thereof, wherein G is 73. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 .

74. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N, and Z is N.

75. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is N.

76. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is N, and Z is CR 3 .

77. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 , and Z is CR 3 .

78. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Y is CR 2 .

79. A compound according to any one of claims 67 to 72 or 78, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N, and Z is N.

80. A compound according to any one of claims 67 to 72 or 78, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is N.

81. A compound according to any one of claims 67 to 72 or 78, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N, and Z is CR 3 .

82. A compound according to any one of claims 67 to 72 or 78, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Z is CR 3 .

83. A compound according to any one of claims 67 to 72, or a pharmaceutically acceptable salt or solvate thereof, wherein Z is CR 3 .

84. A compound according to any one of claims 67 to 72 or 83, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N, and Y is N.

85. A compound according to any one of claims 67 to 72 or 83, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is N.

86. A compound according to any one of claims 67 to 72 or 83, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N, and Y is CR 2 .

87. A compound according to any one of claims 67 to 72 or 83, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR 1 , and Y is CR 2 .

88. A compound according to any one of claims 67 to 87, or a pharmaceutically acceptable salt or solvate thereof, wherein K is N; and E is CH.

89. A compound according to any one of claims 67 to 87, or a pharmaceutically acceptable salt or solvate thereof, wherein K is CH; and E is N.

90. A compound according to any one of claims 67 to 89, or a pharmaceutically acceptable salt or solvate thereof, wherein: M stands for CR 5 ; Q is CR 5 ; and T is N.

91. A compound according to any one of claims 67 to 89, or a pharmaceutically acceptable salt or solvate thereof, wherein M stands for CR 5 ; Q is N; and T is CR 5 .

92. A compound according to any one of claims 67 to 89, or a pharmaceutically acceptable salt or solvate thereof, wherein: M is N; Q is CR 5 ; and T is CR 5 .

93. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For H.

94. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is a halogen.

95. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For fluorine.

96. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an optionally substituted alkyl group.

97. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is an optionally substituted cycloalkyl group.

98. A compound according to any one of claims 67 to 92, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted cycloalkylalkyl.

99. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 2 For H.

100. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 It is a halogen.

101. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 For fluorine.

102. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted alkyl group.

103. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is an optionally substituted cycloalkyl group.

104. A compound according to any one of claims 67 to 98, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 is optionally substituted cycloalkylalkyl.

105. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 For H.

106. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a halogen.

107. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 For fluorine.

108. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is an optionally substituted alkyl group.

109. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is an optionally substituted cycloalkyl group.

110. A compound according to any one of claims 67 to 104, or a pharmaceutically acceptable salt or solvate thereof, wherein: R 3 is optionally substituted cycloalkylalkyl.

111. A compound according to any one of claims 96, 102 or 108, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted alkyl group is selected from C1-C5 optionally substituted alkyl groups.

112. A compound according to any one of claims 97, 103 or 109, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted cycloalkyl group is selected from C3-C4 optionally substituted cycloalkyl groups.

113. A compound according to any one of claims 98, 104 or 110, or a pharmaceutically acceptable salt or solvate thereof, wherein: The optionally substituted cycloalkylalkyl group is selected from C4-C7 optionally substituted cycloalkylalkyl groups.

114. A compound according to any one of claims 67 to 113, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 is F or CH3.

115. A compound according to any one of claims 67 to 91 or 93 to 114, or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH.

116. A compound according to any one of claims 67 to 90 or 92 to 114, or a pharmaceutically acceptable salt or solvate thereof, wherein: Q is CF.

117. A compound according to any one of claims 67 to 89 or 91 to 114, or a pharmaceutically acceptable salt or solvate thereof, wherein: T is CH.

118. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted nitrogen-containing heterocyclic group.

119. The compound according to claim 118 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from optionally substituted pyrrolidine, optionally substituted 2,5-dihydro-1H-pyrrole, optionally substituted piperidine or optionally substituted 1,2,3,6-tetrahydropyridine.

120. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is an optionally substituted nitrogen-containing heteroaryl group.

121. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted pyridyl, optionally substituted pyrimidinyl, optionally substituted triazinyl or optionally substituted pyrrolyl.

122. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted pyrazinyl, optionally substituted imidazolyl, optionally substituted triazolyl or optionally substituted tetrazolyl.

123. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted pyrazin-3-yl, optionally substituted pyrazin-4-yl, optionally substituted pyrazin-5-yl, optionally substituted imidazol-4-yl or optionally substituted imidazol-5-yl.

124. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted 1,2,3-triazol-4-yl, optionally substituted 1,2,3-triazol-5-yl or optionally substituted 1,2,4-oxadiazol-5-yl.

125. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted oxazol-2-yl, optionally substituted oxazol-4-yl or optionally substituted oxazol-5-yl.

126. The compound according to claim 120 or a pharmaceutically acceptable salt or solvate thereof, wherein: W is optionally substituted thiazol-2-yl, optionally substituted thiazol-4-yl or optionally substituted thiazol-5-yl.

127. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heterocyclic group further substituted by an optionally substituted cycloalkyl group or an optionally substituted cycloalkylalkyl group.

128. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein W is an optionally substituted nitrogen-containing heteroaryl group further substituted by an optionally substituted cycloalkyl group or an optionally substituted cycloalkylalkyl group.

129. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

130. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

131. A compound according to any one of claims 1 to 47, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

132. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

133. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

134. A compound according to any one of claims 67 to 117, or a pharmaceutically acceptable salt or solvate thereof, wherein: W is selected from:

135. A compound as provided in Table 1, or a pharmaceutically acceptable salt or solvate thereof.

136. A pharmaceutical composition comprising a compound according to any one of claims 1 to 135 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.

137. A method of preparing a pharmaceutical composition, the method comprising mixing a compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof, with a pharmaceutically acceptable carrier.

138. A compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.

139. A compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treating cancer or a tumor disease.

140. Use of a compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for the treatment of cancer or a tumor disease.

141. A method of treating cancer in a patient in need thereof, comprising administering to the patient a compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof.

142. A method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound according to any one of claims 1 to 135, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.